

33. A pharmaceutical preparation for inhibiting gastric acid secretion comprising a compound according to claim 32 in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier.

34. A method for inhibiting gastric acid secretion in mammals comprising administering an amount of a compound according to claim 32 sufficient to inhibit gastric acid secretion.

35. A method for the treatment of gastrointestinal inflammatory diseases in mammals comprising administering an amount of a compound according to claim 32 sufficient to treat gastrointestinal inflammatory disease.

36. A method for providing gastrointestinal cytoprotective effects in mammals comprising administering an amount of a compound according to claim 32 sufficient to provide gastrointestinal cytoprotective effects.--.

R E M A R K S

This is in response to the Official Action dated October 24, 1986 for the above-captioned application. Applicant requests a three-month extension of time, and encloses the appropriate fee under 37 C.F.R. § 1.17(c).

Reconsideration of the application, as amended, in view of the remarks hereinbelow is respectfully requested.

Applicant thanks Examiner Fan for kindly granting an interview to discuss the subject matter of this application with the undersigned attorneys and representatives of

BEST AVAILABLE COPY

AB Hassle. This paper will serve as a summary of the interview. At the interview, the methodology of stability testing and the mechanism of degradation of neutral omeprazole and the claimed salts were discussed to demonstrate to the Examiner why the claimed anionic salts are more stable. The Examiner, however, requested a showing to counter the points in the Official Action including her belief that salts are generally more stable than neutral compounds.

Claims 1-4 and 16-31 stand rejected under 35 U.S.C. § 103 as obvious over U.S. Patent No. 4,472,409 to Senn-Bilfinger, European Patent Application 5,129, European Patent Application 45,200 and U.S. Patent No. 4,323,567 to Narisada et al. The Examiner has argued that the claimed base addition salts of omeprazole would have been obvious over the cited disclosures of omeprazole in neutral form and of salts of omeprazole analogs. To overcome this argument, applicant submitted data showing the superior stability of the claimed salts relative to the cited prior art. In the outstanding Official Action, the Examiner cited five reasons why this stability evidence was not considered persuasive. Each of these reasons is addressed hereinbelow.

The Examiner's first reason for finding the stability evidence unpersuasive was based on her doubts as to whether the testing methods represented appropriate art recognized procedures. In particular, she questioned the use of elevated temperature and humidity in the tests, and requested the submission of appropriate references.

To demonstrate the art-recognized nature of the test methodology used, applicant encloses a copy of an FDA document entitled "Draft Guideline for Stability Studies for

Human Drugs and Biologics" March 1984 (Exhibit A) and an excerpt from Connors et al., Chemical Stability of Pharmaceuticals (Exhibit B). Looking first to the FDA Guidelines, it can be seen on page 1 that "accelerated testing" is a recognized method of testing drugs under "exaggerated storage conditions." In particular, page 4 of the FDA Guidelines points out that these exaggerated conditions should include, inter alia, open and closed containers, variable temperature and variable humidity. Similarly, page 109 of Connors et al. shows typical stability testing programs which includes testing at 37°C and 50°C.

From these references, it is clear that accelerated testing of drug decomposition is an art-recognized procedure for obtaining stability results within a reasonable period of time. Thus, the data submitted in the Declaration of Ake Gunnar Pilbrant should not be discounted on this ground. A revised declaration incorporating these references will be filed as soon as it is received from Sweden.

The Examiner's second argument is that there is no general rule to correlate oxidative decomposition with thermal decomposition. This statement is entirely correct, but it is not at all clear what relevance it has to the probative value of the evidence submitted which show both oxidative and thermal decomposition. In the declaration, results were presented for samples stored in closed containers at 50°C (thermal), and for samples stored in open containers at 37°C and 80% humidity (oxidative) precisely because oxidative decomposition and thermal decomposition rates do not necessarily correlate well. Under both oxidative and thermal stress, neutral omeprazole was substantially

less stable after six months storage than any of the claimed salts stored under the same conditions.

The third reason offered by the Examiner for maintaining the rejection concerns the magnitude of the difference in stability between the neutral compound and the claimed salts. The Examiner argues that the formation of 4 to 6% degradation products for neutral omeprazole as compared to less than 2% for the omeprazole salts is a difference of degree and not of kind. Applicant respectfully disagrees.

In dealing with drugs for human use, the amount of degradation which can be tolerated is quite low. For example, most authorities (e.g. FDA) will accept drugs which include up to about 0.5% of a degradation product during the shelf life of the product. If the amount of degradation product exceeds 0.5%, however, the degradation product must be identified, synthesized and fully tested for safety, including long-term toxicology testing in at least two animal species. Accordingly, it follows that even a small difference in stability can have a significant impact on the ultimate usefulness of a compound as a drug.

Moreover, drugs which degrade to form highly colored degradation products can be limited for use in finished drug products, even if the amount of degradation product is less than the 0.5% limit. An objective measure of such discoloration is the spectrophotometric absorbance of a solution of the drug at the wavelength of visible light. The most frequently used wavelength is 440 nm.

In comparing the discoloration due to degradation of neutral omeprazole with that of the claimed salts, one finds that the neutral compounds exhibit substantial

discoloration while the color of the salts in de minimis. For example, 2% solutions of neutral omeprazole, sodium omeprazole, and magnesium omeprazole were prepared following various periods of storage at 25°C and the absorption was measured. These results are summarized in Table 1.¹ Visually, the omeprazole sample after 24 months has a strong red color, while the omeprazole salt solutions are practically colorless.

TABLE 1

Absorbance of 2% solutions at 440 nm and 500 nm using 1-cm. cells

Storage Time (Months)	Omeprazole	Omeprazole Sodium Salt	Omeprazole Magnesium Salt
	440 nm	500 nm	440 nm
24	0.44 [*]	0.22	
25			0.009
26			0.06
36	1.68	0.84	

* calculated from the measured value at 500 nm/24 months and the absorptivity ratio at 36 months.

From this comparison, it can be seen that the stability differences described between omeprazole and the claimed salts are not merely differences of degree, but in fact have a significant impact on the usefulness of the compounds as therapeutic agents. Accordingly, the improved stability of omeprazole salts presented in the declaration of Ake Gunnar Pilbrant is a significantly superior and unexpected result.

¹ The new declaration which is being prepared will set forth this data and will be submitted as soon as it is available from Sweden.

The fourth ground for maintaining the rejection is the Examiner's belief that the test results are not commensurate with the scope of the claim. In particular, the Examiner has argued that titanium salts, $N(R^1)_4^+$ salts, and $C(NH_2)_3^+$ salts are different and cannot be extrapolated from the results presented for monovalent and divalent salts. In view of this argument, claim 1 has been amended to recite only lithium, sodium, potassium, magnesium and calcium salts, such that this argument clearly no longer applies to claims 1-4 and 16-31. Because applicant disagrees with the argument, however, claims 32-36 have been added reciting just the titanium, tetraalkyl ammonium, and triaminocarbonium salts.

The Examiner has argued that the salts of claims 32-36 are distinct from those tested, but has not provided a rational scientific basis for this position. For example, the charge of the cation alone cannot be said to be a distinguishing feature since two of the cations objected to are monovalent like sodium which was tested. Moreover, in view of the mechanism of decomposition of neutral omeprazole explained at the interview which involves a charged intermediate which is not readily reached from the omeprazole anion, there is a reasonable basis to expect that all of the claimed salts will exhibit enhanced stability regardless of the valence or identity of the cationic counter ion.

The Examiner's final reason for maintaining her rejection is her belief that base addition salts would be expected to be more stable. In support of this position she cites Narisada et al. (Col. 3, lines 43-48) which states that salts of cephalosporins are selected from the view point of safety, solubility, and stability etc. This passage does not

in fact teach anything about the relative stability of salts, but rather teaches that if a salt is to be used, then the particular salt should be selected in view of safety, solubility and stability considerations.

Even if Narisada did teach that salts of cefalosporins were more stable than the neutral compounds, however, this still would not provide any teaching of relevance to omeprazole, because there is no general rule in chemistry that base addition salts are more stable. In fact, there is no reliable way of predicting the influence of a particular salt species on the behavior of the parent compound (Exhibit C, Page 1), particularly in the absence of knowledge of the degradative pathway (Exhibit C, Page 9).

The chemical stability of drug substances in solid state or in solid pharmaceutical systems, e.g. tablets and capsules, is influenced by numerous factors. The most important factors affecting stability are the presence of moisture, the storage temperature, and exposure to light and air. Furthermore, various pharmaceutical excipients such as buffer substances may affect the chemical decomposition. The chemical form of the drug, i.e. whether it is an acid, a base, or a salt, can also have a profound influence on chemical stability.

Drug substances may decompose by various mechanisms, the most common of which are hydrolysis and oxidation. For degradation of drugs in solid systems, hydrolysis takes place in solution in moisture absorbed as a thin film on the surface of the solid. Oxidation can occur either in solution or in the absence of moisture.

Depending on the route of degradation, a salt of an acidic or basic drug may decrease or enhance the stability of


the drug. Most often, however, a salt of a drug appears to be more unstable than the neutral form. The principal reason for this is the fact that salts are often more water soluble than the neutral form. Therefore, such salts have a greater ability to dissolve and react in an adsorbed moisture layer. Furthermore, for oxidation sensitive drugs, the ionized salt form is generally more reactive than the unionized neutral form.

Specific examples of such behavior are available from the scientific literature. Many base addition salts are actually less stable than the neutral compounds. For example, aspirin salts are less stable than neutral aspirin (Exhibit D, Page 1054), and sodium ascorbate is less stable than ascorbic acid (Exhibit E, Page 231).

This argument that the stability of the claimed omeprazole salts is unexpected has been incorporated in a Rule 132 declaration by Dr. Hans Bundgaard which will be submitted as soon as it is received in executed form. This declaration clearly states that salts of acidic drugs appear to generally be more unstable than the neutral form.

In view of these remarks, and the two declarations to follow, the grounds for rejection are overcome. Reconsideration and allowance of claims 1-4 and 16-36 are respectfully requested.

Respectfully submitted,


M. Andrea Ryan
Patent Office Reg. No. 28,469

Marina T. Larson
Patent Office Reg. No. 32,038

Attorneys for Applicant
(212) 408-2580

Enclosures

CHAPTER 4

IMIDAZOLES AND CONDENSED IMIDAZOLES

EDGAR S. SCHIPPER and ALLAN R. DAY

University of Pennsylvania

CONTENTS

	PAGE
INTRODUCTION.....	196
IMIDAZOLES.....	196
Nomenclature.....	196
Structure of Imidazole.....	197
Tautomeric Nature of the Imidazole Nucleus.....	198
Aromatic Character of the Imidazole Nucleus.....	199
Directive Influence of Substituents.....	202
Association of Imidazoles.....	204
Reactions of Imidazoles.....	204
Salt Formation.....	204
Substitution of the Imino Hydrogen Atom.....	205
Oxidation.....	206
Hydrogenation.....	207
Halogenation.....	207
Nitration and Sulfonation.....	208
Coupling with Diazonium Compounds.....	208
Hydroxymethylation.....	208
Preparation of Imidazoles.....	209
Dehydrogenation of Imidazoles.....	209
The Debus Method and Modifications.....	209
The Mequenne Method.....	212
From N,N'-Dialkylloxanides (Wallach Synthesis).....	213
Formation of Imidazoles from Oxazoles.....	214
The Marchwald Synthesis.....	214
Preparation of Imidazole-5-carboxylic Acid Esters from Glycine and Substituted Glycine Esters.....	218
Synthesis of Imidazoles from Amidines.....	219
Synthesis of Imidazoles from Amino Nitriles and Aldehydes.....	221
Synthesis of 2,4,5-Triarylimidazoles from Aromatic Aldehydes and Ammonia.....	221
Preparation of Aminoimidazoles.....	223
Biologically Important Compounds Containing the Imidazole Nucleus.....	224
Histamine.....	224
Antihistaminic Agents.....	228
Histidine.....	229

Compounds Related to Histidine.....	233
The Pilocarpine Alkaloids.....	235
IMIDAZOLINES.....	238
Syntheses of Imidazolines.....	239
Direct Reaction between Acids and 1,2-Diamines.....	239
Cyclization of 1,2-Diamides.....	240
Imidazolines from Ethylenediamine and Ethylenethiourea.....	240
Imidazolines from Nitroguanidine and Ethylenediamine.....	240
Pharmacological Uses of 2,3-Imidazolines.....	243
Industrial Uses of Imidazolines.....	244
IMIDAZOLIDONES.....	245
Oxo Derivatives of Di- and Tetra-hydropyrimidazoles.....	245
Imidazolidones.....	245
Syntheses of 2-Imidazolidones.....	246
Cyanate Method.....	246
Urea Method.....	246
Properties and Reactions of 2-Imidazolidones.....	247
Synthesis of 4(3)-Imidazolidones.....	248
Imidazolidones.....	250
Syntheses of 2-Imidazolidones.....	250
Biotin.....	251
Syntheses of 4-Imidazolidones.....	254
Hydantoin.....	254
Syntheses of Hydantoin.....	256
From α -Amino Acids or Their Ethyl Esters.....	256
From Amino Nitriles.....	258
Bucherer Synthesis.....	258
From Malonamides.....	260
Other Methods for Preparing Hydantoin.....	260
Medicinal Uses of 5,5-Disubstituted Hydantoin.....	262
Allantoin.....	262
Inimothydantoin, Glycocyamine, and Creatine.....	263
Diminothydantoin, Porphyrin, and Porphyrindin.....	265
Triketonimidazolidines.....	266
Parabanic Acid.....	266
CONDENSED OR FUSED AROMATIC IMIDAZOLE RING SYSTEMS.....	267
Benzimidazoles.....	267
Nomenclature.....	267
Properties and Reactions.....	267
Tautomeric Nature of Benzimidazoles.....	268
Association of Benzimidazoles.....	268
Substitution of the Imino Hydrogen Atom.....	269
Oxidation.....	270
Hydrogenation.....	270
Substitution in the Benzene Nucleus.....	270
Reactions of 2-Aminobenzimidazole.....	271
Reactions of 2-Methylbenzimidazole.....	272
Reactions of Benzimidazole-2-carboxylic Acid, Benzimidazole-2-acetic Acid, and Benzimidazole-2-propionic Acid.....	273
Reactions of 2-(α -Chloroalkyl)benzimidazoles.....	274

CHAPTER 6

Solid-State Chemical Decomposition

7. W. J. M. Underberg, *J. Pharm. Sci.*, **67**, 1133 (1978).
8. L. Fryklof, *Farm. Rev.*, **53**, 317 (1954). Also discussed by S. A. Shou, *Am. J. Hosp. Pharm.*, **17**, 153 (1960).
9. J. Philip and D. H. Szulcowski, *J. Pharm. Sci.*, **62**, 1479 (1973).
10. H. Okada, V. Stella, J. Haslam, and N. Yata, *J. Pharm. Sci.*, **64**, 1665 (1975).
11. L. J. Ravin, L. Kennon, and J. V. Swintosky, *J. Am. Pharm. Assoc., Sci. Ed.*, **47**, 760 (1958).
12. *The United States Pharmacopoeia*, 19th rev., (USP XIX), 1975, p. 643.

The chemical decomposition of drugs in the solid state, has been the subject of many papers and reviews. However, the mechanism whereby drugs degrade in their pure solid forms is still a matter of debate. The problem is further complicated when the drug is formulated in a complex matrix such as a tablet or capsule; now, not only may the drug itself be intrinsically unstable, but the various excipients (lubricants, fillers, binders, etc.) may act as reactants or catalysts.

In all the earlier chapters, chemical decomposition in solution usually followed pseudo-first-order kinetics. When the same drugs were formulated as suspensions their overall degradation followed pseudo-zero-order kinetics because only that fraction of the drug in solution underwent chemical degradation. In the same way, solid state drug degradation mainly occurs in a solution phase, that is, in solvent layers associated with the solid phase. The source of the solvent for the solid-state decomposition reaction may be

- (a) a melt from the drug itself or an ingredient in the formulation that has a low melting point;
- (b) residual moisture or solvent from wet granulation;
- (c) moisture adsorbed onto excipients such as starch, lactose, or microcrystalline cellulose;
- (d) adsorbed atmospheric moisture; or
- (e) a solvate or hydrate that loses its "bound" solvent with time or temperature fluctuation.

Since only a fraction of the solid drug is in solution in the tablet, the overall loss of drug often follows pseudo-zero-order kinetics. However, as will

Copyright © 1979 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

Library of Congress Cataloging in Publication Data:

Connors, Kenneth Antonio, 1932-
Chemical stability of pharmaceuticals.

"A Wiley-Interscience publication."

Includes bibliographical references and index.

1. Drug stability. I. Amidon, Gordon L., joint author. II. Kennon, Lloyd, 1929- joint author.
III. Title. [DNLM: 1. Drug stability—Handbooks.
2. Kinetics—Handbooks. QV38 C572c]

RS189.C628 615'.19 78-1759
ISBN 0-471-02653-0

Printed in the United States of America.

10 9 8 7 6 5 4 3

81/207

Hässle
Biblioteket

Assumption: E_a for the drug decomposition is constant over the entire temperature range, that is, from the highest temperature experimentally studied to the extrapolation temperature (usually 25°).

Criterion: $E_a = 10$ kcal/mol and 20 kcal/mol provide reasonable and conservative limits for the temperature dependence of the reaction.

Criterion: The shelf-life is the time for product content to decrease to 90% of initial value or label claim.

This assumption is subject to experimental verification, and the criteria can be altered by the formulator to suit the requirements of a particular problem. The slopes of the lines in Figure 6.1 (which is essentially an Arrhenius plot) are determined by the chosen E_a values. The vertical displacement of the lines is controlled by the definition of shelf-life. Thus if more than a 2-yr goal estimate were desired, lines parallel to each of the curves in Figure 6.1 could be drawn that would meet the room-temperature abscissa at 36, 48, or 60 mo. Then a whole new plan of action could be generated analogous to the one described here.

C. STABILITY PROTOCOL

1. General Considerations

Although there is extensive variation in the stability-assessment programs within the pharmaceutical industry, we give some general considerations and an example of a stability protocol.

The main variables to be considered in a stability program are temperature, light, and moisture. In addition, container properties, preservative (microbial) stability, and physical characteristics (color, hardness, etc.) are part of many programs. The effect of light is usually studied in a light cabinet using clear and amber bottles, the effect of moisture by varying the relative humidity, and the effect of temperature in constant temperature cabinets.

A typical program might be as shown in Table 6.III where an X indicates that a sample is to be taken and

ion is constant
a range, that
nature experi-
trapolation

al/mol provide
e limits for the
the reaction.

for product
of initial

rim tal verifi-
by the formula-
cular problem.
which is essen-
d by the chosen
of the lines is
life Thus if
sired, lines
re 6.1 could be
ture abscissa at
in of action
e described here.

tion in the sta-
pharmaceutical
rations and an

ed in a stability
isture. In addi-
ve (microbial)
s (color, hard-
The effect of
binet using clear
ure by varying
of temperature in

own : Table 6.III,
to L taken and

assayed at that time. Samples may be also stored at high humidity (>65%), a cycling test may be included, for example, 1 day at 10°C followed by 1 day at 30°C, and so on, and an actual shipping test, in which the product is shipped to a warehouse for a period of time and then returned for assay, may be included. Although the expiration date should be based on room temperature (or a specified temperature) data, the high-temperature data are often used to make preliminary estimates of the expiration date as discussed in the preceding section.

TABLE 6.III. Typical Stability-sampling Program

t (°C)	Sample time (mo)											
	0	1	2	3	4	6	12	18	24	36	48	60
4°							X		X			
25°	X	X		X		X	X	X	X	X	X	X
37°		X	X	X	X	X			X			
50°		X	X	X	X							

The protocol discussed here is typical for new product formulations. In many cases a more limited program could be used when, for example, minor formulation changes are made or a new container is to be introduced.

2. Experimental Designs

ORI 9600-2

During the development of formulations, several formula variables are studied. Examples of these are flavors, colors, antioxidants, surfactants, chelating agents, buffers, and pH values. Normally these factors are studied by varying them in two ways, that is, by changing their concentrations (or level, as in the case of pH), or by omitting them from one formula and including them in another. It is obvious that trying to study too many variables simultaneously results in the need to make a large number of formulations to

Effect of Silica Gel on Stability and Biological Availability of Ascorbic Acid

Exhibit E

10

E. De RITTER, L. MAGID, M. OSADCA, and S. H. RUBIN

Abstract □ The alleged interaction of silica gel and ascorbic acid has been investigated in model experiments and in practical tablet trials, using wet granulation procedures. In simple mixtures stored for 3 weeks at 45° in closed tubes, losses of ascorbic acid increase progressively with increasing moisture content, whether or not silica gel is present, although losses are higher in the presence of silica gel. At an equivalent percentage of water in such mixtures, the amount of silica gel or the prior adsorption of 1½ times its weight of vitamin E on the silica gel, did not influence the loss of ascorbic acid. The data show that silica gel binds a certain fraction of the water present and that the loss of ascorbic acid is directly proportional to the amount of unbound water in the system. Sodium ascorbate is more sensitive than ascorbic acid to aerobic oxidation in the presence of moisture. Other commonly used tablet excipients, as well as silica gel, enhance losses of ascorbate. However, proper technology applied to wet granulation procedures yields excellent recoveries and stability of ascorbic acid or sodium ascorbate in dried granulations and in finished multivitamin tablets. The human bioassay technique, in which extra urinary excretion of ascorbic acid after tablet dosage is compared to that after dosage of ascorbic acid in water, has been used to demonstrate the full physiological availability of ascorbic acid in the presence of silica gel. Storage of such tablets for 3 months at 45° did not alter the complete bioavailability of the ascorbic acid.

Keyphrases □ Ascorbic acid—stability, biological availability □ Stability, ascorbic acid—humidity, excipient effects □ Silica gel effect—ascorbic acid stability, bioavailability □ Moisture concentration—ascorbic acid stability □ Biological availability, ascorbic acid—silica gel effect

Diffuse reflectance spectroscopy has been used by Lach and Bornstein (1-3) to study interactions of a number of drugs with various adjuvants after treatment of the mixtures by equilibration in aqueous or nonaqueous media, by compression, and by exposure to controlled humidity conditions. Such an interaction of ascorbic acid and silica gel has been claimed by Lach (4). Since silica gel is a useful adsorbent for converting liquid vitamins such as vitamin E and panthenol into free-flowing, dry powders, it became important to evaluate this alleged interaction of silica gel with ascorbic acid. This has been done in model experiments with simple mixtures and under practical conditions of formulating multivitamin dosage forms. In addition, physiological availability tests in humans have been utilized to check for possible influence of silica gel contained in multivitamin tablets on the biochemical behavior of ascorbic acid.

EXPERIMENTAL

Model Experiments—(a) *Effect of Graded Moisture Levels*—Experimental mixtures of ascorbic acid with silica gel¹ and with 60% adsorbate of *d,l*- α -tocopheryl acetate on silica gel were prepared both at normal use ratios and at an eightfold higher than normal

¹ Syloid 244, W. R. Grace & Co., Davison Chemical Div., Baltimore, Md.

adsorbent/vitamin ratio. Ascorbic acid alone and the various mixtures were adjusted with distilled water to graded moisture levels up to 40% and stored in closed tubes for 21 days at 45°. The percentage of water added was based in each case on the total weight of the tube contents, except for the vitamin E adsorbate mixtures where the weight of the oil phase was not included. The compositions of the mixtures before addition of water are shown in the legend of Fig. 1. Ascorbic acid was determined after storage by titration with about 0.1 *N* standard iodine solution and starch indicator.

(b) *Rate of Loss of Ascorbic Acid and Sodium Ascorbate at 45° with 11.6% Water*—The stress conditions used in Experiment (a), namely 3 weeks at 45° at high moisture levels, are obviously much more strenuous than those normally encountered in pharmaceutical manufacturing operations, such as wet granulation procedures, in which drying is completed in a much shorter period. It was of interest, therefore, to check the rate of decomposition of ascorbic acid in similar mixtures stored for 1, 2, and 3 days at 45° at one of the lower levels of moisture, namely 11.6%.

Ascorbic acid and the ascorbic acid plus silica gel mixture used in this test, when shaken with water at a concentration of about 20 mg. of vitamin C per ml., yielded a pH of 2.3 and 2.4, respectively. Sodium ascorbate with and without silica gel, at similar dilutions in water, gave a pH of 6.7 with silica gel and 7.2 without. The same stability tests were set up with sodium ascorbate with and without silica gel at 11.6% water.

(c) *Effect of Other Tablet Excipients*—The relative effect of other excipients commonly used in tablets has been compared to that of silica gel in a test similar to that in (b). Three hundred milligrams of sodium ascorbate were mixed with 80 mg. of the particular excipient and water added to give 11.6% by weight. The mixtures were stored in closed tubes for 3 days at 45° and ascorbate determined by iodine titration.

Granulation and Tablet Trials—Multivitamin mixtures containing ascorbic acid or sodium ascorbate and silica gel adsorbates of vitamin E were made by wet granulation procedures with and without iron. To minimize exposure to moisture stress, the granulations were milled through a No. 6, round-hole screen to the minimum practical particle size and dried in layers of 1.27 cm. (0.5 in.) or less with rapidly moving, 45° air. Vitamin C recoveries were determined for the granulations and finished tablets made from these granulations, using iodometric titrations. Stability of vitamin C was determined similarly after accelerated and room temperature storage.

Availability Studies in Men—It has been pointed out (1-3) that drug-adjuvant interactions possibly may result in significant altera-




Figure 1—Effect of silica gel on stability of ascorbic acid at graded percent moisture levels; mixtures stored in closed tubes for 3 weeks at 45°. Key: ●, 300 mg. ascorbic acid alone; ○, 300 mg. ascorbic acid + 80 mg. silica gel; X, 300 mg. ascorbic acid + vitamin E adsorbate (80 mg. silica gel + 120 mg. *d,l*- α -tocopheryl acetate); X, 300 mg. ascorbic acid + 640 mg. silica gel.




Figure 2 Effect of silica gel on stability of ascorbic acid with graded weights of water added; mixtures stored in closed tubes for 3 weeks at 45°. Key: O, 300 mg. ascorbic acid alone; ●, 300 mg. ascorbic acid + 80 mg. silica gel; X, 300 mg. ascorbic acid + 640 mg. silica gel.

tions of the biochemical behavior of a medicament. Although such effects are more likely to occur at low drug to adjuvant ratios, the possible existence of the excipient as a chemisorbed layer on the drug has been mentioned as a factor that might cause similar effects at high drug to adjuvant ratios (2). To determine whether silica gel in a tablet would influence the physiological availability of ascorbic acid, the human bioassay technique described by Melnick *et al.* (9) was applied to several tablet formulations. In this test, comparison is made between the extra urinary excretion of the vitamin following dosage with the test sample and that following administration of the vitamin in pure form.

Five male subjects were saturated with ascorbic acid by daily dosing with 500 mg. for 3 weeks. Dosing with test samples and standard was not initiated until a stable plateau had been obtained for the 24-hr. urinary excretions following a 500-mg. dose, given after 2 days without dosing. Two different tablet formulations as listed in Table VI were tested, both containing vitamin E at a level of 30 mg. per tablet in the form of silica gel adsorbate. The standard dose of pure ascorbic acid taken in water was 450 mg. For the initial test, the dose taken was six tablets (453 and 466 mg. ascorbic acid for the Lot Nos. 73-69/1 and 73-69/3, respectively). For the aged sample, seven tablets (430 mg. ascorbic acid) were given.

One test was performed each week with basal urine collected on the day prior to taking each test dose. After dosage with ascorbic acid alone or in tablets, respectively, urine was collected for the periods 0-6 hr. and 6-24 hr., except for Dose 2 of ascorbic acid where only total 24-hr. collections were made. Basal urines were collected in each case according to the same schedule. Ascorbic acid in urine was determined by the dichlorophenol-indophenol-xylene extraction method, as previously described (10). In each case the extra excretion due to dose was calculated by subtracting the corresponding basal excretion value from the value after dose.

RESULTS AND DISCUSSION

Model Experiments—Effect of Graded Moisture Levels—The results of storage tests on the ascorbic acid plus silica gel mixtures at graded moisture levels for 3 weeks at 45° are shown in Fig. 1. Ascorbic acid alone shows progressively increasing storage losses with increasing moisture content. At low moisture levels (below 6%), no significant difference could be determined between samples with or without silica gel. At higher moisture levels, the losses increase with increasing moisture content in mixtures containing silica gel and are higher than those found with ascorbic acid alone. It is noteworthy, however, that at any percentage moisture level, an eightfold increase in the ratio of silica gel to ascorbic acid caused no




Figure 3 Effect of free water level on stability of ascorbic acid in mixtures with or without silica gel; storage in closed tubes for 3 weeks at 45°. Key: O, 300 mg. ascorbic acid alone; ●, 300 mg. ascorbic acid + 80 or 640 mg. silica gel.

further increase in the ascorbic acid loss above that observed at the lower silica gel level in the 3 weeks at 45° storage tests. This lack of concentration effect of silica gel suggests strongly that the degradation of ascorbic acid is not due to surface interaction. Further, when 60% vitamin E oil was adsorbed on the silica gel, no change in the stability of ascorbic acid was observed. Thus is due undoubtedly to the strongly hydrophilic nature of this adsorbent.

It is of interest to examine the data in Fig. 1 in terms of the losses of ascorbic acid found at equivalent weights of water in the mixtures, rather than at equivalent percentages of water. This type of plot is given in Fig. 2. The circumstance that the higher proportion of silica gel exerts a protective effect indicates that some binding of water by the silica gel is taking place and suggests that the ascorbic acid losses are related to the amount of unbound or free water in the various mixtures. If this is true, then the equivalence of the ascorbic acid losses at the high and low silica gel levels at any particular percentage of moisture would indicate an equivalent amount of free water in these two mixtures.

Assuming that the silica gel binds water as a fixed fraction of its own weight at any given percentage of water, calculation has been made of the fraction that must be bound at both the 80 and 640-mg. silica gel levels in order to yield equal weights of free water at these two levels. A typical calculation is given below for the 25% water level in both mixtures, the compositions of which are as follows: (a) 80 mg. silica gel, 300 mg. ascorbic acid, and 127 mg. water; (b) 640 mg. silica gel, 300 mg. ascorbic acid, and 313 mg. water. If X = bound water level (expressed as percent of silica gel weight) which will yield the same weight of free water for both mixtures, then in both cases the total water minus bound water = free water, and

$$127 - 80 \times \frac{X}{100} = 313 - 604 \times \frac{X}{100}$$

from which $X = 33.2$. Then milligrams of bound water are: (a) $80 \times 0.332 = 26.6$ and (b) $640 \times 0.332 = 212.6$, and milligrams of free water are: (a) $127 - 26.6 = 100.4$ and (b) $313 - 212.6 = 100.4$.

These percentages of bound water and the corresponding weights of free water at the various total water levels are listed in Table I, together with the respective losses of ascorbic acid taken from the curve in Fig. 1. Values at the lower moisture levels are not included in Table I since the magnitude of the ascorbic acid losses in this range of water content is not sharply defined, due to the difficulty of mixing the small quantities of water uniformly, the greater error inherent in the small differences in titrations before and after storage, and the possible effect in some cases of a moisture loss during storage.

Table I—Effect of Moisture Content on Stability of Ascorbic Acid in Presence of Silica Gel*

H ₂ O Added, %	H ₂ O Added, mg. 80 mg. S.G.	H ₂ O Added, mg. 640 mg. S.G.	Bound H ₂ O S.G. wt., %	80 or 640 mg. S.G. Free H ₂ O, mg.	Loss A. A., %
25.0	127	313	33.2	100.4	31.3
29.4	159	392	41.6	125.7	39.7
33.3	190	470	50.0	150.0	47.0
36.9	222	550	58.6	175.0	54.6
40.0	254	627	66.6	200.7	62.3

* Ascorbic acid (A.A.), 300 mg. + 80 or 640 mg. silica gel (S.G.) + indicated percent H₂O storage in closed tubes for 3 weeks at 45°.




Figure 4—Rate of loss of vitamin C in presence of silica gel; storage in closed tubes at 45° with 11.6% water. Key: Δ , 300 mg. ascorbic acid alone; \triangle , 300 mg. ascorbic acid + 80 mg. silica gel; \circ , 300 mg. sodium ascorbate alone; \bullet , 300 mg. sodium ascorbate + 80 mg. silica gel.

The excellent correlation between weights of free water in the mixtures and losses of ascorbic acid is shown by the plot of Fig. 3. The losses of ascorbic acid are directly proportional to the calculated amounts of free water in the mixtures. For the sake of comparison, the data on the ascorbic acid plus water mixtures without silica gel are plotted in Fig. 3. The slope of the latter line is smaller than that of the ascorbic acid + silica gel + water mixtures. Again, in view of the fact that equal losses are found with a given weight of ascorbic acid over an eightfold range of silica gel plus bound water weights, it appears highly unlikely that surface reaction is a significant factor responsible for the higher losses of ascorbic acid in the presence of silica gel. It is believed more likely that trace metals such as iron and copper, which are present in silica gel to the extent of 110 and 1 p.p.m., respectively, are dissolved by the water and exert their well-known catalytic effect on ascorbic acid decomposition in solution (5, 6). Trace metals in the ascorbic acid (less than 10 p.p.m.) are present to the same extent in the tubes with or without silica gel. This mode of decomposition of ascorbic acid is in contrast to that reported by Carstensen *et al.* (7) for thiamine in solid dosage forms, where losses occur in an adsorbed surface monolayer of thiamine dissolved in water.

Rate of Loss of Ascorbic Acid and Sodium Ascorbate at 45° with 11.6% Water.—These data are shown in Fig. 4. The loss of ascorbic acid alone in 3 days at 45° is only about 1%; in the mixture with silica gel the loss in this period is 3.6%. This small effect of silica gel in the 3-day test shows the same trend as described previously for the 3-week test.

The losses of sodium ascorbate, both with and without silica gel, are considerably higher than those found with ascorbic acid. This is to be expected in view of the fact that aerobic oxidation of ascorbic

Table II—Influence of Various Excipients Plus Water on Stability of Sodium Ascorbate*

Excipient	Loss of Ascorbate, %
None	14.5
Cornstarch	16.4
Dicalcium phosphate anhydrous	17.7
Dicalcium phosphate dihydrate (milled)	19.0
Avicel	18.3
Silica gel	22.0
Tricalcium phosphate	25.3

* Excipient 80 mg. + 300 mg. sodium ascorbate + 11.6% water; storage for 3 days at 45°.

Table III—Recovery of Ascorbic Acid in Granulation and Tablets*

Lot No.	Vitamin E, %	Excipient Added	Recovery Theoretical, % Granulation	Recovery Theoretical, % Tablets
73-69-1	33	Dicalcium phosphate dihydrate	98	98
73-69-3	60	Same	100	100
73-69-5	60	Dicalcium phosphate anhydrous	100	100
73-69-6	60	Tricalcium phosphate	100	99

* Theoretical content: vitamin C = 77 mg.; vitamin E = 30 mg. * Adsorbate of *d,l*- α -tocopheryl acetate on silica gel.

Table IV—Stability of Na Ascorbate in Granulation with Vitamin E Containing Silica Gel

Storage Test	Na Ascorbate, Theoretical, % Lot 811-58	Na Ascorbate, Theoretical, % Lot 811-59
Initial	97	98
3 weeks at 25	98	96
3 weeks at 45	96	96
3 weeks at 55	96	96

Table V—Stability of Ascorbic Acid in Coated Multivitamin Plus Iron Tablets

Storage Test	Ascorbic Acid, Theoretical, % Maintenance Formula*	Ascorbic Acid, Theoretical, % Therapeutic Formula*
1 month at 55	100	91
3 months at 45	100	94
6 months at 37	97	88
12 months at 25	100	94

* Contains 30 mg. of *d,l*- α -tocopheryl acetate per tablet as a 33% adsorbate on silica gel. * Contains 30 mg. of *d,l*- α -tocopheryl acetate per tablet as a 60% adsorbate on silica gel; both formulas have a theoretical ascorbic acid content of 77 mg. per tablet.

acid in the presence of metallic catalysts proceeds more slowly in acid solution than in neutral solution (8).

Effect of Other Tablet Excipients.—The losses of ascorbate in the presence of the various excipients at 11.6% water are listed in Table II. Like silica gel, all these other excipients also increase the loss of ascorbate. The magnitude of the effect is undoubtedly dependent on the factors discussed above, including pH, water-binding capacity of the adjuvant, and trace metal content.

Granulation and Tablet Trials.—Table III shows the excellent recoveries of ascorbic acid in dried granulations properly formulated with high levels of vitamin E in the form of silica gel adsorbates. Table IV similarly shows the excellent stability of sodium ascorbate in two dried granulations.

Finished tablets prepared by suitable techniques also show good stability of vitamin C in the presence of silica gel. This is demonstrated by the data in Table V on ascorbic acid stability in tablets prepared with 33 and 60% adsorbates of *d,l*- α -tocopheryl acetate on silica gel.

It has long been known that the sensitivity of vitamin C to oxidation in the presence of moisture is a factor that must be considered in the preparation of multivitamin tablets by wet granulation procedures. This is true whether or not silica gel is present in the granulation. In granulations containing appreciable quantities of silica gel and/or excipients, which are also potential contributors to vitamin C breakdown, it is possible to obtain excellent recovery of either ascorbic acid or sodium ascorbate by suitable wet granulation procedures. However, it is essential that the moisture level be held to the minimum level for effective granulation and that drying be carried out promptly and efficiently.

Table VI—Physiological Availability of Ascorbic Acid from Tablets Containing Silica Gel—24-hr. Test

Subject	Dose (about 450 mg.) Excreted, % Multivitamin Tablets, Vitamin E, 30 mg.				
	Standard Ascorbic Acid Dose		Lot No. 73-69/1 (33% E Adsorbate)		Lot No. 73-69/3 (60% E Adsorbate)
	1	2	Initial	3 mo./45	Initial
BM	45	28	33	32	25
MO	52	57	36	37	46
RG	24	34	41	36	51
JS	39	40	41	53	41
ED	38	36	43	46	39
Average	39.3		38.3	40.8	40.4
Availability \pm SE, %			99 \pm 9	103 \pm 14	104 \pm 13

Table VII Physiological Availability of Ascorbic Acid from Tablets Containing Silica Gel—6-hr. Test

Subject	Standard Ascorbic Acid	Dose (about 450 mg.) Excreted, %		
		Lot No. 73-69/1 (33% E Adsorbate) Initial	3 mo./45°	Lot No. 73-69/3 (60% E Adsorbate) Initial
BM	28	27	27	17
MO	35	25	27	28
RG	18	26	26	37
JS	23	33	28	29
ED	26	29	28	24
Average	26.0	28.0	27.2	26.8
Availability \pm SE, %		108 \pm 13	105 \pm 11	103 \pm 17

Experiences with wet granulation formulations containing ascorbic acid or sodium ascorbate indicate that excellent stability can be achieved if the wet granulation is dried to about 10% moisture within a few hours and to the final, low moisture content within 24 hr.

Order of mixing of ingredients and especially the mode of addition of water can be important. The vitamin C stability may be influenced by the presence of adsorbents that bind water or soluble ingredients that serve as emulsifiers or influence the solubility or reactivity of vitamin C.

Availability Studies in Men—The results of bioavailability tests in men of ascorbic acid in tablets containing silica gel have been calculated on the basis of 24-hr. excretions of test doses. These results are summarized in Table VI. Both lots of tablets show complete bioavailability of the ascorbic acid, and this was not changed by storage for 3 months at 45°. In order to provide information on the question of whether or not silica gel reduces the rate of absorp-

tion of ascorbic acid *in vivo*, calculations of physiological availability also were made on the basis of urinary excretions in the first 6 hr. after dose. These data are given in Table VII. Again, the results show complete availability of ascorbic acid in all three tablet trials, indicating that the ascorbic acid is absorbed normally in the presence of silica gel.

REFERENCES

- (1) J. L. Lach and M. Bornstein, *J. Pharm. Sci.*, **54**, 1730 (1965).
- (2) M. Bornstein and J. L. Lach, *ibid.*, **55**, 1033(1966).
- (3) J. L. Lach and M. Bornstein, *ibid.*, **55**, 1040(1966).
- (4) J. L. Lach, personal communication.
- (5) C. M. Lyman, M. O. Schultze, and C. G. King, *J. Biol. Chem.*, **118**, 757(1937).
- (6) C. F. Timberlake, *J. Sci. Food Agr.*, **11**, 258(1960).
- (7) J. T. Carstensen, M. Osadca, and S. H. Rubin, *J. Pharm. Sci.*, in press.
- (8) A. E. Kellie and S. S. Zilva, *Biochem. J.*, **32**, 1561(1938).
- (9) D. Melnick, M. Hochberg, and B. L. Oser, *J. Nutr.*, **30**, 67(1945).
- (10) S. H. Rubin, F. W. Jahns, and J. C. Bauernfeind, *Fruit Prod. J. Am. Food Mfg.*, **24**, 327(1945).

ACKNOWLEDGMENTS AND ADDRESSES

Received July 18, 1969, from the Product Development Department, Hoffmann-La Roche Inc., Nutley, NJ 07110
Accepted for publication September 23, 1969.

Presented to the Basic Pharmaceutics Section, APhA Academy of Pharmaceutical Sciences, Montreal meeting, May 1969.

The authors wish to express thanks to Mrs. Nancy Ladas and Miss Sandra Economos for assistance in conducting these experiments.

Interfacial Barriers in Interphase Transport II: Influence of Additives upon the Transport of Diethylphthalate Across the Hexadecane-Gelatin-Water Interface

ABDEL-HALIM GHANEM, W. I. HIGUCHI, and A. P. SIMONELLI

Abstract □ The authors recently described a novel method for investigating the effects of an interfacial barrier in interphase transport. The procedures, both theoretical and experimental, were applied to the study of the effects of an adsorbed gelatin at the hexadecane-water interface upon the transport of diethylphthalate between the two phases. The present paper describes the influences of surfactants, electrolyte type, and concentration upon the permeability coefficient for the interfacial barrier. Experiments were conducted as before, employing diethylphthalate as the solute. The transport data were analyzed by the physical model described earlier. The results showed that the two ionic surfactants, sodium lauryl sulfate and dodecylpyridinium chloride, markedly decreased (2 to 12 times) the interfacial barrier even at low concentration

(0.001–0.10% in the stock emulsion). Furthermore, the analysis showed that neither the electrolyte type nor concentration influenced the permeability coefficients, although they significantly altered the interphase transport rates themselves by changing the partition coefficients. These findings are particularly interesting as they may represent types of nonspecific situations that give rise to important barriers in *in vivo* drug transport.

Keyphrases □ Transport, interphase—interfacial barriers □ Diethylphthalate transport—hexadecane-gelatin-water interface □ Electrolyte effect—diethylphthalate transport, hexadecane-gelatin-water interface □ Surfactant effect—diethylphthalate transport, hexadecane-gelatin-water interface □ Permeability coefficients, interfacial barriers—surfactant, electrolyte type, concentration effect.

Recent studies from these laboratories (1, 2) involving the use of a novel method for investigating interfacial barriers in interphase transport have shown that substances adsorbed at the oil-water interface may control the interphase transport rates of solutes. Gelatin ad-

sorbed at the hexadecane-water interface has been shown (1) to give an interphase transport rate for diethylphthalate that is about 1×10^4 times slower than diffusion controlled. A significant reduction in the aqueous to lipid transport rate of cholesterol by an



REVIEW ARTICLE

Determination of the Decomposition of Aspirin

CLARK A. KELLY

Keyphrases ☐ Aspirin decomposition—determination ☐ Decomposition products—aspirin ☐ Hydrolysis, aspirin—mechanism, kinetics, pH effect ☐ Analytical methods—salicylic acid in aspirin and aspirin products ☐ Stability—aspirin and dosage forms

CONTENTS

DETERMINATION OF DECOMPOSITION OF ASPIRIN.....	1053
HYDROLYSIS STUDIES.....	1054
DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS WITH FERRIC IRON.....	1059
DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS BY UV SPECTROPHOTOMETRY.....	1068
DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS WITH THE AID OF A FERRIC-ION CHROMATOGRAPHIC COLUMN.....	1073
DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS BY MISCELLANEOUS METHODS.....	1077

February 27, 1917, the day U. S. Patent No. 644,077 expired, a whole new vista opened to the drug industry. What was, and is, the best seller of all times could easily be classed as the wonder drug of all ages. From the latest available figures of the U. S. Tariff Commission,¹ there would be over 200 tablets available for every man, woman, and child in the United States if all the U. S. yearly production was made into tablets containing 325 mg. (5 gr.) of acetylsalicylic acid, more popularly known as aspirin.

Aspirin has the unique standing in the medical world of still being the most widely used drug, even with the

advent of modern, highly potent therapeutic agents. Aspirin has superior qualities as an antipyretic and as a general analgesic, but more specifically in the relief of headaches, muscular pain, postoperative and traumatic pain, postpartum pain, dysmenorrhea, malignancy, colds and respiratory diseases, rheumatoid arthritis, acute rheumatic fever, and in the field of dental analgesia.

With such a versatile drug, it was obvious that aspirin would be combined with other drugs with the result that a more potent and effective preparation would result. It is the purpose of this review to emphasize the plight that continually plagues the analytical chemist in his constant search for a truly reliable method of measuring the decomposition of aspirin in the presence of other drugs or compounds. What makes this problem even more acute is that aspirin is highly selective of the type of compounds it intimately associates with. In fact, if aspirin acquires even a trace of moisture, it begins to fall to pieces. It thus becomes a problem of product development to finalize a stable formulation that will withstand a "normal" shelflife under all types of adverse conditions such as humidity, temperature, and interreactions with other components, even in the solid state.

DETERMINATION OF DECOMPOSITION OF ASPIRIN

When aspirin was first introduced as a drug, controversies ensued almost instantaneously as to how one could characterize truly good aspirin. Some became experts on detecting trace amounts of acetic acid and so classed the elegance of the aspirin accordingly. Even in those early days, the advertising agencies made the most

¹ From 1968 preliminary report: 31,248,000 pounds of aspirin by U. S. production.

of this purely subjective classification. Very few papers have been presented on the quantitative determination of acetic acid as a decomposition product of aspirin, chiefly because of the known volatility of acetic acid. Unless the original container was completely airtight, one would be measuring only the residual acetic acid, which would not be representative of the total acetic acid formed by the decomposition of the aspirin. General methods evolved in which dry air was passed over and through a thin layer of the finely powdered sample. The acetic acid vapor was trapped in the water and then titrated with very dilute sodium hydroxide. A simpler approach utilized a Conway micro diffusion cell. The more refined approach involved GLC.

It is interesting to note that visually the presence of any whiskers (very thin elongated crystals of salicylic acid) observed on the surface of a solid product containing aspirin is definitely an indication that some of the aspirin has decomposed and that the resulting salicylic acid has sublimed through the solid material. Here, again, if the container is not airtight, the possibility exists whereby the released salicylic acid, through sublimation, would leave the sample area and so not be measured. This crucial point, on the sublimation of salicylic acid, will be discussed more thoroughly in this review. As with most subjective tests, the evaluation of solid aspirin products by the appearance of salicylic acid whiskers is limited. Time is required for this sublimation to take place, so one would not normally apply it to fresh products. Therefore, one could actually have a poorly made aspirin tablet which, on the surface, showed no whiskers but internally had a high content of salicylic acid.

It is the intent of this review, therefore, to pursue a quantitative approach in the determination of the amount of decomposition of aspirin through the presence of salicylic acid rather than acetic acid.


No biological samples, such as blood, containing aspirin will be discussed in this review. Nor will this review include salts of aspirin, such as aluminum aspirin, solutions, or aspirin suspensions. The stability of aspirin in all these cases is definitely limited. The presence of any moisture (with the salts of aspirin, the water of hydration) results in the hydrolysis of aspirin at such a rate that the given formulation does not have a practical or useful shelflife. There is, however, a definite need in the field of pediatrics and geriatrics for a stable liquid formulation of aspirin, because there is no easier or simpler way to give a medicinal than by mouth to infants or to the feeble.

Even limiting this review just to solid preparations leaves a great deal confronting the analyst. A step-by-step evaluation of the approaches published in the scientific literature will be presented. One will readily see the tremendous need for a simple, reliable, universal test for the decomposition of aspirin which can be applied easily and rapidly to a completely unknown preparation containing aspirin.

HYDROLYSIS STUDIES

Decomposition of aspirin results from hydrolysis of the ester group, with the end products being acetic acid

and salicylic acid. The oversimplified reaction for the hydrolysis of aspirin is presented only at this time, so one may visualize the overall picture of the decomposition of aspirin (Scheme 1).



Scheme 1

Those who have made a thorough study of the hydrolysis of aspirin under various well-controlled and stated conditions report that the reaction is very complex. Judged by the number of papers on this subject alone, the reaction is also highly controversial.

The first publication on the hydrolysis of aspirin in water was reported by Rath (1) who conducted his work at an extremely high temperature (100°). As was later found, the hydrolysis of aspirin is very sensitive to temperature changes, even near room temperature. The rate of hydrolysis was determined by titrating the total acidity at stated time intervals. The calculated values indicated a monomolecular reaction. Tsakalotos and Horsch (2, 3) also followed the hydrolysis of aspirin but at more reasonable temperatures (20, 50, and 60°). It took about 100 days to effect complete hydrolysis of aspirin in water at room temperature. Hydrogen ion was found to accelerate the hydrolysis rate, hydrochloric acid being more effective than sulfuric acid. Acetic acid and citric acid caused an initial increase in the rate of hydrolysis; but as the days passed, a decrease in the rate of hydrolysis was noted. The unfounded explanation given by these authors for this slowdown was that the salicylic acid produced was being acylated.

Wolf (4) substantiated the hydrogen-ion effect on the hydrolysis of aspirin by showing that the velocity constant in an acid medium (diluted hydrochloric acid) doubled over that of just water.

Aspirin was solubilized in water at room temperature by Morton (5) with the aid of potassium and sodium citrates and acetates. The degree of hydrolysis was followed by titrating the samples with standard alkali at stated time intervals. The rate of hydrolysis was reported to be independent of not only the concentration of the aspirin but also of the solubilizing salt concentration.

Saponification (alkaline hydrolysis) of aspirin was reported by La Mer and Greenspan (6) at $25.000 \pm 0.005^\circ$. The reaction was stopped by making the given sample (not an aliquot of the bulk solution as is the usual approach in hydrolysis studies) acidic with standard sulfuric acid. The excess acid was then titrated with 0.02 *M* sodium hydroxide. It is assumed that this back titration was conducted immediately; otherwise, hydrolysis of aspirin in the strongly acidic medium would become an unwanted factor in the calculation of the saponification rate. This study showed that aspirin underwent a simple ionic bimolecular reaction with sodium hydroxide in aqueous solution. Thus, a second-order rate constant was calculated.




Figure 1—pH-rate profile for hydrolysis of aspirin. [Reprinted, with permission, from L. J. Edwards, *Trans. Faraday Soc.*, 46, 723(1950).]

Continuing this same approach, Sturtevant (7) analyzed the rate of saponification of aspirin at 35° calorimetrically with the aid of a thermocouple. His conclusion is not often seen in print other than by authors commenting about the previous contributions in relationship to their own work: "The results of these experiments have shown, however, that it would be very difficult to get accurate heat data on these reactions, and it has, therefore, not been considered worthwhile to carry the measurements any further."

A complete and thorough kinetic study of the factors involved in the hydrolysis of aspirin in dilute solution ($3 \times 10^{-3} M$) was conducted by Edwards (8, 9). Using a UV spectrophotometric method for simultaneous determination of aspirin and salicylic acid, he observed the rate of decomposition to be first order at a fixed pH value (between pH 0.53 and 12.77) and constant ionic strength at 17°. Figure 1 depicts the relationship between velocity (rate) constant and pH. This curve was subject to only slight alteration with change in ionic strength. Temperature dependence of this aspirin reaction was studied between 10 and 50°. The pH-rate profile was of the same shape for every temperature, with displacement upward with increasing temperature. This plot of $\log k$ against pH helps to show visually that the hydrolysis was catalyzed appreciably by hydrogen

Table I Comparison of Hydrolysis Rates of Aspirin in Various Media

Investigator	k , Day ⁻¹	Medium
Rath (1)	4.35×10^{-2}	Water
Edwards (8)	4.1×10^{-2}	Water
La Mer and Greenspan (6)	7.05×10^{-4}	Sodium hydroxide
Sturtevant (7)	7.2×10^{-4}	Sodium hydroxide
Edwards (8)	7.50×10^{-3}	Sodium hydroxide
Morton (5)	0.103	Potassium citrate buffer about pH 7
Edwards (8)	0.117	pH 7

ion (section AB of figure) and very strongly by hydroxyl ion (section FG of figure). Over the pH range 5-8 (section DE of figure), the rate was constant; in the pH range 2-3 (section C of figure), there was a pronounced minimum rate where the reaction velocity dropped to less than a quarter of the stationary value (DE) which is usually taken to represent the "spontaneous reaction." Edwards explained the relationship between the rate constant and pH on the assumption that the hydrolysis of aspirin may take place *via* the six simultaneous reactions shown in Scheme II.

Through many relationships involving these six equations, the observed unimolecular (first-order) velocity constant could be expressed as a function of the six second-order constants (Eq. 1):


$$k = \frac{k_1 C_H + k_2 C_{H_2O} + k_3 C_{OH^-}}{1 + K/C_H} + \frac{k_4 C_H + k_5 C_{H_2O} + k_6 C_{OH^-}}{1 + C_H/K} \quad (\text{Eq. 1})$$

When each of the six components of k was plotted on a pH-log k diagram, four types of curves were obtained. The combination of these four individual curves into one overall curve resulted in a single final curve similar to that depicted in Fig. 1, including the previously inexplicable minimum (C in figure), which Edwards calculated as being at pH 2.44. (The observed minimum was at pH 2.5.)

A comparison of the results of this work (Table I) with those obtained by previous investigators showed good agreement in the rate constant when expressed in the same terminology and conditions.

The hydrolysis of aspirin was accounted for over the whole pH range by considering all the possible bimolecular reactions between the five species present in the equilibrium as: $2H_2O \rightleftharpoons H_3O^+ + OH^-$ on the one hand and the equilibrium: $CH_3COOC_6H_4COOH \rightleftharpoons CH_3COOC_6H_4COO^- + H^+$ on the other hand.

The mechanism of intramolecular catalysis of the hy-



Scheme II

hydrolysis of aspirin in the pH region of 5-8 led Davidson and Auerbach (10) to investigate the behavior of aspirin in nonaqueous media. In the presence of dissolved base, aspirin possessed acid anhydride properties and functioned as an effective acetylating agent. They postulated the existence of a cyclic intermediate which results from the intramolecular nucleophilic attack by the ionized carboxyl group on the ester carbonyl. They also postulated that this base-catalyzed isomerization was the rate-controlling step for the hydrolysis of aspirin in the pH 5-8 range. This work was done with organic solvents, and there was no evidence for reactions of this type in aqueous solution.

Ferroni and Baistrocchi (11) measured the rate of hydrolysis of aspirin by determining the liberated salicylic acid fluorometrically. They reported that the reaction followed first-order kinetics and the rate constant was evaluated as 0.0122 hr.^{-1} at 18.5° and pH 9.42.

Hydrolysis rate constants for aspirin, reported by Miyamoto *et al.* (12), agreed with the k_3 rate constant of Edwards (8): 2.625×10^{-3} at 24° and 6.909×10^{-3} at 37° . A general comment was made that aspirin hydrolyzed more quickly in simulated intestinal fluid than in simulated gastric fluid.

Garrett (13), extending the work of Edwards (8) to include a number of acyl salicylates in a very complete investigation, looked more thoroughly into the pH-rate profile of aspirin hydrolysis, particularly in the pH 4-8 range. Edwards' own demonstration that the hydrolysis was not catalyzed by acetate ion (varied from 0.005 to 0.3 M) was not consistent with the mechanism involving an attack by a water molecule on the aspirin anion, because the acetate ion is a considerably more powerful nucleophile than water. Garrett's work pointed rather to intramolecular nucleophilic catalysis by the ionized carboxyl group. Even though the carboxylate ion is an unfavorable case from the point of view of nucleophilicity, it apparently participates catalytically in a number of intramolecular catalyses of esters. The hydrolysis of aspirin may be regarded as a classical example. On increasing the alcohol concentration greatly in the pH-independent region of the pH-rate profile, a very unexpected increase was found.

In this light, alcohol would have to be considered a more active nucleophile than water. To clarify this anomalous enhancement of "spontaneous" hydrolysis with increasing alcohol content (0-60%), Garrett made a thorough study. The addition of alcohol to the solvent increased the rate of solvolysis: ethyl acetate was a resulting product. He ruled out the possibility that the rate increase was a generalized solvent effect by showing that the addition of dioxane had very little effect on the rate of hydrolysis of aspirin. He tried to explain his results by proposing a mechanism involving nucleophilic attack by alcohol on the tetrahedral carbon atom of an intermediate compound. This explanation has not been generally accepted. Nevertheless, the demonstration that the addition of alcohol increased the rate of solvolysis did suggest strongly that the question of the involvement of a molecule of solvent in the transition stage ought to be studied.

Using the same four acyl esters of salicylic acid as in the mentioned studies, Garrett (14) studied the stability

of their saturated solutions. Prediction of stability in such solutions was made from separate studies of solubility rates and homogeneous rates on dilute solutions of these esters, since solvolytic degradation was a function of these two rates. This study did show that aspirin was the least stable of the esters studied.

Okano and Kojima (15) investigated the effect of salicylic acid upon the rate of aspirin decomposition in solution. They observed deceleration of the aspirin hydrolysis between pH 2.2 and 7 with increasing amounts of salicylic acid being added to the medium. Below pH 2.2 the opposite effect was noted. These studies were conducted for 10 days at 35° , or 8 hr. at 50° , and the rate constants were calculated. The reversal effect of the salicylic acid on the hydrolysis of the aspirin is in the vicinity of the minimum shown by Edwards' (8) pH-rate profile of aspirin hydrolysis.

The hydrolysis of aspirin at pH 6 in water containing 4.3 atom % of ^{18}O produced, after 22 hr. refluxing, salicylic acid containing 6% of the excess ^{18}O in the water. This result was in agreement with the theoretical prediction made by Bender *et al.* (16) and gave backing to the hydrolysis mechanism of aspirin postulated by Garrett (14) and others. This involved an intramolecular attack of the carboxylate ion on the carbonyl carbon atom of the ester to produce acetylsalicyl anhydride, which subsequently hydrolyzes rapidly to produce acetate and salicylate ion, or alternatively that the addition of the carboxylate ion to the carbonyl group of the ester is followed by some reaction with water leading to the same products. It can be calculated from the relative rates of hydrolysis of ethyl acetate and ethyl salicylate that the reaction producing salicylic acid- ^{18}O should occur to the extent of 2.5%. The 6% observed was considered to be reasonable and consistent with the postulated reaction in which water was involved.

Using a BPC mixture of aspirin, James (17) investigated the kinetics of the hydrolysis of aspirin from aqueous suspension by comparative, rather than quantitative, means. As long as there was a good excess of aspirin suspension present at the different temperatures, the hydrolysis rate was zero order. Thus, the more concentrated the suspension, the more stable was the aspirin. After 62 days at room temperature, suspensions of 3.3, 6.5, and 13.0% aspirin showed the following percent of intact aspirin remaining: 90, 94, and 97%, respectively. This follows, as the hydrolysis rate depends on the amount of aspirin in solution. Hence, suspensions show a low degree of hydrolysis relative to the total amount of aspirin in suspension.

While James used a titration procedure to follow the rate of hydrolysis in his study, Blaug and Wesolowski (18) used a more refined UV procedure in a pH 3 buffer. This pH was selected because it is the pH of a saturated solution of aspirin (approximately 4 g./l.). The effect of the following additives (calcium gluconate, glycerin, *N*-methyl-2-pyrrolidone, polyethylene glycol 6000,² polyvinylpyrrolidone, salicylic acid, sorbitol, pH 3.0 buffer, and water) on the stability of aspirin suspensions (6.5% of 100-mesh and 13% of 60-mesh aspirin) was followed

² Carbowax 6000, Union Carbide Corp.

by measuring the salicylic acid content at 298 m μ . The thermodynamic values reported in the paper were calculated from the data obtained with these various suspensions. The suspensions (in duplicate) were stored in a $50 \pm 0.5^\circ$ mechanical shaker for 24 hr. Samples were removed from the suspensions at hourly intervals for assay. Calcium gluconate accelerated the hydrolysis by increasing the pH of the medium, while the *N*-methyl-2-pyrrolidone or glycerin enhanced the solubility of the aspirin, thus increasing the hydrolysis. The presence of saturated salicylic acid did not affect the hydrolysis rate. The most promising additives were polyethylene glycol 6000 and polyvinylpyrrolidone, but physically they were unsatisfactory at this temperature as they formed gummy, insoluble masses of the suspension. Only sorbitol showed any potential stabilizing effect on the aspirin suspension.

In continuing his studies on the effect of alcohol on the hydrolysis rate of aspirin, Garrett (19) synthesized the mixed anhydride of aspirin and acetic acid to help establish his mechanism for the hydrolysis reaction. This compound did not form ethyl acetate as expected in the alcohol medium, so a logical explanation regarding the experimental evidence was still lacking.

Further studies with deuterium oxide solvent isotope effects in the nucleophilic reactions of phenylesters were reported by Bender *et al.* (20). One of the continuing problems associated with the hydrolytic reactions of carboxylic acid derivatives is to distinguish between nucleophilic and general basic catalysis of hydrolysis. The former involves the attack of a nucleophile upon a substrate, leading to the formation of an unstable intermediate which spontaneously breaks down to give the product and regenerates the catalytic entity. The latter catalysis involves the attack of a general base on the substrate removing a proton in a rate-determining stage. Either of these two processes may be carried out by a given substance which, by definition, is at one and the same time both a nucleophile and a general base. The deuterium oxide solvent isotope effect has been used to distinguish between these two possibilities.

The aspirin hydrolysis has been shown, on the basis of kinetic and isotopic experiments, to involve an intramolecular nucleophilic-catalyzed hydrolysis involving an anhydride intermediate. For the purpose of calculation, it has been assumed that the transition state of the reaction was one in which the carboxylate ion has been added to the carbonyl group of the ester, forming a tetrahedral addition intermediate. The formation of this intermediate is, in general, the slow step in the nucleophilic reactions of carboxylic acid derivatives. The authors concluded that the use of deuterium oxide solvent isotope effects as a criterion to distinguish between general base- and nucleophilic-catalyzed reactions was ambiguous; but when applied in a restricted sense, it may be empirically rewarding.

Nogami *et al.* (21) examined the effect of cationic (cetyltrimethyl ammonium bromide and benzalkonium chloride), anionic (sodium lauryl sulfate), and nonionic (polyoxyethylene lauryl ether) surfactants on the suppression of the hydrolysis of aspirin which exists in anionic and undissociated forms in aqueous solution. The decomposition-rate constants in the buffer

solutions (pH 1-7.5) were obtained, with or without the surfactant, and compared. Samples were kept at $37 \pm 0.1^\circ$, with aliquots being removed at given intervals and assayed for salicylic acid with a ferric nitrate reagent. The color was determined spectrophotometrically at 530 m μ .

The hydrolysis of aspirin was found to follow a pseudo-first-order reaction in the media studied. In the pH 5-7.5 range, aspirin was chiefly in the anionic form. Due to electrostatic attraction, it formed a complex with the cationic surfactant which moved into micelles composed of excess surfactant. Thus, the hydrolysis of aspirin in this pH region was suppressed only by a cationic surfactant. In the pH 1-5 range, all the surfactants suppressed the hydrolysis of aspirin. Because the undissociated aspirin existed in this region, it moved into micelles and was less hydrolyzable. Near pH 1, only the anionic surfactant lost its effect on suppressing the hydrolysis of aspirin. This was explained by the promoting effect of sodium lauryl sulfate on the hydrolysis of aspirin, due to the attracted hydrogen ion on the micelle environment competing with the suppressing effect of the solubilization. Even though this report shows suppression of the hydrolysis of unionized aspirin by all the surfactants and the suppression of the anionic form by cationic surfactants, it by no means implies that these solutions could be used as a stable pharmaceutical formulation.

Nelander (22) reported the heat of hydrolysis of aspirin at 25° by a calorimetric procedure. The $-\Delta H$ (kcal./mole) for aspirin was 25.39 ± 0.03 in 0.8 *N* sodium hydroxide in water-alcohol, 2:3. The heat of solution in aqueous tromethamine solution, ionic strength 0.1, initial pH 8.05, for aspirin was 5.72 ± 0.08 kcal./mole.

The first application of ultrasonic energy in accelerated drug stability studies was published by Mario and Gerraughty (23). Duplicate samples of aspirin in the given buffer (pH 2.00, 4.00, or 5.95) were put in two constant-temperature baths at 21, 25, 35, and 45° , one with ultrasonic energy and the other (control) without. Aliquots from both baths were taken at stated time intervals and assayed for salicylic acid at 302 m μ ; the content was calculated from standard curves of salicylic acid in the same buffer. Aspirin runs were done at two different concentration levels. The agreement of duplicate runs was good and indicated that the experimental technique was reproducible.

Pseudo-first-order rates were found at all pH values and with varying temperatures, both with and without ultrasonic energy. The hydrolysis rate constant, *k*, was calculated. The Arrhenius relationship was followed in all cases, and the heat of activation of the hydrolytic degradation of aspirin was not changed by the introduction of the ultrasonic energy. The increase in the rate found with the ultrasonic samples was equivalent to increasing the reaction mixture temperature within the range of 1.8 - 2.9° . This range was consistent, regardless of the pH or temperature used. Although the effects of ultrasonic energy were not startling on increasing hydrolysis, these studies did show the potential of this new technique, particularly with heat labile ingredients.

Table II Apparent Zero-Order Rate Constants of Salicylic Acid at Constant pH

Aspirin plus Lubricant	k, mg. FSA/hr.	pH
None	0.123	2.60
Stearic acid	0.133	2.62
Hydrogenated vegetable oil	0.123	2.68
Talc	0.133	2.71
Aluminum stearate	0.281	3.16
Calcium stearate	0.986	3.75
Magnesium stearate	1.314	4.14

Needham and Gerraughty (24) pursued further the hydrolysis of aspirin in mixed solvent systems by ultrasonic energy. The solvent systems were: alcohol-water, 10, 30, 50, and 70%; ether-water, 3 and 5%; and ethylene glycol-water, 5, 10, 30, and 50%. The pH for all of the media was kept at 3.67. Since the thermal energy (use of dual constant-temperature baths) was kept constant for both ultrasonified and control systems, it was apparent that the ultrasonic energy was responsible for the increase in the kinetic rates. With the ethylene glycol-water system, as the concentration ratio was increased, the subsequent increase in viscosity apparently reduced the movement of molecules caused by the ultrasonic vibration, as shown by the smaller rate constants for the hydrolysis of aspirin.

In studying the interaction of aspirin with urea, Santopadre and Bolton (25) shook saturated solutions of aspirin in water at 30° with known varying amounts of urea (0 through 10 *M*) for 5 hr. Kinetic studies were made at pH 2.0, 2.5, 2.75, 3.0, and 3.5 at 30 ± 0.2°. First-order rate constants were calculated. Urea increased the rate of hydrolysis below pH 2.75 and decreased the rate of hydrolysis at pH values greater than 2.75. It is interesting to note that this "crossover" occurs at a pH corresponding to the pH of maximum stability, as reported by Edwards (8). This pH may thus represent a point where the hydrolysis mechanism changes, and this could provide an explanation for the change in the effect of urea.

Murthy and Rippie (26) studied the hydrolysis of aspirin in the presence of polysorbate 80. Saturated solutions of aspirin at 30 ± 0.1° were prepared in 0, 1, 2.5, and 4% solutions of polysorbate 80 at the following pH's: 2.63, 3.63, 4.10, 4.21, and 4.43. Kinetic studies were carried out on suspensions, saturated solutions, and half-saturated solutions for 48 hr. at 30 ± 0.1°. Samples were removed at stated times and assayed by the UV method described by Edwards (8).

With the suspensions, the observed increase in degradation-rate constants (pseudo-zero-order) with added polysorbate 80 was due to the instability of undissociated aspirin in the micellar phase. With the homogeneous solutions, the rate of hydrolysis of aspirin in the polysorbate micelles, while lower than in the aqueous phase, was not negligible. The solubility determinations in the various media showed the absence of dissociated aspirin in the micellar pseudophase of the polysorbate 80 solutions.

Hydrolysis of solubilized aspirin in the presence of the nonionic surfactant, cetomacrogol, was studied by Mitchell and Broadhead (27). All the studies were con-

ducted at 37 ± 0.1° in the pH range of 1-7 on solutions of aspirin with cetomacrogol concentrations of 0.1 through 0.07 *M*.

The hydrolysis of aspirin proceeds as a first-order reaction, both in aqueous buffer and in buffered cetomacrogol solutions. Reaction rate constants were determined. At the pH of maximum stability, pH 2.27, where aspirin exists largely in the unionized form, the half-life increased with cetomacrogol concentration. In 0.07 *M* cetomacrogol, the half-life was approximately twice that in the control buffer. In the plateau region where aspirin is largely ionized, the rate of hydrolysis was independent of cetomacrogol concentration.

Kornblum and Zoglio (28) evaluated the commonly used tablet lubricants as to their effect on the stability of aspirin. Suspensions of aspirin with the various lubricants (talc, hydrogenated vegetable oil,³ stearic acid, aluminum stearate, calcium stearate, and magnesium stearate) were prepared. The lubricants were also in excess to ensure saturation through the experiments.

The suspensions were maintained at 30°, with appropriate aliquots withdrawn at various time intervals for pH and salicylic acid determination by adding ferric chloride and reading at 540 mμ in a spectrophotometer. From the kinetic studies of these suspensions, the reaction rate appeared to be of zero order. The pH remained relatively constant through the 30-hr. study for the given suspension.

The results are summarized in Table II.

With both calcium and magnesium stearates, the rate of decomposition of aspirin was due to more than just the increase in pH. The authors showed that this increase was due to the high solubility of calcium and magnesium aspirin which were formed in these suspensions. The mechanism primarily involves a reaction of the alkali cation with aspirin in a solution to form a salt of aspirin which, in the presence of solvated aspirin, comprises a buffer system at a pH detrimental to the stability of aspirin.

Reduction of the water content in the aspirin-calcium stearate suspension was done to approach that found in a solid dosage form, the ultimate aim being the achievement of reproducible data which would permit subsequent extrapolation to the tablet or capsule dosage form. A major conclusion from this interesting study is that stearate salts should be avoided as tablet lubricants in preparing aspirin formulations.

In their study on salicylic acid sublimation, Gore *et al.* (29) determined the hydrolysis rates for aspirin at temperatures ranging from 17.2 to 30.2 ± 0.1° at pH 7.4 and reading the resulting salicylic acid at 296.5 mμ. Their data are summarized in Table III. These values are in close agreement with those reported by Morton (5) and Edwards (8).

It is only by pure coincidence, but certainly quite appropriate, that the last papers dealing with hydrolysis of aspirin in this review clarified the situation immensely. In an attempt to circumvent the problems raised by the kinetic equivalence of the several possible mechanisms, Fersht and Kirby (30, 31) looked first at

³ Sterotex, Capitol City Products, Columbus, Ohio.

Table III Rate Constants for the Hydrolysis of Aspirin in pH 7.40 Buffer Solution at Various Temperatures

Temperature	k, Day ⁻¹
17.2	0.0937
21.3	0.1506
25.5	0.2067
30.2	0.3429


the reactivity toward hydrolysis of a series of substituted aspirins. The results suggested, unambiguously, that the most likely mechanism for the hydrolysis of aspirin was one in which the carboxylate group acts not as a nucleophile but as a general base.

The rate of hydrolysis of aspirin was measured in these studies by following the initial rate of release of salicylate at the isosbestic point, 298.5 mμ, and at 39.0 ± 0.03°. The ionic strength was maintained at 1.0 with added potassium chloride. It was this fact that showed why Edwards (8) failed to detect catalysis by acetate ion, because the ionic strength was not kept constant in his experiments. Fersht and Kirby (30, 31) found that the small acceleration due to the addition of a given concentration of acetate was almost exactly equal to the opposite effect of the increase in ionic strength. If Edwards had only known this fact, there no doubt would have been fewer controversial papers dealing with the mechanism of the hydrolysis of aspirin.

The pH-rate profile for aspirin hydrolysis, measured by Edwards (8), shows that the transition state for hydrolysis in the pH-independent region involves the aspirin anion, either alone in a unimolecular reaction or together with one or more molecules of solvent. Three mechanisms were consistent with this kinetic result for intramolecular catalysis of the hydrolysis of aspirin by the carboxyl group:

1. A unimolecular process in which the carboxylate group acts as a nucleophile. There was no longer any evidence that specifically supported the nucleophilic mechanism. It was not consistent with the effect of substituents on the reaction, and there were several indications that the rate-determining step was not a unimolecular process.

2. A general acid catalysis of the attack of hydroxide ion by the undissociated carboxylic acid group. This mechanism was rejected because intermolecular general acid catalysis by the carboxy group of aspirin should be observed for attack by acetate as well as by the hydroxide ion.




Scheme III—Mechanism of hydrolysis of aspirin as a classical general base catalysis

3. A general base catalysis of the attack of a water molecule by the carboxylate anion. There seems little doubt that the intermolecular reaction of acetate with the aspirin anion represents general base catalysis. There is even less doubt that intramolecular catalysis of hydrolysis by the carboxylate group of aspirin involves the same mechanism as the intermolecular reaction with acetate ion.

In actuality, it seems probable that the aspirin reaction lies close to the borderline between nucleophilic and general base catalysis (Scheme III).

DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS WITH FERRIC IRON

Until 1965, the most prominent method of determining salicylic acid in aspirin, or products containing aspirin, was the reaction with ferric iron under a variety of conditions. The complex produced on mixing ferric ion and salicylic acid (a bidentate ligand) results in the formation of a series of intensely colored metal chelates having ligand-ferric-ion ratios of 1:1, 2:1, and 3:1. The formation of the cyclic chelate structure (I) involves the displacement of the weakly acidic, phenolic hydrogen by the metal, resulting in the formation of a six-membered ring by coordination of the metal through the phenolate and carboxylate groups of salicylic acid:



In the first of these publications, in 1911 (32), the sample containing aspirin was shaken with water or alcohol and filtered; then one drop of ferric chloride solution was added. On standing, the color changed from red-dish to dark violet. This, in essence, was the beginning of the official compendia tests for salicylic acid in aspirin. It was noted very early by Melzer (33) that the presence of either sodium phosphate, tartaric acid, or borax masked the iron-salicylic acid color reaction. The useful suggestion was made that the tablets first be extracted with ether, since only the aspirin and salicylic acid would be extracted; thus a simple separation from the interfering compounds was easily accomplished. This immediately brings to mind that it would be easy to obtain false negative tests for salicylic acid if such a compound was incorporated in the aspirin tablet and no prior separation were made. Before the year was over, Linke (32) had refined the method for determining free salicylic acid in aspirin tablets by comparing the resulting iron-salicylate color to a series of salicylic acid standards. As little as 1 mcg. salicylic acid/ml. could be detected.

A limit test of 0.1% salicylic acid in aspirin was described by Leech (34), using a small volume of alcohol to dissolve the aspirin completely and then diluting with water before the addition of the ferric chloride reagent. This test became the basis for USP procedure when aspirin became official in 1926. It was emphasized that the standard salicylic acid tube should contain the same

amount of alcohol as the sample, because the final color was affected (decreased) by the presence of alcohol. Jones (35) stated that for tablets the limit test should be 0.15% salicylic acid and that there should be no turbidity in the final solutions.

Rather than compare the salicylic acid extract from aspirin, as described, Dahm (36) prepared a permanent color series containing various amounts of cobalt chloride dihydrate. After standardization with known quantities of salicylic acid, one could compare directly, under the stated conditions, aspirin extracts and "read" the percent free salicylic acid (FSA) directly. As these cobalt colors were of a permanent nature, it would save the analyst preparing a fresh salicylic acid reference standard.

Comments about the BP salicylic acid test made by Nutter-Smith (37, 38) brought forth that the official test was not effective below 0.04% salicylic acid, because the ferric chloride reagent was the limiting factor due to its own color. Using ferric ammonium sulfate corrected this situation. The presence of tartaric or citric acid in tablets (1%) has been shown to mask the presence of 0.2% salicylic acid. Thus, if one obtains a negative test for the FSA in unknown aspirin tablets, proper steps should be taken to separate the salicylic acid from the interfering material. Ruddiman (39, 40) added oxalic and tannic acids as masking agents of the iron-salicylate test and commented that sodium phosphate and borax did not interfere with the iron-salicylate test as had been believed. Incompatibility of aspirin with many drugs was proven by Snidow and Langenhan (41) using ferric alum reagent qualitatively.

Valentin and Lieber (42) showed that if ether was used to extract aspirin and salicylic acid from other materials, the evaporation step must be done with care, because too much heat results in high FSA values. They suggested chilling the ether and passing a stream of air over the solution to expedite the evaporation.

The use of a spectrophotometer in the determination of FSA was introduced by Hoffman (43) in 1929. Since the tablets being analyzed contained magnesium oxide, 4 *N* sulfuric acid was added during the grinding of the tablets. This was added to prevent hydrolysis (although not stated, it would also free any salicylic acid which might have been combined with magnesium ion) of the aspirin before the salicylic acid was extracted with a 1:1 mixture of ether and pentane. After evaporation of the clear extract, alcohol was added to dissolve the salicylic acid, and the iron reagent (ferric chloride) was added. This color was then compared with a standard series in the spectrophotometer.

Chloroform was introduced as a direct extractant of aspirin by Hitchens (44). This chloroform extract was shaken with 2% sodium bicarbonate aqueous solution to remove the aspirin (and salicylic acid). This, in turn, was made acidic with hydrochloric acid and extracted quantitatively with ethyl acetate. The ethyl acetate extract was evaporated under reduced pressure in a water bath maintained between 40–45°. The residue was dissolved in alcohol and diluted with water; ferric ammonium sulfate solution was then added. The resulting color was compared with standards of salicylic acid in the same medium. Because hydrolysis does take place in

alkaline medium. Hitchens showed that, at 20° for 1 hr. in the sodium bicarbonate solution, about 0.25% of the aspirin was hydrolyzed. At 30°, about 0.35% of the aspirin was hydrolyzed. Since the procedure described took less than 20 min. in the alkaline medium, the error caused by this alkaline hydrolysis was called negligible. With standard runs of aspirin USP, the FSA content was less than 0.15% by this extraction procedure. With various mixes and commercial tablets, the FSA found was never over 0.2%. The purpose of this extraction procedure was to isolate quantitatively the aspirin from compounds such as acetphenetidin, caffeine, acetanilid, antipyrine, amidopyrine, and phenylsalicylate.

In 1937, Banchetti (45) made a critical evaluation of many of the pharmacopeias in regard to their FSA tests which used various ferric iron reagents after extraction of the aspirin and salicylic acid. It was pointed out that the tests should be done at the lowest practical temperature and as rapidly as possible to minimize hydrolysis of the aspirin while conducting the procedure. If evaporation of a solvent extract is required, it should be done with as little heat as possible to avoid excessive FSA values.

The first reported humidity- and temperature-controlled experiments with aspirin tablets in different packagings was conducted by Canback (46). Tablets were stored in wood boxes, tins, impregnated paper, and glass bottles at $20 \pm 0.2^\circ$ for 1 year at various humidity stations (0, 19, 44, 59, 75, and 100% relative humidity). Using 2.5 *M* acid to acidify the pulverized powder, the aspirin and salicylic acid were extracted with a 1:1 mixture of ether and petroleum ether. An aliquot was evaporated, and the salicylic content was determined by dissolving the residue with diluted alcohol. Ferric chloride solution was added, and the resulting color was read in a colorimeter after standing 15 min. After a year at the various humidity stations, the aspirin tablets stored in glass showed very little change in FSA content. The other packagings were greatly inferior with the wooden one being the poorest in regard to aspirin stability. The higher the humidity, the larger and quicker the FSA values increased (other than in the glass bottles where little change was found at any of the humidity stations).

Using a Duboscq colorimeter, Tsuzuki and Sawada (47) measured the amount of FSA produced after aspirin had been heated at 110 and 128°. The heated sample (after 5–35 min. at the stated temperature) was dissolved in methanol, the ferric chloride reagent was added, and the solution was compared to standards. The relationship of increased FSA with a corresponding lowering of the melting point of the aspirin was shown.

Pankratz and Bandelin (48) made a systematic and comprehensive study of the optimum conditions for the reaction of ferric iron and salicylic acid and its reproducibility. Maximum absorption of the ferric-salicylate complex in a nearly aqueous medium was at 525 μ . This complex was very sensitive to pH changes. On studying pH effect at one pH unit increments from 1.0 through 9.0, the maximum color was found between 3.5 and 8.0. Above pH 6.5 the color faded rapidly, so the useful pH range was between pH 4.0 and 6.0. This emphasizes the point that unless the pH of the sample and of the standard series are close, the equivalent

Table IV—Percent Decomposition of Aspirin of Varying Particle Size after 6 Months* at 37°

Crystal Size, mesh	Relative Humidity, %		
	42	59	84
20-50	0.07	0.08	0.16
50-100	0.08	0.09	0.21
100-200	0.08	0.10	0.59

* Reprinted, with permission, from R. Yamamoto and T. Takahashi, *Ann. Rep. Shionogi Research Lab.*, 3, 112(1953).

amount of color will not result. One variable, the alcohol concentration, was not controlled. But at the levels used, it apparently did not affect the linearity of the color to concentration. With such a study, one would have expected a comparison of the different ferric salts, particularly those which have been used in the past such as ferric chloride and ferric ammonium sulfate. Instead, this is the first paper in which ferric nitrate was used.

A study involving just pure aspirin, by Yamamoto and Takahashi (49), answered many questions which arise when one seriously wonders under what conditions aspirin is stable or the most stable. The effect of the particle size of the aspirin on its decomposition rate was studied at 37° over a storage period of 6 months at three controlled humidities. The data in Table IV indicate that the finer the crystals and the higher the relative humidity, the more aspirin hydrolyzed. One may also conclude that under 60% relative humidity at 37°, the percent decomposition of aspirin did not change with particle size. With today's use of micronized aspirin, this is a valuable fact.

In studies at 60° for a total of 25 hr. at 30, 60, 80, and 100% humidities, decomposition was linear with time, and the linearity seemed proportional to the vapor pressure because the slope of each line increased with an increase in vapor pressure. Although the FSA content never exceeded 0.04%, this study showed that an increase in humidity did result in an increase in the decomposition rate.

At 90° and at low humidity, the authors found that, after a total of 12 hr., aspirin decomposition was linear with time but had not surpassed 0.1%. At 120° (low humidity), over 15% of the aspirin was decomposed within 5 hr., and the rate of decomposition was no longer linear with time. This study emphasized the fact that temperature increases alone accelerated the decomposition of aspirin.

Grinding of aspirin for 15-120 sec. did not increase appreciably the percent decomposition. On repeated compression (three times) of aspirin, the percent decomposition was found not to have increased appreciably.

In another paper dealing with the stability of aspirin when mixed with other compounds, Yamamoto and

Table V—Stability of Aspirin in Various Powder Mixtures at 37° for 15 Days*

Compound Mixed with Aspirin	Ratio of Aspirin to Compound	Percent Loss of Aspirin at --- Relative Humidity	
		42%	84%
Antipyrine	10:3	1.2	21.1
Aminopyrine	10:3	8.2	33.2
Hexamine	10:3	56.4	83.4
Ethyl aminobenzoate	10:3	32.6	60.8
Caffeine	10:3	0.01	0.08
Zinc sulfate	10:3	0.02	0.03
Sodium benzoate	10:3	3.2	80.2
Sodium salicylate	100:5	—	26.3
Calcium glycerophosphate	10:3	0.4	4.2
Pheniramine maleate	100:3	—	6.0
Phenindamine tartrate	100:3	—	6.4

* Reprinted, with permission, from R. Yamamoto and T. Takahashi, *Ann. Rep. Shionogi Research Lab.*, 4, 79(1954).

Table VI—Effect of Ethylenediamine Salts on the Stability of Aspirin*

Salt of Ethylenediamine	k_1	Loss of Aspirin, %
Hydrochloride	—	0.6
Maleate	1.0×10^{-3}	3.1
Succinate	6.4×10^{-3}	10.5

* Reprinted, with permission, from R. Yamamoto and T. Takahashi, *Ann. Rep. Shionogi Research Lab.*, 4, 79(1954).

Takahashi (50) found that such mixtures should be stored at the lowest practical humidity to prevent excessive decomposition of the aspirin (Table V).

In a comparison of aspirin mixtures with various salts of ethylenediamine, the importance of acid strength on the decomposition of aspirin was shown (Table VI). This study was conducted at 37° and 84% relative humidity for 15 days with a 100:3 ratio of aspirin to ethylenediamine salt.

Further investigation of a 10:1 molar ratio of aspirin-antipyrine mixture stored at 37° and 84% relative humidity for 2 months produced salicylic acid and antipyrine salicylate. The mechanism proposed for this interaction is given in Scheme IV.

Scheme IV was explained in the following manner. First there was an acid-base reaction between aspirin and antipyrine; but because this salt was highly unstable, it decomposed rapidly to antipyrine salicylate. Since aspirin and salicylic acid have approximately the same acidity, the excess aspirin present was capable of reacting with the antipyrine salicylate, releasing salicylic acid and regenerating the unstable aspirin-antipyrine salt which, in turn, started the cycle again.

A similar reaction cycle was proposed for the decomposition of aspirin with pheniramine maleate (amine salt of a weak acid), while no reaction took place with pheniramine hydrochloride (amine salt of a strong acid)




Table VII Explanation of Symbols Used in Table VIII

Variable	High Level		Low Level	
	%	Symbol in Table	%	Symbol in Table
Lubricants				
Glycerin monostearate	2	L	0.5	l
Magnesium stearate	2	L	0.5	l
Talc	4	L	1.0	l
Calcium stearate	2	L	0.5	l
Stearic acid	2	L	0.5	l
Mineral oil	4	L	1.0	l
Talc-mineral oil, 1:1	4	L	1.0	l
Pressure	Highest possible	P	Lowest possible	p
Moisture*	1.64	M	0.098	m
Aspirin	14-Mesh granules of 10% starch-aspirin granulation	A	40-Mesh crystals	a

* Refers to moisture content of the phenacetin-caffeine granulation only.

because aspirin was not capable of displacing the hydrochloric acid.

Without the aid of the computer age, Ribeiro *et al.* (51) undertook a massive, well-executed study of variables in the manufacturing of a stable APC tablet (aspirin, phenacetin, and caffeine). To study the probable causes of the decomposition of aspirin, a factorial experiment was set up testing all combinations of lubricants at two levels, pressure at two levels, moisture at two levels, and two types of aspirin; the entire series was repeated for each of the seven different lubricants (a $2^4 \times 7$ factorial experiment). These variables were selected because they seemed to be the most probable causes of aspirin breakdown in APC tablets. An Association of Official Agriculture Chemists (AOAC) (6th edition) procedure for salicylic acid was modified by using absolute alcohol to extract the salicylic acid from the pulverized tablets and to develop the final iron-salicylate color in a 35% alcohol medium. A spectrophotometer was used to read the resulting color at 537 m μ . Concentrations of salicylic acid were obtained from a standard curve of salicylic acid prepared exactly as the samples. These salicylic acid values were converted to aspirin values and reported in this paper as percent of aspirin content that had decomposed.

Before presenting the data in tabular form, a brief explanation of all the symbols used in the table is essential for proper interpretation of the percent decomposition of aspirin in the tablets after being stored in loosely capped bottles at 45° for 27 days. Tables VII and VIII summarize the results.

Interpretation of these results indicated that more stable combinations were possible if the lubricants used were talc, talc plus mineral oil, mineral oil, or glycerin monostearate rather than stearic acid, magnesium stearate, or calcium stearate. Compression pressure levels showed no effect. Moisture levels were not different enough to be consequential. The crystalline aspirin was superior to the starch-aspirin granulation.

Since difficulties arose in applying the BP colorimetric test for the FSA, Edwards *et al.* (52) initiated an investigation of the kinetics of aspirin hydrolysis and of conditions affecting the formation and stability of the ferric-salicylate complex. Time, as already well known, was an important factor, because aspirin hydrolyzes continually once it is in a given solvent (here alcohol and later water). The need for fast filtration was obvious. Higher temperature expedited the hydrolysis of aspirin, so the lowest practical temperature should be used throughout the test. Constant pH for the test was a

Table VIII—Decomposition of Aspirin after 27 Days at 45° under the Stated Conditions Described in Table VII

Combination	% Aspirin Decomposed*						
	Glycerin Monostearate	Magnesium Stearate	Talc	Calcium Stearate	Stearic Acid	Mineral Oil	Talc plus Mineral Oil
MPAL	1.17	8.67	1.10	20.95	8.03	4.11	2.97
MpAL	1.76	8.31	0.97	19.65	8.54	4.59	1.33
MPaL	0.67	7.06	0.55	21.21	0.98	0.99	0.30
MpaI	0.36	2.04	0.00	6.39	0.69	0.39	0.52
MPaI	0.33	1.21	0.00	6.95	0.84	0.31	0.22
MpAl	1.63	3.20	2.76	6.20	3.48	4.70	0.87
MpaL	1.05	6.26	0.00	19.54	2.00	0.99	0.75
MPaI	0.99	2.28	2.21	3.84	1.27	2.40	1.16
mPAL	8.56	6.84	1.41	16.04	7.67	1.18	2.66
mpAL	8.59	7.71	2.65	18.35	12.51	2.03	0.58
mPaL	0.96	15.99	0.54	18.54	3.95	0.92	0.87
mpal	0.80	3.39	0.55	3.53	0.44	0.45	0.97
mPal	0.53	3.03	0.48	4.45	1.28	0.90	0.70
mpAl	0.82	2.45	0.49	8.09	2.09	0.68	0.63
mpaL	0.45	15.26	0.73	19.79	4.14	0.93	0.98
mPaI	1.00	3.22	0.73	6.31	3.84	1.06	0.16

* The freshly compressed tablets showed negligible decomposed aspirin.

must because the rates of hydrolysis of aspirin vary appreciably with pH. The intensity of the ferric salicylate complex depends greatly on the pH of the medium. The maximum intensity was obtained between pH 2.5 and 3.5 and was best maintained using an acetic acid ammonium monochloroacetate buffer. Below or above this pH range the intensity of the color decreased rapidly (intensity at pH 3 was over five times as strong as that at pH 1.5).

As the BP method for FSA is a limit test, a quantitative procedure was developed utilizing the maximum conditions described. If no known interfering materials were present, the aspirin and salicylic acid were dissolved in absolute ethanol diluted with water, all at 25°, and maintained by a thermostated water bath. The time (T_0) was noted when the buffer and ferric ammonium sulfate solution were added and mixed. The volume of the solution was made up to the mark with water, mixed, and kept at 25° for about 10 min. An aliquot was filtered, transferred into an absorption cell, and read at 530 m μ against a reagent blank; the time (T_1) was noted. At least three aliquots were withdrawn at intervals of not less than 10 min. apart. From these values (T_1 , T_2 , and T_3), a value for the extinction coefficient at zero time (T_0) was obtained by extrapolation. From a standard salicylic acid curve, the amount of salicylic acid at T_0 was thus obtained.

If interfering matter such as phosphate or citrate was present, the aspirin and salicylic acid were extracted from the powdered sample in a separator with benzene. The filtered and pooled benzene was then extracted with small volumes of a solution of the buffer and ferric ammonium sulfate reagent, until an aliquot showed no further coloration in the aqueous extract. The pooled aqueous solution was made to volume with the remaining buffered ferric ammonium sulfate solution and filtered, if necessary, before reading at 530 m μ . The FSA was calculated from a standard salicylic acid curve as before, but without having to calculate a T_0 value; the intact aspirin remains in the benzene layer, so no hydrolysis should be taking place in the aqueous layer.

It is of interest to note that the pH of the aqueous solution (2.95 ± 0.05) read at 530 m μ for both procedures was near the minimum of the hydrolysis rate of aspirin in regard to its pH-rate profile. On comparing the FSA values obtained by using these proposed procedures with those of the BP on several commercial products, the proposed procedure consistently found more FSA, which again raises doubt about the sensitivity of the official BP test for FSA.

Quite independently, Strode *et al.* (53) conducted a systematic study similar to Edwards, only this study involved modifying the USP XV free salicylic test from a limit test to a sensitive, reproducible procedure which was applicable in FSA testing not greater than 0.25%. Hydrolysis curves were constructed from transmittance measurements made at timed intervals on thermostated solutions of aspirin and ferric alum. Under the conditions of the spectrophotometric method, these curves indicated that salicylic acid increased at the rate of 0.0028%/min. at 20°, 0.0036%/min. at 25°, and 0.0054%/min. at 30°. This definitely emphasizes the need for reasonably close temperature control. To obtain re-

liable readings, 100-mm. cells instead of the usual 10-mm. cells were used. The ferric alum solution in 0.01 *N* hydrochloric acid was kept refrigerated and prepared fresh each week. The calibration standards were prepared so that they would be at the same pH and essentially of the same composition as the sample solutions being measured. This was accomplished by adding an aliquot of freshly prepared aspirin solution in alcohol (SD 30) and water at 25° to individual standard increments of salicylic acid, and noting the time between addition of the ferric alum solution and the reading of final solution (this should be within 5 min.). Through a simplified calculation, a correction for the hydrolysis of the aspirin during this short time interval may be applied. Thus, this is the first time where the salicylic standards contained essentially the same amount of aspirin as the samples being assayed. With colorless aspirin solutions or those from green-tinted formulations, the final iron-salicylate color was read at 515 m μ while the pink-tinted formulations were read at 575 m μ . Appropriate standard curves were run at these given wavelengths. Within the range of concentration measured, the precision and accuracy of this method were within 0.005% salicylic acid at the 95% confidence level.

They also developed a rapid visual method using matched Nessler tubes and a series of salicylic acid standards, which were prepared exactly as the sample in regard to pH, alcohol (SD 30) content, and ferric alum solution. These standard solutions were stable for 2 weeks. The aspirin sample (colorless for this test) was dissolved in alcohol (SD 30), the appropriate aliquot diluted with water cooled to 10°, then treated with the ferric alum solution, and compared within 30 sec. to the standard series of salicylic acid. The salicylic acid content was estimated visually to the nearest 10 mcg. of salicylic acid. By conducting this comparison test so rapidly and at 10°, the hydrolysis error appeared to be within experimental error.

In a thesis and later a publication, Leeson (54) and Leeson and Mattocks (55) made a very thorough study of the decomposition of aspirin in the solid state, utilizing a modification of the AOAC 6th edition procedure which improved the accuracy and sensitivity of the measurements. The aspirin and salicylic acid were dissolved in absolute alcohol. The final color of a given aliquot, which was developed in a 50% alcohol medium, was read in a spectrophotometer at 532 m μ (a slit width of 0.02 mm.) along with a series of salicylic standards treated exactly as the samples.

The step in which the sample or standard salicylic acid aliquot is diluted to exactly 50 ml. with absolute alcohol is an extremely important one. The original procedure consisted of adding the given aliquot to 50 ml. of absolute alcohol, but since the size of the aliquot varied, the concentration of alcohol in the final dilution was not constant. To determine the effect of alcohol concentration on the iron-salicylate color, three different concentrations of salicylic acid were made. They were read over a varying range of alcohol from 5 through 85% alcohol at increasing increments of 10% alcohol. It was readily concluded that the final concentration of alcohol had a significant effect on color intensity. With

Table IX Stability of Various Aspirin-Antacid Mixtures (2:1)

Antacid	Over 1% FSA Stored for Stated Weeks at		% FSA after 1 Year at	
	RT	37.5	RT	37.5
Dihydroxy aluminum aminoacetate	52+	52+	0.65	0.70
Calcium gluconate	52+	52+	0.80	0.78
Calcium carbonate	28	8	4.4	11.3
Aluminum hydroxide dried gel	12	4	3.9	6.9
Magnesium carbonate	12	2	11.0	42.9
Magnesium oxide	4	2	18.0	24.0
Magnesium hydroxide	2	2	19.5	38.6
Calcium lactate pentahydrate	36	6	71.0	100.0 ^a
Magnesium trisilicate	4	2	100.0	100.0 ^a
Dibasic sodium phosphate, anhydrous	16	2	100.0 ^b	100.0 ^c
Sodium bicarbonate	4	2	100.0 ^b	100.0 ^d

^a Within 48 weeks. ^b Within 44 weeks. ^c Within 40 weeks. ^d Within 28 weeks.

the lowest salicylic acid concentration, alcohol content of 30 ml. instead of 25 ml. could introduce an error of 6.7% in FSA value. This error increases greatly with higher concentration of alcohol. For this reason, although a worker may select any alcohol volume desired, he must keep it constant throughout the study for both the samples and standards.

Under anhydrous conditions in sealed ampuls, aspirin (100-140-mesh) with and without calcium stearate (a lubricant in aspirin tablets which has been shown to expedite the decomposition of aspirin) were stored at 35, 45, 60, 80, 100, and 110°. Samples were removed at various time intervals over a period of 50 days and assayed for FSA content. Samples of aspirin alone showed little or no decomposition at 80° or below, while those with calcium stearate decomposed within 2 days to the extent of about 1% FSA and then remained near this level during the remainder of the study. At both 100 and 110°, with or without calcium stearate, the aspirin showed about 2% FSA in 5 days and then decreased gradually with time. As these samples both melted and changed color, it was not known whether the formation of a polymolecular salicylide accounted for the decrease in salicylic acid.

From these studies, it was believed that the small amount of decomposition found could have been caused by traces of moisture, which contaminated the dry aspirin during the filling and sealing of the ampuls. The amount of water necessary to account for the decomposition observed was approximately 10^{-5} moles. The conclusion was thus reached that below 80°, the decomposition of aspirin in the absence of moisture was of minor importance.

Consequently, the role of humidity, or more specifically vapor pressure, on the decomposition of aspirin was studied at various temperatures (50, 60, 70, and 80°) with vapor pressures varying from 46 through 232.5 mm. At various time intervals over a period of nearly 1 year, samples were taken from the given humidistats and assayed for FSA content. Decomposition was noted at all stations. The amount depended on the length of time in the given humidistat, temperature, and vapor pressure. The higher the temperature and vapor pressure, the more rapid was the decomposition.

Tablets containing aspirin, starch, and talc (washed and unwashed) were prepared and studied under similar conditions as the aspirin crystals. The effect of

washed talc on the stability of the aspirin was not appreciably different from the talc. The complications arose at various humidistats in that the tablets would liquefy, particularly at the 80° stations (but not below 60°), once the salicylic acid content reached a critical level. Once liquefaction occurred, the salicylic acid content decreased sharply and the study with that humidistat was discontinued. Along with previous workers' conclusions, Leeson showed that the compression into tablets did not change the mechanism of decomposition.

The widespread use of aspirin in combination with various antacid compounds as buffering agents led Bandelin and Malesh (56) to study the stability of aspirin with 11 commonly used antacid compounds. Using a modification of the method of Pankratz and Bandelin (48), previously discussed, the FSA content of powder mixtures of two parts aspirin to one part antacid powder, after being stored at room temperature or at 37.5° for periods of time up to 1 year, were assayed at stated time intervals. The antacid powders were used directly from the commercial container so they were not pretreated or dried in any way before using. Table IX summarizes their results.

Both dihydroxy aluminum aminoacetate and calcium gluconate were definitely superior to the other antacids studied in regard to "available" FSA. The word available is used with the FSA reported in that the mixture assayed was extracted directly with acetone. It was not shown, or stated, if aluminum, calcium, or magnesium salicylate was formed during the decomposition of the aspirin, or if the acetone would dissolve these salts. Further, if they did dissolve, would the ferric iron replace the cation in the 50% acetone medium in which the iron-salicylate color was developed?

The unusual was done by Wirth (57) in that he followed the USP XV procedure for FSA *without* any modifications when assaying APC tablets. The FSA values reported were acceptable.

Using the procedure of Ribeiro *et al.* (51), Kral *et al.* (58) studied various mixtures of drugs commonly given with aspirin. Samples of the various mixes were kept at four different stations: room temperature, anhydrous state at room temperature, 97% relative humidity at room temperature, and 37° for periods up to 6 months. The individual mixtures of aspirin with phenacetin, caffeine, phenobarbital, dextrose, sucrose, or lactose were classed as being stable, while those with

Table X Effect of Amphetamine Salts on the Stability of Aspirin

Amphetamine Salt	pK of Parent Acid	
Picrate	0.38	
Acid oxalate	1.19	
Sulfate	1.92*	Increase
Acid maleate	2.00	in accelerating
Acid tartrate	3.02	decomposition of
		aspirin

* Second dissociation constant.

antipyrine, amidopyrine, and quinine hydrochloride decomposed slightly. Mixtures of sodium bicarbonate, hexamethylenetetramine, and caffeine sodium benzoate decomposed rapidly.

In his thesis, Lippmann (59) used the colorimetric procedure developed by Leeson (54), but substituted 95% alcohol for absolute alcohol in his studies of aspirin decomposition with various amphetamine salts. Mixtures of 100 parts of aspirin (50-70-mesh) and 2.935 parts of amphetamine salt as base (60-mesh) were stored in humidity cabinets at 73° and 67% relative humidity. Amphetamine salts used were sulfate, diphenylacetate, *p*-aminobenzoate, 2-naphthoate, phthalate, and picrate. The phthalate salt increased the rate of decomposition of the aspirin the greatest; the order was as follows: phthalate > diphenylacetate = *p*-aminobenzoate = 2-naphthoate > picrate > sulfate.

A relationship between pK of the parent acid in the amphetamine salt and rate of decomposition of aspirin (Table X) correlated well with the acid strength discussed by Yamamoto and Takahashi (50).

Four different tablets of aspirin were manufactured by Nazareth and Huyck (60) to study the effect of calcium salts on the stability of aspirin. The tablets were stored at 9-12, 25-30, and 45° for a period of 8 weeks. Samples were removed weekly and assayed for salicylic acid by essentially the method of Pankratz and Bandelin (48), reading the final color in a 20% alcohol medium. Table XI summarizes their work.

It was noticed that when the percent FSA was over 6, needle-shaped crystals (whiskers) of salicylic acid appeared on the sides and neck of the container. This study showed that aspirin was unstable in the presence of either calcium carbonate or calcium succinate. This was in agreement with Yamamoto and Takahashi (50), who found that the presence of a salt of a weak acid accelerates the decomposition of aspirin.

Continuing the same type of study, Nazareth and Huyck (61) studied the stability of aspirin in four differently manufactured APC tablets. The tablets were stored for 5 weeks and samples removed weekly for the FSA assay.

Only Tablet A in Table XII showed a rapid decomposition of aspirin. It was the only tablet containing magnesium stearate as a lubricant.

As DeMarco and Marcus (62) did not require the sensitiveness described by Leeson (54), they modified the iron reagent to account for larger amounts of salicylic acid and still adhere to Beer's law (Table XIII).

Reagent No. 1 was used by Leeson and was shown to be very sensitive to the alcohol concentration. Reagent No. 4 was recommended, as it was not only insensitive

Table XI Stability of Various Aspirin Tablets

Tablet	Weeks of Storage before 0.5% FSA Found at					% FSA after 8 Weeks at				
	9	12	25	30	45	9	12	25	30	45
I. Aspirin	8+	8+	7	0.3	0.4	0.5				
II. Aspirin + calcium carbonate	7	2	1	0.5	1.2	14.0				
III. Aspirin + calcium succinate	5	1	1	0.6	1.0	88.5				
IV. Aspirin + calcium carbonate and succinate	4	1	1	0.6	1.2	96.7				

to alcohol concentration changes, but the intensity of the iron-salicylate complex was greatly increased. Reagent No. 7 emphasized the need for acid in the color development medium.

Okano *et al.* (63) conducted a factorial experiment (2⁸ × 4) like Ribeiro *et al.* (51) and obtained essentially the same conclusions. Of the lubricants, talc, edible oil, and stearic acid were better than magnesium stearate or calcium stearate at 56°. Room relative humidity caused less decomposition than 84% relative humidity. Storage temperature at 45° caused more aspirin decomposition than room temperature (10-20°). Presence of lactose or diphenylpyraline hydrochloride resulted in an increase in aspirin decomposition. Little effect was noticed on the stability of aspirin, with or without starch, whether it was prism or needle form. The number of times the tablets were compressed at different pressures did not affect the aspirin.

In continuing their studies on the stability of aspirin with other drugs or compounds, Patel and Huyck (64) manufactured aspirin tablets with and without aluminum hydroxide dried gel USP. The tablets were stored for nine weeks and samples removed weekly for FSA assay as previously described.

The results in Table XIV are in agreement with the work reported by Bandelin and Maresh (56).

In two papers, Grabowska (65, 66) reported on the stability of aspirin with other drugs as powders or tablets after a year's storage. No decomposition of aspirin was reported when mixed with caffeine, quinine sulfate, codeine phosphate, phenobarbital, phenacetin, carbromal, urea, or *p*-aminobenzoic acid.

Slight decomposition was reported with quinine hydrochloride or sodium benzoate. The presence of sodium phenobarbital, codeine base, or caffeine sodium benzoate greatly accelerated the decomposition of the aspirin. Four stabilizers, magnesium oxide, aluminum hydroxide, calcium carbonate, and calcium gluconate, were mixed individually with aspirin, sodium phenobarbital, and caffeine mix, and aspirin, caffeine, and so

Table XII—Stability of Various APC Tablets

Tablet	% FSA after 5 Weeks at		
	9-12°	25-30°	45°
A	0.6	1.2	16.0
B	0.1	0.2	1.0
C	0.1	0.2	0.6
D	0.1	0.2	1.3

Table XIII Effect of Iron Reagent and Percent Alcohol on the Iron-Salicylate Color

Iron Reagent	ml. Iron Reagent Added/100 ml. Solution	% Alcohol in Final Solution	Adherence to Beer's Law at 532 m μ , mcg. Salicylic Acid/ml.
1. 2% Ferric ammonium sulfate in 0.125 N hydrochloric acid	2	50	10-20
2. Same as No. 1	5	50	10-60
3. Same as No. 1	5	10	10-80
4. 1% Ferric chloride in 0.1 N hydrochloric acid	5	50	10-80
5. Same as No. 4	5	10	10-80
6. 0.5% Ferric chloride in 0.1 N hydrochloric acid	2	10	10-50
7. 0.5% Ferric chloride, no acid	2	10	None

dium benzoate mix. Magnesium oxide was best with the former mix, while aluminum hydroxide, calcium carbonate, or calcium gluconate was effective in stabilizing the aspirin in the latter formulation.

Control methods used in the Australian pharmaceutical industry for FSA in aspirin formulations were described by Green (67). The method of Strode *et al.* (53) was used in determining the FSA content in aspirin and aspirin-starch formulations. The results were in line with the BP FSA limits. If the formulation contained magnesium hydroxide, it was necessary to release the salicylic acid from its magnesium salt by first adding an aqueous acid and extracting the salicylic acid immediately with 1:1 pentane-ether solution. After evaporation of the mixed solvent the residue was dissolved in alcohol and assayed.

The effect of selected USP talcs on the stability of aspirin in tablets was reported by Gold and Campbell (68), utilizing a direct benzene extraction of the pulverized tablets. After vigorous shaking and centrifuging until clear, an aliquot was shaken with a ferric ammonium sulfate reagent. The clear aqueous layer, after centrifuging, was read in a colorimeter at 515 m μ . FSA content was calculated from a standard series of salicylic acid treated as the sample. Three series of tablets were prepared. The first used the talc, as is; the second used acid-washed talc. The third series used the best of the four talcs. Talc A, plus known amounts of various impurities (aluminum silicate, red iron oxide, calcium silicate, and calcium carbonate which were mixed individually with the talc to prepare the aspirin tablets).

The data indicated that the four USP talcs were different in regard to FSA formation after being stored at 40° and 90% relative humidity for 12 weeks (FSA varied from 0.8 to 25.8%). The decomposition, however, did not appear to be directly related to the pH of

the talc. The acid washing of the talc before use did improve the aspirin stability greatly, particularly with Talc C. Of the added impurities to Talc A, the presence of aluminum silicate or red iron oxide did not significantly affect the stability of the aspirin, while both the calcium salts (carbonate being the worst offender) influenced appreciably the rate of decomposition of the aspirin.

Though the main interest of Troup and Mitchner (69) was on degradation of phenylephrine hydrochloride in tablet formulations containing aspirin, they did assay for FSA according to the Gold and Campbell (68) procedure. For the degradation of phenylephrine in aspirin-containing tablets to occur, the breakdown of the aspirin was prerequisite. This was accelerated greatly by the presence of magnesium stearate as a lubricant in the manufacturing of the tablets. For any one formulation held at elevated temperature (usually 70°), the increase in salicylic acid content plotted against the decrease in phenylephrine content gave a linear relationship.

The effect of four granulating solvents in the manufacturing of aspirin tablets was reported by Trose and Danz (70). Granulations prepared with 95 and 70% alcohol or spiritus gelatine did not increase the decomposition of the aspirin, while the use of 5% gelatin mucilage did. The FSA content was found by extracting the pulverized sample with alcohol, filtering, diluting with water, adding ferric chloride reagent, and reading the resulting color at 530 m μ in a colorimeter. If phosphates are present in the formulation, a preliminary extraction and evaporation must be made with 1:1 ether-petroleum ether mixture.

Jaminet and Evrard (71) evaluated the effectiveness of precirol (a glyceryl palmitostearate), a binder lubricant, in the manufacturing of aspirin tablets. After 3 months at 50° and 80% relative humidity, no FSA was reported from the tablets using this substance. The FSA was determined in the pulverized tablets by first extracting with 1:1 ether-petroleum ether solution, filtering, evaporating, dissolving the residue in alcohol, diluting with water, and adding a ferric ammonium sulfate reagent. The solutions were read at 520 m μ .

The effects of humidity on aspirin, on its mixtures and tablets, with five different fillers were reported by Wisniewski and Piasecka (72). The FSA was determined by dissolving the aspirin in alcohol, filtering if

Table XIV—Aspirin Dosage Form Stability

Tablet	% FSA after 9 Weeks at		
	10°	RT	37.5°
Aspirin	0.13	0.13	0.16
Aspirin and aluminum hydroxide dried gel	1.16	2.04	3.30




Figure 2—Relationship between the rate of formation of salicylic acid and of DAPAP.

required, and adding an aliquot to a Nessler cylinder containing water and the ferric ammonium sulfate reagent. These were compared with the prepared salicylic acid standard solutions. The samples were stored over a period of 4 months at 93, 58, and 20% relative humidity along with changing humidity conditions in the laboratory. The decomposition at 93% relative humidity took place in the following decreasing order of filler used: magnesium oxide > magnesium carbonate > calcium carbonate > magnesium stearate > no filler. This same decomposition order existed at 58 and 20% relative humidity, along with ambient conditions. It is one of the few times that magnesium stearate has not led the list in degree of decomposition of aspirin. During these studies, it was shown that alcohol concentration affected the final color, as did varying amounts of acetic acid. None of the fillers used altered the final color.

In a paper similar to that of degradation of phenylephrine (69), Koshy *et al.* (73) reported on the acetylation of acetaminophen (APAP) in tablet formulations containing aspirin. With tablets stored at 50° for a period of 6 weeks, the formation of diacetyl-*p*-aminophenol (DAPAP) indicated a linear relationship between the rate of formation of salicylic acid through a 4-week period (Fig. 2). The same trend existed in various samples stored at ambient conditions, although at lower salicylic acid and DAPAP levels. Commercial tablets of unknown age, purchased from retail outlets and containing both APAP and aspirin, showed this same relationship of aspirin decomposition and formation of DAPAP. As one of these lots showed high DAPAP, a study was conducted at 50° for 4 weeks on the effect of stearic acid in one and magnesium stearate in the other. The magnesium stearate mix produced nearly 1000 times as much DAPAP as the stearic acid or regular mix.

Continuing their study on the stability of aspirin, Jaminet and Louis (74) made tablets with various lubricants. On assaying these tablets after being stored 6 months at 50° and 80% relative humidity, the lubricants may be listed in order of increased amounts of salicylic acid being found. Magnesium stearate was the poorest lubricant in that nearly 90% of the aspirin was decomposed, the next being polyethylene glycol 6000 (about 15% being decomposed) > glycerol monostearate II > stearic acid > stearyl alcohol > glycerol monostearate I > precinol = geleol. The last two lubri-

Table XV—Effect of Common Active and Inactive Aspirin Product Components on Color Development*

Component	Component-Salicylic Acid Ratio	Interference
Lactose	40:1	Nil
Meprobamate	100:1	Nil
Methylcellulose	40:1	Nil
Polyvinylpyrrolidone	20:1	Nil
Phenacetin	60:1	Nil
Calcium stearate	10:1	+20%
Magnesium stearate	10:1	+20%
Stearic acid	10:1	+30%
Alginic acid	10:1	Nil
Ion-exchange resin ^b	10:1	Nil
Caffeine	40:1	Nil
Ethoheptazine citrate	20:1	Nil
	100:1	-15%
Citric acid	15:1	-20%
Dihydrocodeine	20:1	Nil
Codeine phosphate	20:1	Nil
Phenergan HCl	3:1	+100%
Hydrogenated vegetable oil ^c	10:1	Nil
Talc	20:1	Nil
Meperidine HCl	40:1	Nil
Starch	70:1	Nil

* Reprinted, with permission, from L. F. Cullen *et al.*, *Ann. N.Y. Acad. Sci.*, 153, Art. 2, Table 1 (1968). ^b Amberlite, Rohm & Haas Co. ^c Sterotex.

cants were the best in protecting the aspirin from decomposing under these conditions.

It is befitting that the last paper using an iron reagent would be titled "An Automated Colorimetric Method for Determination of Free Salicylic Acid in Aspirin-Containing Products," by Cullen *et al.* (75). The number of salicylic acid determinations required in the development of a stable aspirin product, or in production quality control, can be overburdening. The need to automate the salicylic acid analysis was, and is, great, as the saving in analytical time, effort, manpower, and expense can be tremendous.

The method selected for automation was that of Pankratz and Bandelin (48), as they had reported on the optimum conditions needed in order to obtain the greatest accuracy and reproducibility in the quantitative determination of salicylic acid in pharmaceutical preparations. A flow diagram (Fig. 3) is presented at this time only to show the equipment arrangement utilizing a standard Technicon automated system which was programed at 15 samples/hr. Specificity studies are summarized in Table XV.

Turbidity accounted for the high values given by the presence of calcium and magnesium stearate and stearic acid. The quenching effect (negative interference) was brought about by citric acid which forms a nonionized salt with iron. Phenothiazine derivatives react directly with the ferric iron and so must be removed if present in the aspirin formulation. Linearity of the salicylic acid in the microaperture flow-through cells was excellent. The precision of standard salicylic acid showed a repeatability deviation of 1.5%, while replicate samples of a commercial tablet were within 2%. Good accuracy was demonstrated by recovery of known amounts of standard salicylic acid added to powdered commercial tablets and by comparing this to the manual procedure.




Figure 3 Flow diagram for the determination of salicylic acid in aspirin-containing products. Key: 1, 0.8 ml./min. air; 2, 4.06 ml./min. SDA No. 30 alcohol; 3, 2.76 ml./min. sample; 4, 2.03 ml./min. sample; 5, 2.76 ml./min.; 6, 2.76 ml./min. $\text{Fe}(\text{NO}_3)_3$ reagent; 7, 2.00 ml./min. air; 8, 2.50 ml./min. flowcell; and 9, reservoir-SDA No. 30 alcohol. [Reprinted, with permission, from L. F. Cullen et al., *Ann. N. Y. Acad. Sci.*, 153, Art. 2, Fig. 1 (1968).]

DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS BY UV SPECTROPHOTOMETRY

Until Tinker and McBay (76) introduced their simple and rapid spectrophotometric method of analysis for aspirin and salicylic acid, two separate determinations had to be made for the intact aspirin and hydrolyzed aspirin. In selecting the solvent for the UV studies, they found that in using chloroform A.R. grade, both aspirin and salicylic acid had higher absorbances and stabilities than in either aqueous or alcohol solutions. Also, the greatest difference between maximum and minimum absorbance values for any given concentration was observed in chloroform. The maximum absorbance for aspirin and salicylic acid was found to be 278 and 308 $\text{m}\mu$, respectively, as shown in Fig. 4. Beer's law was conformed to in the concentration ranges used. Equations were developed for this two-component mixture, and the application to aspirin, aspirin tablets, or capsules was valid and had an error of less than 0.2%. Samples of aspirin were dissolved in chloroform (filtered if necessary) and read at 308 $\text{m}\mu$ for salicylic acid content. A portion of the bulk solution was diluted 100 times and then read at 278 $\text{m}\mu$ for aspirin content. Both readings were against a chloroform blank.

Ebert (77) found that the existing methods for determining amphetamine sulfate, phenacetin, and aspirin in the corresponding tablets involved many laborious

time-consuming extractions. After the separations were completed, lengthy titrations or a gravimetric procedure were required. With all this work, very little, if any, reliable information was available in regard to subtle changes such as the presence of salicylic acid which could be formed from the decomposition of the aspirin. Ebert, with meticulous care, designed a three-component spectrophotometric method for the simultaneous determination of aspirin, phenacetin, and salicylic acid. It was not only a more rapid method of analysis, but was found to give increased accuracy and precision. Alcohol was selected as the solvent of choice. In this medium, aspirin was found to have an absorption maximum at 226 $\text{m}\mu$, salicylic acid at 235 $\text{m}\mu$, and phenacetin at 250 $\text{m}\mu$. As there was a great deal of overlapping of the three absorption curves, it was important to prove that the absorbance of this mixture, particularly where the aspirin showed 0, 50, and 100% hydrolysis, represented the sum of the absorbances of the individual compounds comprising the mixture at that wavelength. The validity of this was well proven by Ebert's work. From all these basic data, the appropriate validated equations were derived. The equations were then tried on tablets which had been extracted with ether. The three compounds in alcohol were then determined spectrophotometrically. The estimate of the accuracy and precision compared favorably with those methods used in the past. Though the major emphasis of this work was on the stability of sympathomimetic amine salts when combined with aspirin and phenacetin, interesting facts evolved about the stability of aspirin in these combinations. It might be added that in all the stability studies conducted here, phenacetin did not show any appreciable change.

Stability studies on tablets containing amphetamine sulfate, aspirin, and phenacetin were conducted in regard to the effects of temperature, moisture, and lubricants on these compounds. All the tablets were packaged in loosely capped amber bottles. These bottles were stored under the following conditions: room temperature, 0% relative humidity; room temperature, 95% relative humidity; 43°, 0% relative humidity, and 43°, 95% relative humidity. After a year's storage and many assays, the important finding was that aspirin decom-




Figure 4- UV spectrocurves of aspirin (---) and of salicylic acid (—) in chloroform.

position appeared to be associated with the disappearance of the amphetamine sulfate. The aspirin decomposition appeared to be dependent upon the lubricant present in the following decreasing order: magnesium stearate > talc and magnesium stearate > stearic acid > talc. The increase of temperature accelerated the decomposition of aspirin, but the increase of humidity at the same temperature had a much greater effect. Methamphetamine hydrochloride was substituted for the amphetamine sulfate in a similar stability study, and the conclusions were the same as mentioned for amphetamine sulfate. It is of interest to note that no aspirin decomposition occurred in any of the formulas stored at room temperature, 0% relative humidity, regardless of the ingredients present. In another study, salicylic acid replaced aspirin in the tablet with the result that it had little or no effect on the amphetamine sulfate.

Ebert checked on the possibility that aspirin might be capable of acetylating amphetamine. Working with the pure compounds, he isolated acetylamphetamine which proved this belief. The addition of an equivalent amount of salicylic acid and acetic acid in place of the aspirin in that study did not result in the isolation of any acetylamphetamine. Isolation of any acetylamphetamine from the tablets studied was not successful. Today, with the aid of TLC and GLC, such a decomposition product could readily be detected quantitatively.

Though Leeson's work with aspirin (54) involved chiefly a colorimetric procedure, he used the UV procedure developed by Ebert. This was done to check that no loss of salicylic acid (through volatilization) from the vials on stability had occurred. As the tablets used here did not contain amphetamine sulfate or phenacetin, the interpretation required was simpler. Absolute alcohol was used in place of the 95% alcohol. This would assure better stability of the aspirin during the assay. Readings were taken at 226 m μ (slit width of 0.8 mm.) and at 235 m μ (slit width at 0.6 mm.) against absolute alcohol. On assaying many tablets randomly, the summation (in moles) of the aspirin and salicylic acid found accounted for all the aspirin originally employed. In short, no salicylic acid was being lost through volatilization under the storage conditions.

In the first of a series of many interesting and valuable publications dealing with the determination of the stability of aspirin in many products, Levine (78) introduced a rapid chromatographic assay for APC tablets which included the determination of salicylic acid. Previous papers using this column technique did not discuss the determination of salicylic acid.

The pulverized APC sample was extracted with chloroform containing a small amount of acetic acid (to convert any aspirin salt to the free acid and so be extracted by the chloroform). Without filtering off the insoluble excipient material, an aliquot was diluted with freshly water-washed ether and passed directly to the single duplex column which had just been washed using water-washed ether. The upper segment of the column contained 1 N sodium bicarbonate on diatomaceous earth⁴ which acted as the supporting phase. The sodium bicarbonate trapped both the aspirin and salicylic acid.

The lower segment of the column contained 4 N sulfuric acid on diatomaceous earth. The sulfuric acid retained the caffeine while the phenacetin passed through into an evaporating dish. Water-washed ether was passed through the column in small portions to elute quantitatively all the phenacetin. A volumetric flask was placed under the column and sufficient water-washed chloroform was passed through the column to elute quantitatively the caffeine. Immediately, the column was eluted with acetic acid in chloroform (previously water-washed before adding the acetic acid) into another volumetric flask. This last eluate was read immediately in a suitable spectrophotometer at 280 m μ for aspirin and 310 m μ for salicylic acid, as aspirin was not stable in this medium. The caffeine was read at 276 m μ while the phenacetin was evaporating. The residue in the evaporating dish was dissolved in a little chloroform and then diluted with isooctane in a volumetric flask and read at 285 m μ .

This entire procedure, from grinding of the tablets to the final UV readings, took less than 1 hr. Though it was not emphasized, the aspirin should not be left on the column any longer than necessary, as it has been found to hydrolyze readily. From experience it has been found that the phenacetin may be dissolved and diluted with chloroform; thus another solvent (isooctane) is unnecessary.

In calculating, standards of the three drugs and salicylic acid are read in the UV at the stated wavelength in the same medium as the sample. For practical purposes, it was assumed that aspirin's absorbance at 310 m μ was negligible (100 mcg. aspirin/ml. read 0.010). Thus, any reading at 310 m μ was calculated as salicylic acid. From this absorbance value at 310 m μ , the absorbance due to the salicylic acid at 280 m μ can be calculated from the values of the standard salicylic acid read at these two wavelengths and deducted from the total absorbance at 280 m μ ; the remainder can be considered to be the absorbance of the intact aspirin.

This partition chromatographic procedure compared excellently with the old and very laborious NF X procedure. The fact of the matter is that Levine's work was so convincing (and deservedly so) that in the next revision of the NF (NF XI) his procedure replaced the old official method except for the FSA limit test. There were also other firsts in this paper; Levine broke tradition with conventional partition chromatography techniques by altering the nature of the immobile phase (neutralizing the sodium bicarbonate phase of the column with acetic acid) as a step in the process. In so doing, the versatility of partition chromatography was thus broadened to permit separations not previously possible. In earlier techniques, the constitution of the immobile phase remains unchanged.

In 1959 and 1960, Smith (79, 80) reported on an AOAC collaborative study of the Levine method for APC. As a result of these studies, the Levine method became official in the Tenth Edition of the Methods of Analysis of the AOAC. These collaborative tests did show a weakness in the procedure, in that the values reported for the salicylic acid content varied appreciably (from 0.15 to 3.17% as hydrolyzed aspirin). As stated before, with care the hydrolysis of the aspirin on the

⁴ Celite 545, Johns-Manville Corp., New York, N. Y.

sodium bicarbonate column can be avoided, chiefly by eluting the column as quickly as possible. Smith suggested that the aspirin and salicylic acid content could be calculated by simultaneous equations rather than make the assumptions already discussed in the Levine paper.

Heuermann and Levine (81) and later Heuermann (82) expanded the usefulness of Levine's original work to the analysis of combinations of aspirin, phenacetin, and caffeine with other drugs. The other drugs were pyrilamine maleate, chlorphenpyridamine maleate, phenindamine tartrate, methapyrilene hydrochloride, doxylamine succinate, thonzylamine hydrochloride, codeine sulfate or phosphate, phenobarbital, or cyclopentylallylbarbituric acid. In neither paper were there any salicylic acid values reported, although discussion was made of its determination. An absorbance figure greater than 0.020 at 310 $m\mu$ indicated that partial hydrolysis of the aspirin had taken place and must be accounted for in the calculations of the aspirin content of the sample. Simultaneous equations were used in determining the intact aspirin and the FSA content of the sample.

In the application of his partition chromatographic procedure to just aspirin and aspirin tablets, Levine (83) required only the sodium bicarbonate segment of the column. With this paper, he clarified the salicylic acid status in that if 5% or more FSA was found, the aspirin and salicylic acid contents of the given sample were found simultaneously by the described UV procedure. If the FSA was under 5%, another technique was used. (This technique will be described later in this Review Article.)

With the UV procedure, it was noted earlier that aspirin was not stable in chloroform so a little acetic acid was added to acidify the medium. However, in the case of buffered tablets, a stronger acid was needed, not only to stabilize the aspirin but to protect it from the hydrolytic effect of the buffering agents present. This was accomplished by preparing a 0.24 *N* hydrochloric acid solution in methanol and adding a small amount of this solution to the original extraction medium of chloroform. The amount of acid present did not affect the efficiency of the chromatographic column, even if the tablets being assayed were not buffered. An aliquot of the aspirin solution was passed through the column with the aid of more chloroform (no ether was required as with APC tablets). The aspirin was eluted with acetic acid in chloroform and determined at 280 $m\mu$, while the reading at 310 $m\mu$ showed the salicylic acid content. If the absorbance at 310 $m\mu$ was 0.075 or higher, it represented a concentration of 5% or more FSA. The aspirin reading at 280 $m\mu$ was corrected for this FSA absorbance so that the intact aspirin could be reported. If the FSA was below 5%, another method was used in reporting FSA since this spectrophotometric procedure resulted in too low an absorbance reading to be accurate. This procedure was successfully applied to regular aspirin tablets (white), pink aspirin tablets, orange-colored and flavored children's aspirin tablets, enteric-coated tablets, buffered aspirin tablets, and aluminum aspirin tablets.

The stability of aspirin compounded with 10 different

kinds of antacids was reported by Kubo *et al.* (84). The samples were stored for a total of 90 days at: 5%, 52% relative humidity; 20%, 75% relative humidity; and 30%, 92% relative humidity. Samples were removed intermittently for assay by a UV spectrophotometric assay. The FSA content was calculated directly from the value at 308 $m\mu$, while the intact aspirin value at 275 $m\mu$ had to be corrected for the salicylic acid absorbance value. The antacids studied were aluminum silicate, magnesium carbonate, magnesium trisilicate, calcium gluconate, calcium lactate, sodium phosphate, dried aluminum hydroxide gel, calcium carbonate, magnesium oxide, and sodium bicarbonate. Only the 5° station showed good stability with these antacids. At the 30° station, the last four mentioned antacids were completely incompatible with aspirin, as shown by the high FSA values.

Even though pyrilamine was known to interfere with the salicylic acid reading at 308 $m\mu$, Siegel *et al.* (85) used the Tinker and McBay (76) UV procedure to expedite the analysis of tablets of pyrilamine resin adsorbate with aspirin and ascorbic acid. Tablets were stored at 60° for 1 week and for a total of 12 weeks at 45°. Samples removed at various time intervals showed an unexpected trend because the type of container closure and degree of fill were of prime importance for evaluating these products by accelerated temperature studies. Tablets stored in open bottles, or those with polyethylene snap caps, had greater stability than those with Bakelite screw caps. Filled containers appeared to have greater instability than partially filled ones; bottles that had been opened frequently, compared to those opened only once, appeared more stable. The following explanation was offered by the authors: the passage of air would remove moisture as well as gaseous acidic degradation products which promote instability in these tablets; thus, in tightly closed and well-filled bottles, this would not take place to as large a degree.

Chapman and Harrison (86) determined FSA in soluble aspirin tablets by dissolving the aspirin in glacial acetic acid, filtering, and reading the absorbance at 320 $m\mu$ against glacial acetic acid. The salicylic acid content was found from a standard calibration curve of salicylic acid run exactly as the sample. This solvent was selected because aspirin was not stable in chloroform for UV studies, and the results obtained were more reproducible than the BP procedure.

A more thorough study of the Tinker and McBay (76) procedure was reported by Ladomery (87). Chloroform was replaced with absolute spectral alcohol as the solvent for aspirin and salicylic acid. At the wavelength of maximum absorbance for salicylic acid, 300 $m\mu$, Beer's law held through 80 mcg./ml. of absolute spectral alcohol. Similar equations were calculated, only using the absorption data acquired from the alcohol medium. Application of this method was acceptable and accurate.

For APC preparations which contain both barbituric acid derivatives and certain organic bases, it was the objective of Turi (88) to develop a single method rather than using two procedures as described by Heuermann and Levine (81). He was successful with capsules

or tablets containing aspirin, phenacetin, caffeine, itobartol, and one of four phenothiazine derivatives (chlorpromazine hydrochloride, promethazine hydrochloride, thiethylperazine dimaleate, or thioridazine hydrochloride). No mention, however, was made of determining salicylic acid by this column procedure other than that a prolonged stay (on Column III) would result in a partial *in situ* degradation of the aspirin.

For the determination of aspirin, caffeine, and acetaminophen (APAP), Koshy (89) found that the reversal of the column arrangement described by Heuermann and Levine (81) was all that was required. The three active ingredients could be assayed beside the potential decomposition products, salicylic acid and *p*-aminophenol. After the two columns were prepared in the usual manner and placed in tandem, such that the top column contained the sulfuric acid as the immobile phase and the bottom column contained the sodium bicarbonate as the immobile phase, they were both washed with ether. The powdered sample was dissolved in ethyl acetate, an aliquot of which was then passed through the two columns and collected in a volumetric flask. The columns were further eluted with ether. This fraction contained intact APAP. The columns were then eluted with chloroform. This fraction contained the caffeine. The two columns were then separated, and the bottom column (sodium bicarbonate phase) eluted immediately with acetic acid in chloroform. This fraction contained the aspirin and salicylic acid and was assayed in the usual manner. The top column (sulfuric acid phase), containing *p*-aminophenol, was washed with ether to remove the chloroform. The diatomaceous earth support was then extruded from the column with air under pressure and collected in a beaker. The ether was evaporated from this material, and 0.1 *N* hydrochloric acid was added to dissolve the *p*-aminophenol. This extract was filtered and an aliquot was assayed colorimetrically using 1-naphthol as described by Greenberg and Lester (90).

The effect of water vapor pressure on moisture sorption and the stability of aspirin and ascorbic acid in tablet matrixes reported by Lee *et al.* (91) utilized the Tinker and McBay (76) procedure in evaluating the stability of the aspirin in these studies. Conclusions reached from these studies showed that the moisture adsorptive capacity of each compressed tablet formulation affected the stability of the two drugs to a great extent and were directly related to the moisture sorption and tablet hardness. (The harder the tablet, the less moisture it sorbed and the more stable the drug.) Of the six diluent systems studied, calcium sulfate and cellulose produced the most stable tablets of aspirin and ascorbic acid, while amylose produced the least stable. Under stress-storage conditions, screw-cap glass bottles proved to be a better moistureproof container than snap-top plastic vials. Cellophane and aluminum foil strip packaging materials were about equally effective. Both were more effective than the glass or plastic containers.

Reed and David (92) described a simple direct spectrophotometric determination of salicylic acid in either one complete capsule or one intact tablet of an aspirin containing medicinal, provided no interference by the

other components with the salicylic acid absorption at 300 $m\mu$ was encountered. The entire dose unit is shaken with alcohol for 1 hr. along with a similar freshly prepared unit dose as a "blank" (as this was generally not available, an equivalent amount of fresh aspirin was weighed and used as the blank). This exposure to an alcoholic medium for 1 hr. could lead to generated hydrolysis in the case of aspirin tablets containing buffers as there is no mention of pH control here or in the aqueous dilution being read at 300 $m\mu$. The sample was read against the blank so that the effect of the intact aspirin would be cancelled out, provided the difference between the two concentrations was not great.

Application of the Tinker and McBay (76) procedure was applied by Day *et al.* (93) in following the stability of two mixtures official in the BPC. They reported the accuracy of the method to be $\pm 2.5\%$.

In a general paper on the use of UV for analysis of drugs in pharmaceuticals, Sattler (94) applied the method described by Ladomery (87) which was a modification of the Tinker and McBay procedure.

A direct spectrophotometric determination of five compounds, aspirin, salicylamide, caffeine, phenacetin, and salicylic acid, in tablets or powders without any preliminary separation was reported by Clayton and Thiers (95). The powdered sample was extracted with chloroform. From this extract, three aliquots (same volume size) were added to separate volumetric flasks, one to be an acidic medium, another to be a basic medium, and the third a hydrolyzed medium. A mixed solvent consisting of isopropanol, water, and a small amount of hydrochloric acid was added to each flask followed by a solution of 50% sodium hydroxide to the basic and hydrolyzed labeled flasks. After hydrolysis of the aspirin was complete at room temperature (about 15 min.), concentrated hydrochloric acid was added to the hydrolyzed labeled flask, rendering it acid again. On diluting all flasks to volume with the mixed solvent, the solutions were then read at the following wavelengths along with the appropriate reference blank solution. The acidic labeled solution was read at 250, 273, and 310 $m\mu$, the basic labeled solution at 333 $m\mu$, and the hydrolyzed labeled solution at 301 $m\mu$. Using a variety of equations, the content of the individual components was calculated. The comment was made that if salicylic acid were absent, it was possible to omit one step, but the omission is not recommended, since this step provides a measure of any hydrolysis of aspirin which might have occurred during storage or manufacture of the product analyzed.

Use of the isosbestic point as a base line in differential spectrophotometry was applied to aspirin and salicylic acid by Shane and Routh (96). When a series of concentrations of salicylic acid were used to prepare differential absorption spectra, monosodium salicylate (at pH 9) in the reference cell *versus* disodium salicylate (at pH 13.5) in the sample cell, two maxima at 246 and 319 $m\mu$, two minima at 233 and 203 $m\mu$, and two isosbestic points at 268 and 300 $m\mu$ were observed. If differential absorption spectra of aspirin solutions were prepared by the same procedure (monosodium acetylsalicylate in the reference cell *versus* disodium salicylate equivalent to the monosodium acetylsalicylate in the sample cell), a




Figure 5 Differential spectra of salicylic acid (A, B, C) and aspirin (A', B', C'). [Reprinted, with permission, from N. A. Shane and J. I. Routh, *Anal. Chem.*, 39, 414, (1967).]

maximum at 300 $m\mu$, a minimum at 268 $m\mu$, and an isosbestic point at 272 $m\mu$ were observed. Figure 5 illustrates the differential absorption spectra of three concentrations of salicylic acid (A, B, and C) compared to the spectra of three concentrations of aspirin (A', B', and C') in the region from 260 to 340 $m\mu$. Each curve is constructed from the two spectra of the same concentration of either salicylic acid or aspirin obtained at pH 9 and 13.5 by subtracting one spectrum from the other spectrum, resulting in the differential absorption spectrum of the given compound. The isosbestic point in differential spectrophotometry would be the wavelength at which each difference curve crosses the zero line. The correlation of the isosbestic point at 300 $m\mu$ for salicylic acid, and the maximum at the same wavelength for aspirin, permits the use of the isosbestic point as the zero or base line for the quantitative determination of intact aspirin in the presence of salicylic acid. Thus, one would not need to do a FSA determination as the value reported for aspirin is for the intact aspirin.

A very much needed publication on the significance of salicylic acid sublimation in stability testing of aspirin-containing solids was presented by Gore *et al.* (29). A more than negligible loss of salicylic acid formed from the decomposition of aspirin would preclude the common practice of analytically determining changes in salicylic acid content in solid dosage forms of aspirin as a measure of degrading aspirin. The salicylic acid method could obviously underestimate the extent of decomposition of aspirin and, therefore, provide false confidence in the stability of the tested products. It thus became necessary to develop a method of gauging aspirin stability in solids which would be unaffected by any loss of salicylic acid.

A simultaneous spectrophotometric assay, based chiefly on the work of Edwards (8), was developed for aspirin and salicylic acid in a Clark and Lubs buffer, pH

Table XVI—Constants for Aspirin and Salicylic Acid UV Assay

Compound	Concentration Range, mcg./ml. of pH 7.4 Buffer	Absorptivity Value at	
		262 $m\mu$	296.5 $m\mu$
Aspirin	0-160	3.2	0
Salicylic acid	0-10	3.3	—
Salicylic acid	0-30	—	26.0

Table XVII—Sublimation Rates of Salicylic Acid at Various Temperatures

Temperature	Rate of Sublimation, mg./hr.
40 \pm 0.05°	0.026
50 \pm 0.20	0.062
70 \pm 0.20°	0.372

7.4. It was found that this aqueous medium resulted in improved precision over the chloroform medium used by earlier workers. This slightly alkaline medium afforded a relatively rapid solution of solid aspirin and salicylic acid, and a medium in which slight variation in the pH would not introduce an error into the determination as a consequence of the differential absorption of ionized and unionized aspirin or salicylic acid. The rate of hydrolysis of aspirin has been reported (8) to be independent of pH in the range of 4 through 8. Hydrolysis rate constants were determined at pH 7.4 and 25.5°, and showed a delay of 13 min. between the sample preparation and reading on the spectrophotometer would cause an error of approximately 1%. The actual error was reduced to below 0.1% by maintaining the solutions below 15°, usually at 0°, and reading them within 5-10 min. of their preparation.

Table XVI presents the pertinent data required in the construction of the calibration curves used here.

Before applying this UV procedure, several sublimation studies were conducted in which the need for such an assay was demonstrated quite convincingly. Using an electrobalance, the weights of salicylic acid were monitored continually at the stated temperatures for 12 hr. From this study the following rates of sublimation were calculated (Table XVII).

An Arrhenius-type plot of the apparent zero-order sublimation rates was shown. The slope of the curve was predominately determined by the enthalpy of sublimation of salicylic acid. The observed rates of sublimation may be expected to depend directly upon the area through which the mass transfer occurred. These results, therefore, were not intended to be quantitatively indicative of sublimation loss of salicylic acid during the stability testing, but merely substantiate that such a loss can occur even at moderately elevated temperatures.

A similar sublimation study of purified aspirin revealed no significant loss of weight up to 70°. It was concluded that aspirin does not appreciably sublime under the conditions of the experiment.

With a 9:1 mixture of aspirin-salicylic acid, the results from 12 hr. at 70° indicated that only salicylic acid was lost. This was verified by using the UV procedure discussed.

Aspirin tablets were stored at 50° and 81.2% relative humidity for a period of 98 days. At various time intervals tablets were removed and assayed by first grinding to a fine powder and dissolving in pH 7.4 buffer maintained at 0°. After filtration, an aliquot of the filtrate was further diluted with the cold pH 7.4 buffer and the absorbance measured at 262 and 296.5 $m\mu$. In this application, an error of 0.003 absorbance unit at 262 $m\mu$ could contribute an error of approximately 1% in the

Table XVIII Comparison of Aspirin Tablet Stability Testing Results at 80% and 81.2% Relative Humidity, Based on Determination of Aspirin and Salicylic Acid Content of the Tablets*

Time, Days	Aspirin Content Based on Analysis of Aspirin, %	Aspirin Content Based on Analysis of Salicylic Acid, %	Error Due to Sublimation of Salicylic Acid, %
0	100	100	0
15	99.1 \pm 0.038	99.1 \pm 0.028	0
30	98.4 \pm 0.042	98.8 \pm 0.215	0.4
45	97.2 \pm 0.123	98.7 \pm 0.075	1.5
60	97.1 \pm 0.178	98.6 \pm 0.023	1.5
98	95.0 \pm 0.288	97.9 \pm 0.311	2.9

* Each value is the average of four determinations recorded with ± 1 standard deviation.

determination of the aspirin content of a solid consisting of 80% aspirin using a 50-mg. aliquot for analysis. The results of this study are presented in Table XVIII.

The last column does show that salicylic acid is lost from these tablets by sublimation under the stated conditions of the experiment.

By employing the UV procedure presented in this publication, the determination of the residual aspirin, rather than the apparent salicylic acid, in a solid can be used as a valid means of gauging the stability of the formulation. This method of analysis showed an accuracy within at least 1.5%.

DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS WITH THE AID OF A FERRIC-ION CHROMATOGRAPHIC COLUMN

Analytically, the need has always been great to separate and isolate the salicylic acid from aspirin as well as other components in the pharmaceutical preparation. The potential susceptibility of aspirin to hydrolysis is constantly prevalent, so the more rapidly the intact aspirin is removed from the medium, once a given procedure is begun, the truer the reported FSA values will be.

Again Levine (83) appeared to be first in breaking away from the traditional methods of determining salicylic acid in aspirin formulations. On using the chromatographic columns he had introduced in 1957 with a diatomaceous earth-2% ferric chloride mix, the passage of a chloroform solution of aspirin and salicylic acid resulted in the trapping of the salicylic acid (shown by a purple zone on the column). The aspirin passed through, and by using several washes with chloroform, the aspirin was completely removed from the column. The bound salicylic acid was then eluted quantitatively with chloroform containing acetic acid. This eluate was read at 310 m μ for FSA. For the procedure to be valid, the purple zone should not reach the bottom of the tube during the washing out of the aspirin. If it does, the procedure must be repeated with another prepared column. As the original procedure was written, this was a major downfall in using this technique, because too many times the purple zone moved partially off the column during the aspirin removal step.

This procedure was applied to pink aspirin tablets, children's flavored and colored aspirin tablets, buffered aspirin tablets, and aluminum aspirin tablets. With the colored tablets, the dyes remained at the top of the

column throughout the entire assay. With the buffered tablets, the chloroform-insoluble salts of aspirin or salicylic acid must be transformed to soluble acids in order that the FSA could be eluted in the proper fraction. Acetic acid could not be used since it would dissociate the ferric ion-salicylic acid complex on the column. Boric acid, however, was used for this transformation without affecting the column performance. A solution of boric acid in methanol was added to the sample, followed by chloroform to dissolve the freed aspirin and salicylic acid.

For enteric-coated tablets it was found best to mount in tandem a column containing just diatomaceous earth above the regular ferric ion-diatomaceous earth column. The plain diatomaceous earth column removed the surface-active agents present in these tablets, so the aqueous phase would not be stripped off the regular ferric ion-diatomaceous earth column during both the pre-washing step and elution of the salicylic acid. This double column setup could be used also where dyes are present in the original chloroform extract, as well as for large amounts of excipient material in the sample being added to the column.

As will be seen with later papers dealing with this novel approach of Levine's, a delicate balance was being maintained with the ferric chloride content on the diatomaceous earth. A sufficiently low concentration of ferric chloride must be maintained to trap the salicylic acid, but at the same time a sufficiently large quantity of ferric chloride must be present to provide an excess over the amount removed during the washing step. It is thus recommended that the modifications of this procedure, to be discussed in this review, be used rather than the method described in this publication. Just the introduction of this approach to the literature served a very worthwhile purpose as the official compendia now use a procedure based on this original study.

Green (67) applied this described procedure by Levine and as he did not present any comments in his paper, it could be assumed that he did not experience any major difficulty with the columns.

In 1961 Weber and Levine (97) made note that "several investigators have encountered difficulty with the published method" (83). During the elution of the aspirin, the salicylic acid migrated slowly down the column (as evidenced by the position of the purple complex) and spread out into a diffuse band, which sometimes becomes difficult to discern.

In this publication, this was rectified by modifying the ferric chloride reagent. This radical improve-

ment in the chromatographic separation was achieved by having a high concentration of urea in the ferric chloride solution. The resultant effects were tremendous: the band of the ferric salicylate complex obtained with this new reagent was more deeply colored than that obtained with just the simple ferric chloride reagent. The dense, sharply delineated band migrated only slightly during the elution of the aspirin.

It, therefore, became feasible to use a shorter column which did not require extraordinary care in packing. This column even accommodated larger samples of aspirin.

Optimum conditions were obtained with an immobile phase containing 5% ferric chloride solution which was 10 *M* with respect to urea. The pH must be maintained between 3.1 and 3.3. At lower pH levels the salicylic acid band became diffuse and more loosely retained, while at higher pH levels, recovery of salicylic acid from the column may be incomplete using the specified volume of eluant.

For aspirin or aspirin tablets, the pulverized sample was dissolved with chloroform and passed through the column with the aid of several more portions of chloroform to wash the intact aspirin through the column. A volumetric flask containing some hydrochloric acid in methanol was placed under the column, and the column first eluted with acetic acid in ether followed by chloroform. Concomitantly the absorbance of this solution and of the standard salicylic acid in the same medium was determined at 306 $m\mu$.

For APC tablets and flavored tablets, a column containing a small pad of cotton was placed in tandem over the regular ferric chloride-urea column. The sample in the chloroform was passed first through the cotton column to remove the dyes and any insoluble excipients. Another portion of chloroform was passed through the two columns, and then the top column was discarded. The regular column was then washed with chloroform and the salicylic acid eluted.

As moderate amount of urea was eluted together with the salicylic acid from the column, the hydrochloric acid in the receiving flask was added to maintain acidity of the eluate. The methanol was present to achieve miscibility of the acid with the eluting solvent.

With buffered aspirin tablets, the boric acid was replaced with oxalic acid in methanol, as the oxalic acid was more effective in releasing the bound salicylic acid from the antacid. The oxalic acid solution recovered quantitatively salicylic acid from its calcium salt. However, neither this nor any other reagent thus far tested quantitatively released salicylic acid from aluminum hydroxide gel without causing extensive hydrolysis of aspirin.

Excellent reproducibility on replicate analyses of a wide variety of commercial samples was shown.

Though Weber's publication (98) on the analysis of salicylic acid and benzoic acid does not deal with aspirin, *per se*, it had a valuable innovation regarding the ferric chloride-urea-diatomaceous earth column. When eluting salicylic acid of larger quantities than usual, the occasional leakage of ferric chloride was noted which invalidated the assay. This was seen visually by the presence of a yellow color rather than the usual colorless

clear eluate. If any yellow is present in the solution read, the reading at 306 $m\mu$ would have to be voided. Weber found that a small layer of diatomaceous earth with 30% phosphoric acid as the immobile phase placed at the bottom of the column on top of the glass wool support, and then followed by the regular ferric chloride-urea-diatomaceous earth mix, resulted in no ferric chloride leakage. The phosphoric acid retained any ferric chloride which might be removed during the elution step of the salicylic acid.

In their study on the formation of acetylcodeine from aspirin and codeine, Jacobs *et al.* (99) used the original Levine procedure (83) in isolating the salicylic acid which resulted from the previously mentioned reaction.

On discussing pharmaceutical heterogeneous systems, Zoglio *et al.* (28) have presented four papers regarding the hydrolysis of aspirin. The salicylic acid resulting from the degradation of aspirin in the various formulations was determined by a modification of Levine's iron-diatomaceous earth procedure (83). The first paper [Kornblum and Zoglio (28)] is discussed in the *Hydrolysis Studies* portion of this review. They demonstrated that calcium or magnesium stearate accelerated the production of salicylic acid from aspirin through the solubilization of aspirin as a calcium or magnesium salt. More aspirin would thus be in solution which in turn would hydrolyze in the existing pH which was conducive to hydrolysis. This effect was not as pronounced when aluminum stearate was used as a lubricant, as the aluminum salt of aspirin has a low solubility in water.

On pursuing this alkali stearate effect, Zoglio *et al.* (28) prepared capsules containing aspirin (20 parts), magnesium stearate (1 part), and 0, 1, 2, 5, 10, and 20 parts of hexamic, maleic, malic, or tartaric acids, or maleic anhydride. These capsules were stored at 22, 40, and 50° for 30 days. A minimum of 20% by weight of hexamic, maleic, or malic acid was required to retard the hydrolysis of aspirin in these capsules. Tartaric acid or maleic anhydride was not effective at the higher temperatures. Besides the lower desired pH contributed by the added acid, the mechanism of inhibiting the degradation of aspirin involved the additive acid and aspirin competing for the magnesium ion.

Maulding *et al.* (28) showed that stearic acid USP, which is nearly a 1:1 mixture of stearic and palmitic acids, promoted the decomposition of aspirin more than either reagent grade stearic or palmitic acid. On preparing various synthetic mixtures of reagent stearic and palmitic acids, the one simulating the amounts of the two acids in stearic acid USP behaved similarly as the stearic acid USP in accelerating the decomposition of aspirin. This ratio of stearic and palmitic acids was also the melting point minimum of the various mixes of these two acids. The possibility exists, therefore, of a liquid or semiliquid being present in formulations containing stearic acid USP which might serve as the medium for aspirin hydrolysis.

The fourth paper dealt with the acceleration of aspirin hydrolysis by various common additives (hexamic acid, aluminum hydroxide calcium stearate, magnesium stearate, or magnesium trisilicate), at a 5 or 10% level of the powder mix or tablet. The formulations con-

taining magnesium trisilicate resulted in the largest amount of FSA (about 13%) after 45 days at 40°. Hexamic acid, under these storage conditions, retarded aspirin hydrolysis. The salicylic acid values resulting from these various formulations were in good agreement with values obtained from extrapolating apparent zero-order rates of aspirin suspensions of the same powder mix as used in the tablet. These studies show that stability prediction for solid dosage forms from apparent zero-order rates of suspensions is feasible and informative.

The determination of the FSA in buffered aspirin tablets by Levine and Weber (100) explored further the usefulness of their ferric chloride-urea-diatomaceous earth column. It was essential that the entire amount of aspirin and salicylic acid be dissolved in the mobile phase before the chromatographic treatment, and that the aspirin was not hydrolyzed during the preparation of that solution. These two requirements are not readily achieved in the case of buffered aspirin tablets. Chloroform solutions of aspirin, in the presence of basic materials such as those which comprise the buffering components of the tablets, undergo hydrolysis together with aspirin anhydride formation. Boric acid stabilizes the solution, at least with respect to the hydrolysis of aspirin, but does not achieve the necessary release of the aspirin and salicylic acid from the buffer components to permit their complete solution in chloroform.

In designing a valid assay procedure, the acid which is used must: (a) produce only minimal hydrolysis of aspirin under the conditions of the assay; (b) rapidly and completely release aspirin and salicylic acid from the buffer components of the tablet; (c) be soluble in chloroform; and (d) be readily removed from the chloroform, so that the ferric-salicylic acid complex will not be dissociated during the following step of the analysis.

These requirements were fulfilled by 98-100% formic acid. The distribution of formic acid between chloroform and inorganic acids was greatly in favor of the aqueous phase; therefore, the formic acid was removed from the chloroform solution by passage over dilute hydrochloric acid.

In the analysis of buffered aspirin tablets, two columns are prepared and placed in tandem. The top column consists of diatomaceous earth with 0.05 *N* hydrochloric acid as the immobile phase. It is here that the formic acid in the chloroform is removed. The packing of this column should be such that a flow rate of chloroform of 12 ml./min. is obtained.

The bottom column consists of a layer of diatomaceous earth with 30% phosphoric acid as the immobile phase. The phosphoric acid retains any ferric iron which may be eluted during the procedure. The upper stage of this column consists of the 5% ferric chloride and 10 *M* urea as the immobile phase on diatomaceous earth.

In the procedure, water-saturated solvents were used throughout. To a ground sample of tablets in a volumetric flask, the 98% formic acid was added with swirling to wet the sample completely (not more than 30-45 sec.) followed by chloroform. This mixture was shaken for 10 min. The extent of hydrolysis of aspirin

during the period of contact of the sample with the formic acid before dilution lies in the range of 0.01-0.02% min., so here the extent of hydrolysis will be in the order of 0.01%. After dilution with the chloroform, the hydrolysis of aspirin sharply decreased to an average of only 0.03%/hr. Thus a negligible amount of hydrolysis occurs during the 10-min. shaking period for dissolving the aspirin and salicylic acid. On diluting to volume with chloroform and mixing, the solution was filtered through a loose plug of glass wool. An aliquot of this filtrate was then passed through the double columns which were washed with more chloroform to remove the aspirin. The eluate and the top column were discarded. A receiver containing hydrochloric acid in methanol was placed under the remaining (bottom) column, and ether containing acetic acid was passed through the column followed by chloroform containing acetic acid. This eluate was read at 306 m μ along with a salicylic acid standard in the same medium.

By this method, great strides have been made in regard to freeing salicylic acid from various antacids. It was shown that the formic acid treatment readily recovers salicylic acid from its calcium or magnesium salts but that aluminum salicylate was quite refractory to this treatment. As dried aluminum hydroxide gel is present in several of the commercial buffered aspirin tablets, the need is still acute for a method which will recover salicylic acid from its aluminum salt.

On studying the USP XVII limit test for salicylic acid in aspirin tablets containing buffers, Guttman (101) obtained spurious and nonreproducible results. Low recoveries were explained by an adsorption phenomenon. Significant adsorption of salicylic acid occurred when solutions of chloroform were in contact with chloroform-insoluble agents which are commonly employed as buffers in aspirin tablets. The affinity of salicylic acid for magnesium carbonate and aluminum glycinate was high, but the capacity of these solids for the acid was rather low. These two compounds held tenaciously to the salicylic acid, as it was impossible to elute completely adsorbed material by repeated contacts with fresh solvent.

High recoveries of salicylic acid resulted from a surprisingly rapid transformation of aspirin to a product having the chromatographic characteristics of salicylic acid. This was observed only when solid basic material (here magnesium carbonate) was suspended in the chloroform solution of aspirin. This transformation of aspirin was thus surface catalyzed.

On repeating this experiment with different commercially available buffered aspirin products, the same phenomenon occurred except with one—and it contained citric acid monohydrate besides two antacid compounds. With this sample, the salicylic acid content did not increase appreciably with time of contact with the solid suspension. With all these suspension studies, it was of interest to note that, upon filtration, immediate cessation of salicylic acid production resulted. This was shown by the readings in the UV at 278 and 306 m μ on the chloroform filtrate or when the ferric chloride-urea-diatomaceous earth column procedure (USP XVII) was used.

Table XIX Results Obtained when Various Methods Were Employed to Estimate Salicylic Acid (SA) Contents of a Number of Commercial Buffered Aspirin Products

Product	Buffers Present	USP Procedure	%, SA Found Using		
			Citric Acid Procedure for FSA	Weber and Levine (97) Procedure	Citric Acid Procedure for Total Nonaspirin Salicylates
1	Aluminum hydroxide Magnesium hydroxide	2.19	4.02	6.59	6.64
		2.80	4.02	6.53	6.58
		3.03	3.89		6.62
2	Aluminum glycinate Magnesium carbonate	Not detectable	0.211	0.64	0.728
			0.236	0.69	0.718
			0.219	0.62	0.739
3	Aluminum hydroxide Glycine Magnesium carbonate	0.455		0.67	
			1.01	3.79	3.78
				3.91	3.58
4	Calcium phosphate Sodium bicarbonate Citric acid	—	5.22	3.52	3.58
					5.92
5	Aluminum hydroxide Glycine Magnesium carbonate	—	0.682	—	2.81
6	Aluminum hydroxide Magnesium hydroxide	—	1.82	—	3.39
7	Calcium carbonate Magnesium carbonate	—	1.96	—	3.37

On further studies with aspirin in chloroform and magnesium carbonate in suspension with and without an equal weight of citric acid monohydrate, it was found that no salicylic acid was produced in 200 min. at 25° with citric acid present. After 60 min. of magnesium carbonate being in contact with the aspirin solution, the addition of citric acid monohydrate resulted in no further salicylic acid production. It was visually observed that the addition of citric acid had a pronounced effect on the nature of the suspension. Marked flocculation of particles was apparent immediately after the addition of citric acid monohydrate. Citric acid which had been previously oven-dried showed a much less marked effect in inhibiting salicylic acid production. This showed that presence of water from the hydrate was essential in this reaction with suspended material. Applying this citric acid monohydrate to the previously studied commercial buffered tablets on an equal weight basis showed that in all systems studied here, the citric acid was effective in markedly reducing the catalytic ability of suspended solids in the production of salicylic acid from the aspirin in chloroform.

Repeating the magnesium carbonate-aspirin adsorption experiment discussed earlier, only this time with and without an equal amount of citric acid monohydrate, it was found that in the presence of citric acid there was no appreciable adsorption of the aspirin from the chloroform. It is also of interest that treatment of antacid compounds in suspension in chloroform with citric acid monohydrate significantly reduced their capacities for adsorbing salicylic acid.

Guttman's study demonstrated very convincingly that finely divided solids of antacids do catalyze a conversion of aspirin to a product which, by the analytical method employed, was determined as salicylic acid. The reaction occurred under essentially anhydrous conditions, and adsorption of the aspirin was apparently a prerequisite for the transformation. The presence of citric

acid monohydrate was shown to be effective in inhibiting the formation and adsorption of salicylic acid in the systems reported here. A feasible explanation was given: citric acid monohydrate, which is essentially chloroform insoluble, inhibits the reaction by releasing water of hydration to the surface of the adsorbent. A neutralization reaction takes place in the hydrate layer which modifies the surface characteristics of the adsorbent so as to destroy the adsorption sites. Thus, the catalytic production of salicylic acid from aspirin is never initiated.

Results from studies presented in this paper showed that addition of citric acid monohydrate to the official chromatographic procedure in the original extraction of the sample resulted in almost quantitative recovery of salicylic acid. It was also noted that this citric acid treatment was not effective in displacing salicylic acid from metallic salts which are known to form in buffered aspirin products.

In applying the procedure suggested in the preceding paper, Guttman and Salomon (102) compared its usefulness (and superiority) over the existing USP XVII FSA test for buffered tablets of aspirin. The method consisted of treating, by trituration, a powdered sample with an equal weight of citric acid monohydrate, and dissolving the aspirin and the FSA from the powder mass with chloroform. The remaining residue was treated with an aqueous solution of a strong acid (hydrochloric acid), and this solution was extracted with chloroform. The two chloroform extracts (one containing the FSA and the other containing the non-aspirin salicylates) were combined, and the salicylic acid content determined by the chromatographic method of Weber and Levine (97). With the assumption that the citric acid treatment results only in desorption of salicylic acid and aspirin and does not cause conversion of salicylate salts to free acid, one would have a method available for the estimation of the FSA content




Figure 6: Gas chromatogram of aspirin in alcohol. [Reprinted, with permission, from J. G. Nikelly, *Anal. Chem.*, 36, 2248 (1964).]

as well as total nonaspirin salicylate contents of buffered tablets of aspirin. Table XIX summarizes the results on applying four different procedures to commercially available buffered aspirin tablets: USP XVII (using boric acid in the initial extraction), Guttman's citric acid procedure, Guttman and Salomon's citric acid procedure for total nonaspirin salicylates, and the Levine and Weber procedure (100) which used formic acid in the initial extraction medium.

Inspection of this table makes obvious that the FSA values, as determined by the USP procedure, were consistently and significantly lower than those determined by the other methods. It is logical to assume that these low values resulted from adsorption of significant amounts of salicylic acid during sample extraction, and to the insensitivity of the procedure to salicylic acid which is present in the sample in the form of salts. The latter two methods appear to be equally precise. It is interesting to note the difference between the citric acid procedure for FSA and the citric acid procedure for total nonaspirin salicylates. The differences reflect the fact that significant amounts of salicylic acid can be present in buffered tablets as chloroform-insoluble salts. It is also apparent that no relationship exists between the FSA content and total nonaspirin salicylate content of these tablets.

DETERMINATION OF SALICYLIC ACID IN ASPIRIN AND ASPIRIN PRODUCTS BY MISCELLANEOUS METHODS

Schulek and Burger (103) stated that on using BrCl as a brominating agent, salicylic acid could be brominated quantitatively in 2 min., even in the presence of aspirin. With the usual amounts of FSA present in aspirin products, it is debatable whether such a titration would be sensitive enough to be of value.

The application of differential thermal analysis (DTA) and thermogravimetric analysis (TGA) to aspirin was published by Wendlandt and Hoiberg (104). No mention was made of the effects of the presence of salicylic acid, but application of this approach would definitely be of interest in evaluating the purity of aspirin.

Gas chromatography has a great potential in the analysis of aspirin products, but only two papers have mentioned the possibilities. Crippen and Freimuth (105)

stated that their proposed procedure would differentiate aspirin from salicylic acid only if the temperature of 100–125° and a 1.23–1.83-m. (4–6-ft.) column were used. Nikelly (106) showed (Fig. 6) that under the stated conditions used in the determination of aspirin, the amount of acetic and salicylic acids could be estimated.

In applying an IR spectrophotometric assay of aspirin anhydride, Garrett and Johnson (107) concluded that the insignificance of salicylic acid in these lots of varied purity showed that little definition was lost on ignoring it. Though samples of aspirin were not used here, the usefulness of IR studies on the purity of aspirin in regard to salicylic acid would be of value.

The need for actual physical separation of salicylic acid from aspirin is great. The work by Vietti-Michelina (108) and Wagner (109) on paper chromatographic or paper electrophoretic separation of aspirin and salicylic acid might be applied successfully by using the latest techniques available in this field.

A too often neglected technique in drug studies in the United States is the application of polarography. In 1949 Korshunov *et al.* (110) reported on the reduction of weak acids at a dropping-mercury cathode. The half-wave potentials were given as 1.52 to 1.65 (for 1–7 mmoles/l.) for aspirin and 1.66 to 1.83 (for 1–9 mmoles/l.) for salicylic acid in 0.05 *N* tetramethylammonium iodide. With the more sensitive polarographs of today, such an approach in the analysis of aspirin products could prove to be useful.

Quantitative separation of aspirin and salicylic acid by sephadex G gel filtration was reported by Lee *et al.* (111). No detectable (fluorometrically) hydrolysis of aspirin on the column was noted.

TLC should be an invaluable tool in aspirin stability studies. By using a mixture of hexane, glacial acetic acid, and chloroform (20:5:5), Reimers (112) separated aspirin and salicylic acid. After resolving the mixtures of aspirin-salicylic acid on thin-layer plates [using ascending technique and a hexane, glacial acetic acid, and chloroform mixture (85:15:10), *R_f* values of 0.2 and 0.35 were obtained for aspirin and salicylic acid, respectively], the spots were removed from the dried plates, packed in an appropriate cell, and determined by UV reflectance spectroscopy. A linear relationship at 302 mμ between absorbance and the square root of the concentration was observed by Frodyma *et al.* (113) with spots containing up to 3.0 μmoles of either compound.

An exhaustive paper on differentiating nonaqueous titration of salicylic acid and aspirin by Lin (114) showed that such a procedure was feasible. Dimethylformamide was the solvent of choice along with the titrant of 0.1 *N* tetrabutylammonium hydroxide in benzene-methanol (10:1) using either a glass-calomel or platinum-calomel electrode pair.

REFERENCES

- (1) J. Rath, *Ann.*, 358, 98(1908); through *Chem. Abstr.*, 2, 1002(1908).
- (2) D. E. Tsakalotos and S. Horsch, *Bull. Soc. Chim.*, 15, 743(1914); through *Chem. Abstr.*, 9, 787(1915).
- (3) *Ibid.*, 17, 401(1915); through *Chem. Abstr.*, 10, 591(1916).
- (4) A. Wolf, *Sc. Kem. Tidskr.*, 29, 109(1917); through *Chem. Abstr.*, 11, 2634(1917).

- (53) C. W. Strode, Jr., F. N. Stewart, H. O. Schott, and O. J. Coleman, *Anal. Chem.*, **29**, 1184(1957).
- (54) L. J. Leeson, Ph.D. dissertation, University of Michigan, Ann Arbor, Mich., 1957.
- (55) L. J. Leeson and A. M. Mattocks, *J. Amer. Pharm. Ass. Sci. Ed.*, **47**, 329(1958).
- (56) F. J. Bandelin and W. Malesh, *J. Amer. Pharm. Ass. Pract. Ed.*, **19**, 152(1958).
- (57) C.-M. P. Wirth, *Pharm. Acta Helv.*, **34**, 283(1959).
- (58) J. Kral, H. Bielezova, and Z. Drozdova, *Farm. Obzr.*, **29**, 298(1960); through *Chem. Abstr.*, **61**, 2910h(1964).
- (59) I. Lippmann, Ph.D. dissertation, University of Michigan, Ann Arbor, Mich., 1960.
- (60) M. R. Nazareth and C. L. Huyck, *J. Pharm. Sci.*, **50**, 608(1961).
- (61) *Ibid.*, **50**, 620(1961).
- (62) J. D. DeMarco and A. D. Marcus, *ibid.*, **51**, 1010(1962).
- (63) H. Okano, H. Kawata, S. Tsutsumi, and Y. Umezaki, *Yakuzai-gaku*, **23**, 279(1963); through *Chem. Abstr.*, **61**, 537h(1964).
- (64) H. M. Patel and C. L. Huyck, *Mfg. Chem.*, **34**, 100(1963).
- (65) I. Grabowska, *Gdansk. Tow. Nauk., Rozpr. Wyzd.*, **3**, 193(1964); through *Chem. Abstr.*, **64**, 14029a(1966).
- (66) *Ibid.*, **3**, 207(1964); through *Chem. Abstr.*, **64**, 15678b(1966).
- (67) A. R. Green, *Australas. J. Pharm.*, **45**, S88(1964).
- (68) G. Gold and J. A. Campbell, *J. Pharm. Sci.*, **53**, 52(1964).
- (69) A. E. Troup and H. Mitchner, *ibid.*, **53**, 375(1964).
- (70) D. Trose and R. Danz, *Pharm. Prax.*, **1966**, 228.
- (71) F. Jaminet and G. Evrard, *Pharm. Acta Helv.*, **41**, 601(1966).
- (72) W. Wisniewski and H. Piasecka, *Acta Pol. Pharm.*, **24**, 291(1967).
- (73) K. T. Koshy, A. E. Troup, R. N. Duvall, R. C. Conwell, and L. L. Shankle, *J. Pharm. Sci.*, **56**, 1117(1967).
- (74) F. Jaminet and G. Louis, *Pharm. Acta Helv.*, **43**, 153(1968).
- (75) L. F. Cullen, D. L. Packman, and G. J. Papariello, *Ann. N. Y. Acad. Sci.*, **153**, 525(1968).
- (76) R. B. Tinker and A. J. McBay, *J. Amer. Pharm. Ass., Sci. Ed.*, **43**, 315(1954).
- (77) W. R. Ebert, Ph.D. dissertation, University of Michigan, Ann Arbor, Mich., 1956.
- (78) J. Levine, *J. Amer. Pharm. Ass., Sci. Ed.*, **46**, 687(1957).
- (79) G. Smith, *J. Ass. Offic. Agr. Chem.*, **42**, 462(1959).
- (80) *Ibid.*, **43**, 241(1960).
- (81) R. F. Heuermann and J. Levine, *J. Amer. Pharm. Ass., Sci. Ed.*, **47**, 276(1958).
- (82) R. F. Heuermann, *J. Ass. Offic. Agr. Chem.*, **43**, 243(1960).
- (83) J. Levine, *J. Pharm. Sci.*, **50**, 506(1961).
- (84) F. Kubo, K. Imaoka, and A. Kaneko, *Ann. Rep. Kyoritsu Coll. Pharm.*, **6/7**, 1(1961-1962); through *Chem. Abstr.*, **60**, 375d(1964).
- (85) S. Siegel, R. H. Reiner, J. A. Zelinskie, and E. J. Hanus, *J. Pharm. Sci.*, **51**, 1068(1962).
- (86) W. B. Chapman and A. J. Harrison, *J. Ass. Pub. Anal.*, **1**, 64(1963).
- (87) L. G. Lodomery, *Australas. J. Pharm.*, **44**, 10(1963).
- (88) P. Turi, *J. Pharm. Sci.*, **53**, 369(1964).
- (89) K. T. Koshy, *ibid.*, **53**, 1280(1964).
- (90) L. A. Greenberg and D. Lester, *J. Pharmacol. Exp. Ther.*, **88**, 87(1946).
- (91) S. Lee, H. G. DeKay, and G. S. Banker, *J. Pharm. Sci.*, **54**, 1153(1965).
- (92) R. C. Reed and W. W. Davis, *ibid.*, **54**, 1533(1965).
- (93) M. D. Day, J. F. Harper, and O. J. Olliff, *Chem. Drug.*, **186**, 127(1966).
- (94) H. Sattler, *Pharm. Ztg.*, **111**, 1395(1966).
- (95) A. W. Clayton and R. E. Thiers, *J. Pharm. Sci.*, **55**, 404(1966).
- (96) N. A. Shane and J. I. Routh, *Anal. Chem.*, **39**, 414(1967).
- (97) J. D. Weber and J. Levine, *J. Pharm. Sci.*, **55**, 78(1966).
- (98) J. D. Weber, *J. Ass. Offic. Agr. Chem.*, **48**, 1151(1965).
- (99) A. L. Jacobs, A. E. Dilatush, S. Weinstein, and J. J. Windheuser, *J. Pharm. Sci.*, **55**, 893(1966).
- (100) J. Levine and J. D. Weber, *ibid.*, **57**, 631(1968).
- (101) D. E. Guttman, *ibid.*, **57**, 1685(1968).
- (102) D. E. Guttman and G. W. Salomon, *ibid.*, **58**, 120(1969).
- (54) C. Marton, *Quart. J. Pharm. Pharmacol.*, **6**, 492(1933).
- (61) V. K. La Mer and J. Greenspan, *J. Amer. Chem. Soc.*, **56**, 1492(1934).
- (71) J. M. Sturtevant, *ibid.*, **64**, 77(1942).
- (81) L. J. Edwards, *Trans. Faraday Soc.*, **46**, 723(1950).
- (91) *Ibid.*, **48**, 690(1952).
- (101) D. Davidson and L. Auerbach, *J. Amer. Chem. Soc.*, **75**, 5984(1953).
- (111) E. Ferroni and R. Baistrocchi, *Sperimentale Sez. Chim. Biol.*, **4**, 7(1953); through *Chem. Abstr.*, **47**, 10974h(1953).
- (121) S. Miyamoto, T. Tsuchiya, and T. Miyamoto, *Ann. Rep. Kyoritsu Coll. Pharm.*, **1**, 26(1955); through *Chem. Abstr.*, **50**, 16898(1956).
- (131) E. R. Garrett, *J. Amer. Chem. Soc.*, **79**, 3401(1957).
- (141) E. R. Garrett, *J. Amer. Pharm. Ass., Sci. Ed.*, **46**, 584(1957).
- (151) S. Okano and S. Kojima, *Yakuzai-gaku*, **18**, 37(1958); through *Chem. Abstr.*, **53**, 6534f(1959).
- (161) M. L. Bender, F. Chloupek, and M. C. Neveu, *J. Amer. Chem. Soc.*, **80**, 5384(1958).
- (171) K. C. James, *J. Pharm. Pharmacol.*, **10**, 363(1958).
- (181) S. M. Blaug and J. W. Wesolowski, *J. Amer. Pharm. Ass., Sci. Ed.*, **48**, 691(1959).
- (191) E. R. Garrett, *J. Org. Chem.*, **26**, 3660(1961).
- (201) M. L. Bender, E. J. Pollock, and M. C. Neveu, *J. Amer. Chem. Soc.*, **84**, 595(1962).
- (211) H. Nogami, S. Awazu, and N. Nakajima, *Chem. Pharm. Bull.*, **10**, 503(1962).
- (221) L. Nelander, *Acta Chem. Scand.*, **18**, 973(1964).
- (231) E. Mario and R. J. Gerraughty, *J. Pharm. Sci.*, **54**, 321(1965).
- (241) T. E. Needham, Jr., and R. J. Gerraughty, *ibid.*, **58**, 62(1969).
- (251) G. Santopadre and S. Bolton, *J. Pharm. Pharmacol.*, **19**, 550(1967).
- (261) K. S. Murthy and E. G. Rippie, *J. Pharm. Sci.*, **56**, 1026(1967).
- (271) A. G. Mitchell and J. F. Broadhead, *ibid.*, **56**, 1261(1967).
- (281) S. S. Kornblum and M. A. Zoglio, *ibid.*, **56**, 1569(1967); H. V. Maulding, M. A. Zoglio, and E. J. Johnston, *ibid.*, **57**, 1873(1968); M. A. Zoglio, H. V. Maulding, R. M. Haller, and S. Brigen, *ibid.*, **57**, 1877(1968); H. V. Maulding, M. A. Zoglio, F. E. Pigois, and M. Wagner, *ibid.*, **58**, 1359(1969).
- (291) A. Y. Gore, K. B. Naik, D. O. Kildsig, G. E. Peck, V. F. Smolen, and G. S. Banker, *ibid.*, **57**, 1850(1968).
- (301) A. R. Fersht and A. J. Kirby, *J. Amer. Chem. Soc.*, **89**, 4853(1967).
- (311) *Ibid.*, **89**, 4857(1967).
- (321) H. Linke, *Apoth. Ztg.*, **26**, 939, 1083(1911).
- (331) H. Melzer, *ibid.*, **26**, 1033(1911).
- (341) P. N. Leech, *J. Ind. Eng. Chem.*, **10**, 288(1918).
- (351) A. J. Jones, *Chem. Drug.*, **91**, 60(1919).
- (361) H. L. Dahm, *J. Ind. Eng. Chem.*, **11**, 29(1919).
- (371) A. Nutter-Smith, *Chem. Drug.*, **93**, 89(1920).
- (381) A. Nutter-Smith, *Analyst*, **45**, 412(1920).
- (391) E. A. Ruddiman, *J. Amer. Pharm. Ass.*, **11**, 796(1922).
- (401) Anon., *Amer. J. Pharm.*, **96**, 592(1924).
- (411) H. V. Snidow and H. A. Langenhan, *J. Amer. Pharm. Ass.*, **14**, 694(1925).
- (421) H. Valentin and A. Lieber, *Apoth. Ztg.*, **41**, 567(1926).
- (431) A. Hoffman, *Dan. Tidsskr. Farm.*, **3**, 82(1929); through *Chem. Abstr.*, **23**, 3050(1929).
- (441) R. M. Hitchens, *J. Amer. Pharm. Ass.*, **23**, 1084(1934).
- (451) A. Banchetti, *Ric. Sci.*, **8**, 290(1937).
- (461) T. Canback, *Sc. Farm. Tidskr.*, **47**, 621(1943); through *Chem. Abstr.*, **38**, 5644(1944).
- (471) Y. Tsuzuki and M. Sawada, *Bull. Chem. Soc. Jap.*, **23**, 23(1950).
- (481) R. E. Pankratz and F. J. Bandelin, *J. Amer. Pharm. Ass., Sci. Ed.*, **41**, 267(1952).
- (491) R. Yamamoto and T. Takahashi, *Ann. Rep. Shionogi Res. Lab.*, **3**, 112(1953).
- (501) *Ibid.*, **4**, 79(1954).
- (511) D. Ribeiro, D. Stevenson, J. Samyn, G. Milosovich, and A. M. Mattocks, *J. Amer. Pharm. Ass., Sci. Ed.*, **44**, 226(1955).
- (521) L. J. Edwards, D. N. Gore, H. D. C. Rapson, and M. P.

- (103) E. Schulek and K. Burger, *Magy. Tud. Akad., Kem. Tud. Oszt. Közlem.*, **12**, 15(1959), through *Chem. Abstr.*, **54**, 12903b (1960).
 (104) W. W. Wendlandt and J. A. Horberg, *Anal. Chim. Acta*, **29**, 539(1963).
 (105) R. C. Crippen and H. C. Freeman, *Anal. Chem.*, **36**, 273 (1964).
 (106) J. G. Nikelly, *ibid.*, **36**, 2248(1964).
 (107) E. R. Garrett and J. L. Johnson, *J. Pharm. Sci.*, **51**, 767 (1962).
 (108) M. Vietti-Michelina, *Atti Accad. Sci. Torino, Cl. Sci. Fis., Mat. Natur.*, **89**, 383(1954-1955); through *Chem. Abstr.*, **50**, 6255b(1956).
 (109) G. Wagner, *Arch. Pharm.*, **289**, 8(1956).
 (110) I. A. Korshunov, Z. B. Kuznetsova, and M. K. Shchenikova, *Zhur. Fiz. Khim.*, **23**, 1292(1949); through *Chem. Abstr.*, **44**, 2873d(1950).
 (111) K. H. Lee, L. Thompkins, and M. R. Spencer, *J. Pharm. Sci.*, **57**, 1240(1968).

- (112) F. Reimers, *Arch. Pharm. Chem.*, **74**, 531(1967), through *Chem. Abstr.*, **67**, 67624h(1967).
 (113) M. M. Frodyma, V. T. Lieu, and R. W. Frei, *J. Chromatogr.*, **18**, 520(1965).
 (114) S. L. Lin, *J. Pharm. Sci.*, **56**, 1130(1967).

ACKNOWLEDGMENTS AND ADDRESSES

Received from *Sterling-Winthrop Research Institute, Rensselaer, NY 12144*

The author thanks Agnes F. Cox, Irene D. DeGraff, Laura A. Fantauzzi, Peter Frank, Patricia A. Lanciault, and Kathleen E. Long for making the initial abstract search for papers related to the decomposition of aspirin; Patricia C. Carroll of the library staff for her tenacity in acquiring the original articles discussed in this review; Harold E. Bauer, Frank S. Lukovits, and Walter R. Wiehler for their thoughts and opinions regarding this review; and Ellen V. Miller who so patiently reconstructed the figures presented in this review.

RESEARCH ARTICLES

Mechanisms of Reactions of Ring-Substituted Bis(1-aziridinyl)phosphinyl Urethan Antineoplastic Agents


C. K. NAVADA, Z. F. CHMIELEWICZ, and T. J. BARDOS*

Abstract □ Bis(*trans*-2,3-dimethylaziridinyl)phosphinyl urethan (IV) was synthesized and compared with the corresponding *cis*-2,3-dimethyl derivative (III). The comparative alkylating activities and rates of hydrolysis of these two stereoisomeric aziridine derivatives, III and IV, were determined and compared with corresponding data for the monomethyl derivative (V) and two other clinically tested members of this series of antineoplastic agents (dual antagonists), AB-100 (I) and AB-132 (II). The structures of the final hydrolysis products of III, IV, and V were determined and confirmed by direct synthesis. The results indicate that the mechanisms of hydrolysis of III, IV, and V (as that of the unsubstituted aziridine derivative, AB-100) are essentially S_N2 , in contrast to the much faster hydrolysis of the 2,2-dimethylaziridine analog, AB-132, which involves a carbonium-ion mechanism. These studies give further support to the hypothesis that the unique pharmacologic properties of AB-132, as compared to other members of this series, may be related to the unique chemical properties of the 2,2-dimethylaziridine moieties.

Keyphrases □ Antineoplastic agents—reaction mechanisms □ Bis(*trans*-2,3-dimethylaziridinyl)phosphinyl urethan—synthesis □ Alkylating activity—*cis*-, *trans*-2,3-dimethylaziridine analogs □ Hydrolysis mechanism—ring-substituted aziridine derivatives □ IR spectrophotometry—identity □ NMR spectroscopy—identity

The synthesis of a series of bis(1-aziridinyl)phosphinyl carbamates, termed "dual antagonists" (I and its analogs containing different carbamate moieties) (1, 2), and their antineoplastic activities in experimental animals (3, 4) and in man (5-9) were previously reported. In an effort to decrease the hematologic toxicity due to the "alkylating" aziridine groups, derivatives were syn-

thesized in which the C-atoms of the aziridine rings were substituted with methyl or ethyl groups (10). One member of this new series, ethyl bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamate (AB-132, II), has been studied to a considerable extent experimentally (11) as well as clinically (12-17). Its interesting pharmacologic properties [e.g., cholinesterase inhibition (18-20)] and its radiation potentiating effect (21-23) suggested that this compound may act by a different mechanism than the C-unsubstituted aziridine derivatives (24). This conclusion was supported by chemical studies of its hydrolytic and alkylation reactions (11, 25), which indicated that the unique properties of II may be related to the ability of the 2,2-dimethylaziridine group to participate in S_N1 reactions with its substituted carbon (by forming a tertiary carbonium ion) and, alternatively,



- I. $R_1 = R_2 = R_3 = R_4 = H$ (AB-100)
 II. $R_1 = R_2 = CH_3$; $R_3 = R_4 = H$ (AB-132)
 III. $R_1 = R_2 = CH_3$; $R_3 = R_4 = H$ (*cis*) (AB-144)
 IV. $R_1 = R_2 = CH_3$; $R_3 = R_4 = H$ (*trans*) (AB-145)
 V. $R_1 = CH_3$; $R_2 = R_3 = R_4 = H$ (AB-143)

Journal of Pharmaceutical Sciences

JANUARY 1977
VOLUME 66 NUMBER 1



REVIEW ARTICLE

Pharmaceutical Salts

STEPHEN M. BERGE **, LYLE D. BIGHLEY *, and
DONALD C. MONKHOUSE *

Keyphrases □ Pharmaceutical salts—general pharmacy, physicochemical properties, bioavailability, pharmaceutical properties, toxicology, review □ Salts, pharmaceutical—general pharmacy, physicochemical properties, bioavailability, pharmaceutical properties, toxicology, review □ Physicochemical properties—dissolution, solubility, stability, and organoleptic properties of pharmaceutical salts, review □ Bioavailability—formulation effects, absorption alteration and pharmacokinetics of pharmaceutical salts, review □ Toxicology—pharmaceutical salts, review

CONTENTS

Potentially Useful Salts	2
Physicochemical Studies	4
Dissolution Rate	5
Solubility	7
Organoleptic Properties	8
Stability	9
Miscellaneous Properties	10
Bioavailability	10
Formulation Effects	11
Absorption Alteration	11
Pharmacokinetics	13
General Pharmacy	14
Pharmacological Effect	14
Dialysis	14
Miscellaneous	14
Toxicological Considerations	15
Toxicity of Salt Ion	15
Toxicity of Salt Form	15
Conclusions	16
References	16

The chemical, biological, physical, and economic characteristics of medicinal agents can be manipulated and, hence, often optimized by conversion to a salt form. Choosing the appropriate salt, however, can be a very difficult task, since each salt imparts unique properties to the parent compound.

Salt-forming agents are often chosen empirically. Of the many salts synthesized, the preferred form is selected by pharmaceutical chemists primarily on a practical basis: cost of raw materials, ease of crystallization, and percent yield. Other basic considerations include stability, hygroscopicity, and flowability of the resulting bulk drug. Unfortunately, there is no reliable way of predicting the influence of a particular salt species on the behavior of the parent compound. Furthermore, even after many salts of the same basic agent have been prepared, no efficient screening techniques exist to facilitate selection of the salt most likely to exhibit the desired pharmacokinetic, solubility, and formulation profiles.

Some decision-making models have, however, been developed to help predict salt performance. For example, Walkling and Appino (1) described two techniques, "decision analysis" and "potential problem analysis," and applied them to the selection of the most suitable derivative of an organic acid for development as a tablet. The derivatives considered were the free acid and the potassium, sodium, and calcium salts. Both techniques are based on the chemical, physical, and biological properties of these specific derivatives and offer a promising avenue for developing optimal salt forms.

Information on salts is widely dispersed throughout the pharmaceutical literature, much of which addresses the use of salt formation to prolong the release of the active component, thereby eliminating various undesirable drug properties (2-6). This review surveys literature of the last 25 years, emphasizing comparisons between the properties of different salt forms of the same compound. Included also is a discussion of potentially useful salt forms. Our purpose is twofold: to present an overview of the many different salts from which new drug candidates can be chosen and

Table I—FDA-Approved Commercially Marketed Salts

Anion	Percent ^a	Anion	Percent ^a
Acetate	1.26	Iodide	2.02
Benzenesulfonate	0.25	Isethionate ⁱ	0.88
Benzoate	0.51	Lactate	0.76
Bicarbonate	0.13	Lactobionate	0.13
Bitartrate	0.63	Malate	0.13
Bromide	4.68	Maleate	3.03
Calcium edetate	0.25	Mandelate	0.38
Camsylate ^b	0.25	Mesylate	2.02
Carbonate	0.38	Methylbromide	0.76
Chloride	4.17	Methylnitrate	0.38
Citrate	3.03	Methylsulfate	0.88
Dihydrochloride	0.51	Mucate	0.13
Edetate	0.25	Napsylate	0.25
Edisylate ^c	0.38	Nitrate	0.64
Estolate ^d	0.13	Pamoate (Embonate)	1.01
Esylate ^e	0.13	Pantothenate	0.25
Fumarate	0.25	Phosphate/diphosphate	3.16
Glucaptate ^f	0.18	Polygalacturonate	0.13
Gluconate	0.51	Salicylate	0.88
Glutamate	0.25	Stearate	0.25
Glycylglycylsarcosinate ^g	0.13	Subacetate	0.38
Hexylresorcinate	0.13	Succinate	0.38
Hydrabamine ^h	0.25	Sulfate	7.46
Hydrobromide	1.90	Tannate	0.88
Hydrochloride	42.98	Tartrate	3.54
Hydroxynaphthoate	0.25	Teclate ^j	0.13
		Triethiodide	0.13
Cation	Percent ^a	Cation	Percent ^a
Organic:		Metallic:	
Benzathine ^k	0.66	Aluminum	0.66
Chlorprocaine	0.33	Calcium	10.49
Choline	0.33	Lithium	1.64
Diethanolamine	0.98	Magnesium	1.31
Ethylenediamine	0.66	Potassium	10.82
Meglumine ^l	2.29	Sodium	61.97
Procaine	0.66	Zinc	2.95

^a Percent is based on total number of anionic or cationic salts in use through 1974. ^b Camphorsulfonate. ^c 1,2-Ethanedisulfonate. ^d Lauryl sulfate. ^e Ethanesulfonate. ^f Glucoheptonate. ^g *p*-Glycylamidophenylsarcosinate. ^h *N,N'*-Di(dehydroabietyl)ethylenediamine. ⁱ 2-Hydroxyethanesulfonate. ^j 8-Chlorotheophyllinate. ^k *N,N'*-Dibenzylethylenediamine. ^l *N*-Methylglucamine.

to assemble data that will provide, for the student and practitioner alike, a rational basis for selecting a suitable salt form.

POTENTIALLY USEFUL SALTS

Salt formation is an acid-base reaction involving either a proton-transfer or neutralization reaction and is therefore controlled by factors influencing such reactions. Theoretically, every compound that exhibits acid or base characteristics can participate in salt formation. Particularly important is the relative strength of the acid or base—the acidity and basicity constants of the chemical species involved. These factors determine whether or not formation occurs and are a measure of the stability of the resulting salt.

The number of salt forms available to a chemist is large; surveys of patent literature show numerous new salts being synthesized annually. Various salts of the same compound often behave quite differently because of the physical, chemical, and thermodynamic properties they impart to the parent compound. For example, a salt's hydrophobicity and high crystal lattice energy can affect dissolution rate and, hence, bioavailability. Ideally, it would be desirable if one could predict how a pharmaceutical agent's properties would be affected by salt formation.

Tables I and II list all salts that were commercially marketed through 1974. The list was compiled from all agents listed in "Martindale The Extra Pharmacopoeia,"

26th ed. (7). Table I categorizes all salt forms approved by the Food and Drug Administration (FDA), while Table II lists those not approved by the FDA but in use in other countries. (Only salts of organic compounds are considered because most drugs are organic substances.) The relative frequency with which each salt type has been used is calculated as a percentage, based on the total number of anionic or cationic salts in use through 1974. Because of simple availability and physiological reasons, the monoprotic hydrochlorides have been by far the most frequent choice of the available anionic salt-forming radicals, outnumbering the sulfates nearly six to one. For similar reasons, sodium has been the most predominant cation.

Knowledge that one salt form imparts greater water solubility, is less toxic, or slows dissolution rate would greatly benefit chemists and formulators. In some cases, such generalizations can be made. Miller and Heller (8) discussed some properties associated with specific classes of salt forms. They stated that, in general, salt combinations with monocarboxylic acids are insoluble in water and lend themselves to repository preparations, while those of dicarboxylic acids confer water solubility if one carboxylic group is left free. Pamoic acid, an aromatic dicarboxylic acid, is an exception since it is used as a means of obtaining prolonged action by forming slightly soluble salts with certain basic drugs. Saia *et al.* (9) reviewed the use of this salt form in preparing sustained-release preparations. More recently, latentiation of dihydrostreptomycin (10)

Table II—Non-FDA-Approved Commercially Marketed Salts

Anion	Percent ^a
Adipate	0.13
Alginate	0.13
Aminosalicylate	0.25
Anhydromethylenecitrate	0.13
Arecoline	0.13
Aspartate	0.25
Bisulfate	0.25
Butylbromide	0.13
Camphorate	0.13
Digluconate	0.13
Dihydrobromide	0.13
Disuccinate	0.13
Glycerophosphate	0.88
Hemisulfate	0.13
Hydrofluoride	0.13
Hydroiodide	0.25
Methylenebis(salicylate)	0.13
Napadisylate ^b	0.13
Oxalate	0.25
Pectinate	0.13
Persulfate	0.13
Phenylethylbarbiturate	0.13
Picrate	0.13
Propionate	0.13
Thiocyanate	0.13
Tosylate	0.13
Undecanoate	0.13
Cation	Percent ^a
Organic:	
Benethamine ^c	0.33
Clemizole ^d	0.33
Diethylamine	0.33
Piperazine	0.98
Tromethamine ^e	0.33
Metallic:	
Barium	0.33
Bismuth	0.98

^a Percent is based on total number of anionic and cationic salts in use through 1974. ^b 1,5-Naphthalenedisulfonate. ^c *N*-Benzylphenethylamine. ^d 1-*p*-Chlorobenzyl-2-pyrrolidin-1'-ylmethylbenzimidazole. ^e Tris(hydroxymethyl)aminomethane.

using pamoic acid resulted in the formation of a delayed-action preparation. Numerous studies using pamoate salts are dispersed throughout the literature (11–15).

Alginic acid also has been used to prepare long-acting pharmaceuticals. Streptomycin alginate was prepared (16) and shown to be effective in sustained-release preparations. A striking example of a long-acting alginate salt is that of pilocarpine. When dispersed in sterile water and dried to a solid gel, this compound was found useful in the preparation of long-acting ophthalmic dosage forms (17). While liquid preparations of the alginate and hydrochloride salts possess similar miotic activity, studies showed that solid pilocarpine alginate flakes constricted pupil size more effectively and increased the duration of miosis significantly when compared with the liquid preparations. Solid dose pilocarpine may be more uniformly available, because it diffuses more slowly through the gel matrix which holds the drug in reserve. In contrast, drops of the commonly employed solution dosage form release the dose immediately to the conjunctival fluid.

Málek *et al.* (18) devised a unique way of prolonging action through salt formation; they showed that the distribution of several antibiotics could be markedly altered by merely preparing macromolecular salts. Since macromolecules and colloidal particles have an affinity for the lymphatic system, streptomycin, neomycin, viomycin, and

streptothrycin were combined with high molecular weight compounds such as polyacrylic acids, sulfonic or phosphorylated polysaccharides, and polyuronic derivatives. Parenteral administration of these compounds produced low blood levels of the antibiotic for long periods, while lymph levels were high. (In comparison, streptomycin sulfate gave high blood levels but low lymph levels.) This alteration in distribution caused the streptomycin to prolong its passage through the body, since lymphatic circulation is quite slow.

The appropriate choice of a salt form has been found to reduce toxicity. It can be rationalized that any compound associated with the normal metabolism of food and drink must be essentially nontoxic. The approach of choosing organic radicals that are readily excreted or metabolized opened up a new class of substances from which to select a salt form. For example, certain salts of the strong base choline have proven to be considerably less toxic than their parent compound. The preparation and properties of choline salts of a series of theophylline derivatives were reported (19), and it was shown that choline theophyllinate possessed a greater LD₅₀ than theophylline or its other salts (20). It was postulated that this agent would be less irritating to the GI tract than aminophylline, because "its basic constituent, choline, is an almost completely nontoxic substance of actual importance to the physiologic economy." This evidence led to the preparation of choline salicylate (21) as an attempt to reduce the GI disturbances associated with salicylate administration. Clinical studies indicated that choline salicylate elicited a lower incidence of GI distress, was tolerated in higher doses, and was of greater benefit to the patient than was acetylsalicylic acid (aspirin).

Amino acids and acid vitamins also have been used as salt-forming agents. Based on the evidence that coadministration of amino acids with aminoglycoside antibiotics reduced their toxicity, a series of amino acid salts of dihydrostreptomycin was prepared (22). In all but one case, the acute toxicities of these salts were lower than the toxicity of the sulfate. The ascorbate and pantothenate also were synthesized and shown to be less toxic than the sulfate. Of the salts prepared, the ascorbate had the highest LD₅₀.

The vitamins most commonly used for forming salts exhibiting reduced toxicity are ascorbic and pantothenic acids. Keller *et al.* (23) were the first to use pantothenic acid as a means of "detoxifying" the basic streptomycetes antibiotics. Parenteral administration of the pantothenates of streptomycin and dihydrostreptomycin had a significantly reduced incidence of acute neurotoxicity in cats as compared with the sulfates. Subsequent studies (24–28) supported this finding and showed that the pantothenates of neomycin and viomycin also are less toxic. The ascorbate of oleandomycin was synthesized and its pharmacological properties were reported (29). Upon intramuscular injection in rats, it produced less irritation than the phosphate.

p-Acetamidobenzoic acid, an innocuous metabolite of folic acid present in normal blood and urine, has been used in preparing salts. In particular, it yields stable salts with amines that otherwise tend to form hygroscopic products with conventional acid components (30).

Often the salt form is chosen by determining a salt

component that will pharmacologically antagonize an unfavorable property or properties exhibited by the basic agent. Salts of *N*-cyclohexylsulfamic acid are an example of the practical application of this approach. *N*-Cyclohexylsulfamic acid salts, better known as cyclamates, have a characteristic sweet, pleasing taste. Although presently under investigation by the FDA for potentially carcinogenic properties, salts incorporating this compound can render unpleasant or bitter-tasting drugs acceptable. For example, the cyclamates of dextromethorphan and chlorpheniramine exhibit greatly improved bitterness thresholds compared to commonly occurring salts (31). Furthermore, their stability in aqueous solution was described as good when maintained at a pH not greater than 4.

N-Cyclohexylsulfamic acid salts of thiamine hydrochloride and lincomycin also have been synthesized. Thiamine *N*-cyclohexylsulfamate hydrochloride was reported to have a more pleasant taste than other thiamine salts while having an equal or greater stability (32). Lincomycin cyclamate, shown to possess an enhanced thermal stability over its hydrochloride, was prepared (33) to test the hypothesis that reduced lincomycin absorption in the presence of small quantities of cyclamates was due to a simple metathetic reaction. However, this assumption was found not to be true. An extensive study of the preparation and characterization of cyclamic acid salts of several widely used classes of drugs including antihistamines, antibiotics, antitussives, myospasmolytics, and local anesthetics was reported (34, 35).

Various salts of penicillin and basic amine compounds have been formulated in an effort to produce a long-acting, nonallergenic form of penicillin. Since antihistamines appear to mitigate the symptomatology of penicillin reactions in some patients, coadministration of the two has been advocated. The preparation of the benzhydralamine salt of penicillin was an attempt to produce a repository form of penicillin with antiallergic properties (36). Blood levels achieved with this salt were comparable to those of penicillin G potassium; however, its antiallergic properties were not evaluated. In fact, the investigators noted that antihistamines can actually cause sensitization at times and stated that "despite their occasionally favorable influence on the symptoms of penicillin sensitivity, they contribute directly to the potential of drug sensitivity when co-administered with penicillin."

Silver salts of sulfanilamide, penicillin, and other antibiotics have been prepared and represent cases where the species (ions) are complementary. When aqueous solutions of the salts were applied topically to burned tissue, they yielded the combined benefits of the oligodynamic action of silver and the advantages of the antibacterial agents (37).

The use of 8-substituted xanthines, particularly the 8-substituted theophyllines, as salt-forming agents was first reported in the preparation of a series of antihistamine salts (38-41). Synthesis of these xanthine salts was an attempt to find a drug to counteract the drowsiness caused by the antihistamines with the stimulant properties of the xanthines. When an electronegative group is introduced into the xanthine molecule at the 8-position, the electron-drawing capacity of the substituent results in the creation of an acidic hydrogen at position 7. Thus, these

moderately strong acidic compounds can undergo salt formation with various organic bases.

The 8-halotheophyllines were the first group of xanthines studied as potential salt-forming agents. Since the report on the preparation of the 8-chlorotheophylline salt of diphenhydramine (42), synthesis of the 8-halotheophyllinates of a number of organic bases has been attempted. The 8-chlorotheophylline salts of quinine, ephedrine, and strychnine were prepared and characterized (43). These salts were less water soluble than the corresponding free alkaloidal bases. In a similar report, the 8-chlorotheophyllinates of three synthetic narcotics, meperidine, levorphanol, and metopon, were prepared (44).

Pharmacological and clinical studies involving the 8-bromotheophylline pyrilamine salt revealed the unusual diuretic properties associated with the 8-halotheophylline portion of the compound (45, 46). This finding initiated an investigation into the preparation of a soluble 8-bromotheophylline salt of high diuretic activity. With readily available amines, over 30 salts were synthesized and screened for diuretic activity (47). When tested against theophylline salts of the same amines, the 8-bromotheophyllinates showed greater activity in every case.

With the successful formation of 8-halotheophyllinates of organic bases, Morozowich and Bope (48) proposed that, if the halogen moiety was replaced with a more electronegative substituent such as a nitro group, a more acidic compound would be formed. Presumably, more stable salts would result and precipitation of the free xanthine derivative in the stomach would be less likely to occur. On this premise, they successfully prepared pharmacologically effective 8-nitrotheophyllinates of several pharmaceutically useful bases.

Duesel *et al.* (19), in their study of choline theophyllinate, prepared the 8-chloro-, 8-bromo-, and 8-nitrotheophylline salts of choline. Oral toxicity studies in mice showed that the LD₅₀ of the 8-nitrotheophyllinate was much greater than that of either 8-halotheophylline. In fact, it remained nonlethal at doses as high as 5 g.

Polygalacturonic acid, a derivative of pectin, has been used to prepare quinidine salts exhibiting reduced toxicity (49, 50). The compound possesses special demulcent properties and inhibits mucosal irritation. The rationale for use of this agent is to reduce the ionic shock to the GI mucosa resulting from the flood of irritating ions liberated by rapid dissociation of the conventional inorganic quinidine salts. Studies have shown that it is four times less toxic orally than the sulfate. This difference was attributed to the slower release of quinidine from the polygalacturonate.

Other compounds reported to be potentially useful as pharmaceutical salt forms are listed in Table III.

PHYSICOCHEMICAL STUDIES

Biological activity of a drug molecule is influenced by two factors: its chemical structure and effect at a specific site and its ability to reach—and then be removed from—the site of action. Thus, a knowledge of the physicochemical properties of a compound that influence its absorption, distribution, metabolism, and excretion is essential for a complete understanding of the onset and duration of ac-

Table III—Potentially Useful Salt Forms of Pharmaceutical Agents

Salt-Forming Agent	Compound Modified	Modification	Reference
Acetylaminooacetic acid	Doxycycline	Solubility	51
<i>N</i> -Acetyl-L-asparagine	Erythromycin	Solubility, activity, stability	52
<i>N</i> -Acetylcystine	Doxycycline	Combined effect useful in pneumonia	53
Adamantoic acid	Alkylbiguanides	Prolonged action	54
Adipic acid	Piperazine	Stability, toxicity, organoleptic properties	55
<i>N</i> -Alkylsulfamates	Ampicillin	Absorption (oral)	56
	Lincomycin	Solubility	57
	Cephalexin	Stability, absorption	58
Anthraquinone-1,5-disulfonic acid	Various alkaloids	Prolonged action	59, 60
Arabogalactan sulfate (arabino)	Cephalosporins	Toxicity	61
Arginine	α -Sulfobenzylpenicillin	Stability, hygroscopicity, toxicity	62
	Erythromycin	Solubility	63
Aspartate	Tetracycline	Gastric absorption	64
Betaine	7-(Aminoalkyl)theophyllines	Activity, prolonged prophylactic effect	65
Bis(2-carboxychromon-5-yloxy)alkanes	Metformin	Toxicity	66
Carnitine	Propoxyphene	Organoleptic properties	67
4-Chloro- <i>m</i> -toluenesulfonic acid	Heptaminol	Prolonged action	68
Decanoate	Thiamine	Stability, hygroscopicity	69
Diacetyl sulfate	Ampicillin	Prolonged action	70, 71
Dibenzylethylenediamine	Cephalosporins	Reduced pain on injection	72
Diethylamine	Tetracycline	Activity	73
Diguaiacyl phosphate	Vincamine	Organoleptic properties	74
Diethyl sulfosuccinate	Kanamycin	Toxicity	75
Embonic (pamoic) acid	2-Phenyl-3-methylmorpholine	Toxicity	76
	Tetracycline	Solubility	77
Fructose 1,6-diphosphoric acid	Erythromycin	Solubility	77
	Tetracycline	Solubility	77
Glucose 1-phosphoric acid, glucose	Erythromycin	Solubility	52
6-phosphoric acid	Erythromycin	Solubility, activity, stability	78
L-Glutamine	Bephenium	Toxicity	79
Hydroxynaphthoate	Prostaglandin	Prolonged action	80
2-(4-Imidazolyl)ethylamine	Theophylline	Stability	81
Isobutanolamine	Vincamine	Organoleptic properties	82
Lauryl sulfate	α -Sulfobenzylpenicillin	Toxicity, stability, hygroscopicity	61
Lysine	Cephalosporins		82
	Pralidoxime (2-PAM)	Solubility	62
Methanesulfonic acid	α -Sulfobenzylpenicillin	Toxicity, stability, hygroscopicity	72
<i>N</i> -Methylglucamine	Cephalosporins	Reduced pain on injection	83
	Phenylbutazone	Toxicity, faster onset of action	72
<i>N</i> -Methylpiperazine	Cephalosporins	Reduced pain on injection	84
Morpholine	Propoxyphene	Organoleptic properties	68
2-Naphthalenesulfonic acid	Heptaminol	Prolonged action	85
Octanoate	Pivampicillin	Organoleptic properties	86, 87
Probenecid	Various amines	Prolonged action	88
Tannic acid	Propoxyphene	Activity	89
Theobromine acetic acid	Tetracycline	Organoleptic properties	68
3,4,5-Trimethoxybenzoate	Heptaminol	Prolonged action	90
	Aspirin	Absorption (oral)	91
Tromethamine	Dinoprost (prostaglandin F ₂)	Physical state	

tion, the relative toxicity, and the possible routes of administration (2).

In a review in 1960, Miller and Holland (92) stated that "different salts of the same drug rarely differ pharmacologically; the differences are usually based on the physical properties." In a subsequent review (93), Wagner expanded upon this statement, asserting that, although the nature of the biological responses elicited by a series of salts of the same parent compound may not differ appreciably, the intensities of response may differ markedly.

The salt form is known to influence a number of physicochemical properties of the parent compound including dissolution rate, solubility, stability, and hygroscopicity. These properties, in turn, affect the availability and formulation characteristics of the drug. Consequently, the pharmaceutical industry has systematically engaged in extensive preformulation studies of the physicochemical properties of each new drug entity to determine the most suitable form for drug formulation. Published information concerning such studies, however, is sparse. Preformulation studies have been outlined, and the influence of the salt form on the volatility and hygroscopicity of an agent under investigation was discussed (94).

In one such study, methylpyridinium-2-aldoxime (pralidoxime) salts were investigated (95). This study set out to prepare a salt with water solubility adequate to allow intramuscular injection of a low volume (2–3 ml) therapeutic dose. The original compound, the methiodide, had the disadvantages of limited aqueous solubility and high potential toxicity, since its high iodide content could result in iodism. On the basis of physiological compatibility, better water solubility, favorable stability, and relatively high percentage of oxime, the chloride salt of pralidoxime was selected for therapeutic administration; it was claimed that "the anion used to form the salt can confer physical properties of importance and significance for the formulation and administration of the compound" (95).

Some physicochemical properties of a series of mineral acid salts of lidocaine also were determined (96). While the hydrochloride and hydrobromide were more hygroscopic, they were more soluble in a number of solvents than the nitrate, perchlorate, phosphate, or sulfate salts.

Dissolution Rate—The dissolution rate of a pharmaceutical agent is of major importance to the formulator. In many cases, particularly with poorly soluble drugs, this characteristic best reflects the bioavailability of the com-

pound. As a rule, a pharmaceutical salt exhibits a higher dissolution rate than the corresponding conjugate acid or base at an equal pH, even though they may have the same equilibrium solubility. The explanation for this result lies in the processes that control dissolution.

Dissolution can be described by a diffusion layer model¹ in terms of an equation developed by Nernst and Brunner (97):

$$\frac{dW}{dt} = \frac{DS}{h} (C_s - C) \quad (\text{Eq. 1})$$

where W is the mass of the solute dissolved at time t , dW/dt is the rate of mass transfer per unit time, D is the solute molecule diffusion coefficient, S is the surface area of the dissolving solid, h is the diffusion layer thickness, C is the concentration of the drug in the bulk solution at time t , and C_s is the saturation solubility of the solute in the diffusion layer.

The driving force for dissolution in Eq. 1 is the difference between the saturation solubility of the drug and the concentration of the drug in the bulk fluid. If the drug is not rapidly absorbed after it dissolves, then C , the concentration in the bulk solution, approaches C_s and the dissolution rate is retarded. When this occurs, absorption is "absorption rate" limited (or "membrane transport" limited). If the absorption rate is rapid (or if the absorption mass transfer coefficient is much larger than DS/h of Eq. 1), however, C becomes negligible compared to C_s and dissolution occurs under "sink" conditions. Absorption is then said to be dissolution rate limited, which is what occurs with most poorly soluble drugs. In either case, an increase in C_s , as in salt formation, increases dissolution.

Salts often speed dissolution by effectively acting as their own buffers to alter the pH of the diffusion layer, thus increasing the solubility of the parent compound, C_s , in that layer over its inherent solubility at the pH of the dissolution medium. Hence, dissolution is controlled by solubility in the diffusion layer which, in turn, is determined by the pH of that layer. The influence of K_{sp} on the solubility term, C_s , and dissolution rate, should an accumulation of ions be allowed to occur, will be treated later.

Nelson (98), in a study of theophylline salts, was the first to show the correlation between diffusion layer pH and dissolution rate. The major impact that this study had on the pharmaceutical sciences was its conclusion that, if other factors remained constant, the dissolution rate of a compound determined the rate of buildup of blood levels with time and the maximum levels obtained. Those salts of the acidic theophylline with high diffusion layer pH's had greater *in vitro* dissolution rates than those exhibiting a lower diffusion layer pH. And, indeed, the rank order of dissolution rates correlated well with clinically determined blood levels. Presumably, the higher pH in the diffusion layer retards hydrolysis of the salt, thereby maintaining the anionic charge of the theophyllinate ion. This report led to many additional studies which illustrate the influence of the salt form on dissolution and the beneficial effects of changing nonionized drugs into salts.

Juncher and Raaschou (99) demonstrated that the rank order of peak blood levels of penicillin V, obtained upon

administration of three different salts and the free acid, was the same as the rank order of their rates of dissolution *in vitro*. While the investigators ascribed these differences to the solubility properties of the salts, their experiments actually compared dissolution rates, not solubilities. The relative order of dissolution rates and mean maximal blood levels was: potassium salt > calcium salt > free acid > benzathine salt.

Nelson (100) determined dissolution rates for several weak acids and their sodium salts in media whose pH's represented GI fluids. In all cases, the sodium salt dissolved more rapidly than the free acid. This finding resolved the misconception that absorption of drugs is related only to solubility in the appropriate medium; rather, solubility affects absorption only to the extent that it affects dissolution rate. Absorption of drugs is a dynamic process, and the ultimate solubility of a drug in fluid at absorption sites is of limited consequence since absorption prevents the attainment of saturated solutions. Therefore, dissolution rate, more than solubility, influences absorption since it is a preceding process.

In two subsequent studies, Nelson and coworkers further illustrated the effects of changing nonionized drugs into salts. A report concerning tolbutamide (101), a weak acid, showed that the initial dissolution rate of tolbutamide sodium was approximately 5000 times more rapid than the free acid in acidic media and 300 times more rapid in neutral media. This difference, measured *in vitro*, reflected the differences observed between the free acid and the salt when administered to human subjects. Oral administration of tolbutamide sodium produced an immediate drop in blood sugar comparable to that produced by intravenous injection of the salt, while the slowly dissolving tolbutamide produced a smooth, sustained fall in blood sugar (102).

Correlation of urinary excretion rates and dissolution rates of tetracycline and some of its acid salts also was demonstrated by Nelson (103). The salts that exhibited greater *in vitro* dissolution rates showed greater urinary excretion rates, indicating more rapid absorption.

Benet (104), in a discussion of the biopharmaceutical basis for drug design, referred to the influence of the salt form on dissolution. He compared the dissolution rates of tetracycline and tolbutamide and their salts, as reported in the studies previously cited, and explained why the rates differ at the pH's exhibited by physiological fluids.

Although salt formation usually increases the dissolution rate of a drug, studies with aluminum acetylsalicylate (105, 106), warfarin sodium (107), and benzphetamine pamoate (108) showed that administration of the salt *slowed* dissolution of the drug and subsequent absorption compared to the nonionized form. This decrease appeared to result from precipitation of an insoluble particle or film on the surface of the tablet. Such a phenomenon decreases the effective surface area and prevents deaggregation of the particles. Theoretical considerations of the processes controlling dissolution of an acid salt of a base (108) and the sodium salt of a weak acid (109, 110) in reactive media have been discussed.

Tablet processing and various formulation factors can decrease the dissolution rate of a salt in human gastric juice over its nonionized form (111). Granulation and tableting caused the dissolution rate of phenobarbital sodium to

¹ Although there are a number of other models, this one was chosen simply for convenience.

decrease but had the opposite effect on phenobarbital. Therefore, as a tablet dosage form, the dissolution rate of the sodium salt was slower than that of the free acid. These results were attributed to differences in the disintegrating properties of the tablets; in some instances, rapid dissolution may in fact be a problem for very soluble drugs.


Others have illustrated a phenomenon that decreases the dissolution rate of a salt below that of its nonionized form. Lin *et al.* (112) studied the relationship between salts and biological activity by dissolving three salts and the free base of an experimental antihypertensive in water, 0.1 *N* HCl, and pH 7.2 phosphate buffer. The dissolution rate of the monohydrochloride salt was lower than that of the free base in 0.1 *N* HCl and higher than the free base in both water and phosphate buffer. These authors ascribed this variation to the common ion effect and substantiated it experimentally. Although the biological activity of the monohydrochloride was greater than that of the free base, the implications of altered absorption characteristics on the activity of any other hydrochloride salt in GI fluids must be considered. Similar results also were reported for hydrochloride salts of some tetracyclines (113).

Some consideration must be given to the influence of salt formation on oral toxicity, which often reflects the relationship between the *in vivo* dissolution rate and the appearance of drug in the circulation (114, 115). Morozowich *et al.* (114) showed that the relative toxicities of a series of salts of a drug reflect the rate of absorption, providing the salt-forming agents themselves are relatively nontoxic. They stated that "when absorption is rate-limited by dissolution of the salt in the gastrointestinal tract, as will be the case with slowly soluble salts, the toxicity of a slowly dissolving salt will most probably be lower than that of a more rapidly dissolving salt." The implications of salt formation on toxicology will be discussed under *Toxicological Considerations*.

Several reviews dealt with the influence of the dissolution rate on drug availability and, in particular, salt effects (116, 117). Other reports illustrating the influence of salts and salt form on dissolution rate are listed in Table IV.

Solubility—Knowledge of the solubility characteristics of a pharmaceutical agent is essential, because solubility is usually an important factor in the pharmacokinetic profile, the chemical stability, and, ultimately, the formulation of the drug. As discussed previously, it is certainly a primary factor in controlling dissolution rates. The solubility of a compound depends basically upon the physical and chemical properties of the solute; *e.g.*, a lower melting point for a compound within a series reflects a decreased lattice energy, which would suggest a higher solubility. Solubility depends as well upon such elements as temperature, pressure, solvent properties (such as resulting pH), and, to a lesser extent, the state of subdivision of the solute.

An important solvent property which is often overlooked involves the common ion effect; in particular, hydrochloride salts of drugs often exhibit less than desirable solubility in gastric juice because of the abundance of chloride ions. The equilibrium involved is shown in Scheme 1.



Salt formation is perhaps one of the first approaches

Table IV—Additional References on Salt Form and Dissolution Rate

Topic	Reference
Dissolution rate of mixtures of weak acids and tribasic sodium phosphate	118
Physiological availability and <i>in vitro</i> dissolution characteristics of some solid dosage formulations of aminosalicic acid and its salts	119
Biopharmaceutics, rate of dissolution: chronological bibliography	120
Biopharmaceutics: rate of dissolution <i>in vitro</i> and <i>in vivo</i>	121
Dissolution tests and interpretation of anomalies observed in the dissolution process of sulfaquinoxaline based on salt formation	122
Influence of the dissolution rate of lithium tablets on side effects	123
Dissolution kinetics of drugs in human gastric juice	124
Comparison of dissolution and absorption rates of different commercial aspirin tablets	125
<i>In vitro</i> dissolution rates of aminorex dosage forms and their correlation with <i>in vitro</i> availability	126

considered as a means of increasing a compound's water solubility. As with dissolution rates, however, salt formation does not always confer greater solubility. Liberally dispersed throughout the pharmaceutical literature are studies that compare the solubilities of different salt forms of the same compound with those of its free acid or base (Table IV). Selection of the salt form exhibiting the desired solubility properties is critical, since these properties often dictate the formulation characteristics of the drug.

Phase solubility techniques were used to study the formation of complex salts of triamterene (127). The results indicated that the organic acid salts of basic drugs, such as amines, were more soluble in water than the corresponding inorganic (halide) salts. This consideration is important in the synthesis and selection of a salt form that will exhibit enhanced bioavailability and desirable formulation characteristics.

The hydrogen-ion concentration can significantly affect the solubility of a salt. Anderson (128) discussed the influence of pH on the solubility of pharmaceuticals. Mathematical relationships between pH and solubility of therapeutically useful weak acids and bases and their salts were given along with some considerations in the formulation of solutions of these particular agents.

An extensive study on the solubility interrelationships of the hydrochloride and free base of two pharmaceutically useful amines was reported (129). Mathematical equations describing the total solubility at an arbitrary pH in terms of the independent solubilities of the hydrochloride and free base species and the dissociation constant of the salt were derived and fitted to experimental data with good results. This report elucidated the point that, while the solubility of the amine hydrochloride generally sets the maximum obtainable concentration for a given amine, the solubility of the free base and the pKa determine the maximum pH at which formulation as a solution is possible (assuming that the desired concentration exceeds the free base solubility). Shifting the pH-solubility profile to higher pH values for formulation purposes may require increasing the solubility of the free base. This increase might be accomplished by using an appropriate cosolvent. Since the dissociation characteristics of carboxylic acids and other acidic organic species are similar to those of organic hydrochlorides, it is expected that the pH-solubility profiles

of these organic acids, although reversed, can be characterized theoretically using the same treatment.

Several reports showed that the structure of an organic salt-forming radical influences the solubility of the resulting salt. The water solubilities of 16 salts (carboxylates, sulfates, sulfamates, and phosphates) of the weak base erythromycin were dependent on the size of the alkyl group of the acid (130). In a study with *N*-alkylsulfamates of lincomycin (66), a similar phenomenon was observed: solubility of these salts decreased as the size of the alkyl group attached to the acidic function increased.

Senior (131), in a study on the formulation and properties of the antibacterial chlorhexidine, determined the water solubilities of 35 salts and the free base. He found that inorganic salts had remarkably low solubilities while those of the lower aliphatic acids proved to be somewhat more soluble. Hydroxylation of the acid increased solubility, since salt formation with polyhydroxy acids, particularly the sugar acids, conferred extensive water solubility to the molecule.

Several investigators reported the influence of the solubility of a drug on its formulation and subsequent availability from the dosage form. In a discussion of the preparation and formulation of epinephrine salts in an aerosol system using liquefied gas propellants, Sciarra *et al.* (132) pointed out that the solubility characteristics of the agent are important in two respects. First, the solubility of the therapeutically active ingredient in the various propellants is an important consideration if the product is to be used for either local action in the lungs or systemic therapy. Second, the solubility of the drug in extracellular fluids plays an important role in selection of the compound. The bitartrate, malate, maleate, and fumarate salts of epinephrine were prepared and subjected to solubility and stability studies. While all salts had similar partition coefficients, the solubility of the maleate in several propellants and its stability in formulated aerosols made it the drug form of choice.

Ephedrine hydrochloride was more rapidly released than the free base from theobroma oil suppositories containing different surfactants (133). This enhanced rate of release (dialysis) was ascribed primarily to the greater aqueous solubility of the hydrochloride, which solubilized faster from the oil-in-water emulsion, whereas the ephedrine alkaloid base tended to remain behind in the oil phase.

The solubility of the active ingredient in ointment bases can dramatically influence its diffusion properties. A study of salicylic acid and its sodium salt showed that the diffusion of both was very low from hydrophobic bases, whereas the solubility of the drug significantly affected the diffusion from hydrophilic bases. The more soluble sodium salicylate diffused much faster from these latter bases than did salicylic acid (134).

Additional references on the relationship of salt form and solubility are listed in Table V.

Organoleptic Properties—Modern medicine requires that a pharmaceutical formulation be efficacious, safe, stable, and acceptable to the patient. Of primary importance in the development of oral dosage forms is taste acceptability. This factor presents no major problems when the drug is to be administered as a tablet or a capsule and swallowed as a unit but is clearly a prominent factor in

Table V—Additional References on Salt Form and Solubility

Topic	Reference
Influence of solubility on the rate of GI absorption of aspirin	135
Effect of dosage form upon the GI absorption rate of salicylates	136
Physical-chemical properties of polyene macrolide esters and their water-soluble salts	137
Isolation and reaction products of orotic acid and amines and their solubility in water	138
Solubility and stability of erythromycin salts	139
Studies on pharmaceutical preparations of orotic acid: water-soluble properties of orotic acid salts	140
Solubility of antibiotics in 24 solvents	141, 142
Solubility of antibiotics in 26 solvents	143

patient acceptability when it is to be administered as a liquid, chewable tablet, or lozenge.

Since taste is a chemical sense, a substance must be dissolved if it is to elicit a taste sensation—either by taking it as a solution or by its dissolving in the saliva. Therefore, one method used to minimize undesirable organoleptic properties of pharmaceuticals involves the preparation of a poorly soluble salt form of the drug such that the saturation concentration is less than the taste threshold.

Erythromycin estolate (lauryl sulfate) has approximately one-twelfth the solubility of the free base, is tasteless, and is useful in the formulation of oral suspensions (144). A study on erythromycin salts showed that the bitterness level was dependent on two properties: (a) the water solubility of the salt, which is dependent on the size of the alkyl group attached to the acid function; and (b) the strength of the acid used to form the salt, *i.e.*, the stability of the salt (130). The stearyl sulfamate salt possessed the most desirable organoleptic properties.

Many problems concerned with formulation and stability of topical and oral pharmaceuticals containing bacitracin have been overcome by incorporating bacitracin into the formulation as its zinc salt. One distinct advantage over the parent compound is its lack of taste, caused by its relative insolubility. Thus, it is the preferred drug form for preparations where taste is a factor (145). Taste panel evaluations of the comparative bitterness of bacitracin zinc and bacitracin indicate that the taste of the zinc salt is more easily masked and that the presence of a bitterness-masking adjuvant, such as sucrose, increases the bitterness threshold ratio differences between the two compounds even further (146).

Propoxyphene napsylate, nearly water insoluble, is only slightly bitter to the taste as compared to the highly water-soluble hydrochloride (147) and can be readily formulated into a flavored aqueous suspension. The taste of these suspensions can be improved significantly by the addition of a common ion (sodium or calcium napsylate) to depress solubility further.

A newer approach to the improvement of drug palatability has been to form insoluble salts with ion-exchange resins. Several investigators described and tested the practical application of this method (148-150). Spross *et al.* (149) outlined the conditions necessary for improving the palatability of a drug by adsorbing it onto an ion-exchange resin without appreciably modifying its pharmacological effects. They found that: (a) the degree of drug release from the ion exchange adsorbate depends on the

equivalent quotient between the electrolytes in the surrounding fluid and the ionic drugs, (b) the amount of ions is far less in the saliva than in the gastric juice (the temporary electrolyte contents can be estimated at 0.05 mEq in the saliva and at 10 mEq in the gastric juice), and (c) the exchange rates should allow the equilibria to be attained within a fairly short period. Insoluble drug resins formed between dextran gel² cation exchangers and several basic drugs were in many cases much more pleasant tasting than their parent compounds. Furthermore, release of the drug from the ion-exchange adsorbate was quite rapid and complete under conditions prevailing in the GI tract.

Similar findings were reported using a polymethacrylic acid ion-exchange resin (150). In addition, coating the adsorbate particles with a 4:1 ethylcellulose-hydroxypropyl methylcellulose mixture further reduced bitterness. While *in vitro* release from the uncoated resinate was rapid and complete, release from coated adsorbates varied with the extent of coating.

Another approach to improving the taste properties of pharmaceutical agents is to prepare a pleasant-tasting soluble salt of a poor-tasting parent drug. This approach often can be very difficult, however, since solubilization of the parent compound usually imparts its unpleasant taste to the preparation. Nevertheless, some success has been reported using the artificial sweeteners cyclamate sodium and saccharin.

As described earlier, formation of *N*-cyclohexylsulfamate salts of several drug substances has produced better tasting derivatives with enhanced solubility properties (31, 32). The physicochemical and toxicological properties of benzalkonium saccharinate and a series of saccharinates of other quaternary ammonium compounds were reported (151). While conventional quaternary ammonium compounds have a very bitter taste, their saccharin analogs are sweet.

Potassium salts frequently possess an unpleasant taste and a metallic aftertaste. The palatability of some potassium salts in flavored vehicles was reported (152); while the salts had similar taste thresholds at effective therapeutic levels, all potassium salts exhibited inferior palatability.

Table III includes several samples of other salts that exhibit an improved taste relative to their free acid or base forms.

Stability—The chemical and physical stability of a pharmaceutical must be known, because it can influence the choice of dosage form, the manufacturing and packaging, and the therapeutic efficacy of the final preparation. Systematic determination of the thermal stability, solution stability (at various pH's), and light sensitivity of a drug and its derivatives, both alone and in the presence of common additives, provides essential input toward selecting the most suitable derivative and dosage form.

Depending on the route of degradation, different salt forms impart different stability characteristics to the parent drug by various mechanisms. Most commonly used are sparingly soluble salts which, when used in the formulation of suspensions, reduce the amount of drug in solution and, hence, its degradation. Differences in hygroscopicity of several salts influence the stability of the

drug in the dry state. In some cases, the salt-forming radical itself enhances the stability of the parent agent.

The stability of penicillin G and its salts has been widely studied due to the drug's therapeutic importance and its characteristic instability. Schwartz and Buckwalter (153) described some of the stability characteristics of this antibiotic, stating that, with present techniques, a solution of penicillin cannot be made stable for more than 2 weeks, even at refrigerator temperatures. They also discussed the use of suspensions of sparingly soluble amine salts in aqueous vehicles as a means of "allowing marketing of a 'ready-made' penicillin product." Procaine, benzathine, and hydrabamine salts are marketed, and their acceptable stability as aqueous suspensions is based mainly on their insolubility and the minimization of degradation in solution.

A theoretical treatment of the solubility of these salts was presented in which equations were derived for calculating the solubility as a function of pH and the pH of minimum solubility (154, 155). These equations are based on the mass action law and its relationship to the ionization constants of the amine and the penicillin and the solubility of the salt in water. Since the salt in solution is partially dissociated, further suppression of the solubility may be achieved by the common ion effect. Swintosky *et al.* (156) demonstrated this effect with penicillin G procaine by adding procaine hydrochloride to the preparation and further enhancing its stability. The 8-chlorotheophylline salt (or complex) of penicillin G was reported to be water soluble, yet stable in solution (157). Since 8-chlorotheophylline is acidic, it has been postulated that a buffer effect could account for the stabilization of this "salt."

While penicillin G procaine is more stable in aqueous vehicles, it is less thermally stable than the sodium or potassium salts, decomposing if heated much above 60°. The sodium and potassium salts are known to withstand heating up to 100° for 4 days with little loss in potency (158). This behavior might well be due to differences in melting points—*viz.*, 106° for penicillin G procaine and ~215° dec. for the potassium salt.

Since hydrolysis of penicillin is dependent on moisture content, preparations in which moisture is rigorously excluded are quite stable in the dry state. A study on the effect of moisture on penicillin salts found the calcium salt to be less hygroscopic than the sodium salt and, hence, more stable in moist atmospheres (159). Similarly, penicillin G potassium is also much less hygroscopic than penicillin G sodium and has become the preferred form for marketing in the dry state (160).

Several studies reported the relative stabilities of thiamine salts, particularly the hydrochloride and the mononitrate (161-163). The mononitrate is observed to be less hygroscopic and is accordingly much less water soluble than the hydrochloride. Investigations of various preparations including compressed tablets, multivitamin capsules, and dry-filled vitamin B complex capsules at various temperatures showed that the mononitrate was more stable than the hydrochloride (164, 165). The stabilities of numerous thiamine salts were studied in aqueous solution and in dry powder preparations with various excipients (166, 167). In aqueous solution, the resulting pH was the chief factor controlling hydrolysis and oxidative decomposition of thiamine salts; their stability as powder

preparations was related to their aqueous solubility, with the sparingly soluble salts being more stable (and presumably less hygroscopic).

An orally administered drug must be stable in acidic solution because it generally must pass intact through the acidic environment of the stomach if it is to exhibit therapeutic blood levels. The advantage of erythromycin estolate over the free base lies in its low solubility in gastric juice, which enables it to be administered with food without any decrease in attained blood levels. The salt is more stable in the stomach because it remains undissolved. Therefore, it retains its potency even when exposed to acidic environments for extended periods (144).

In a study on the preparation and characterization of lincomycin cyclamate (33), it was noted that the cyclamate salt had an enhanced thermal stability over the hydrochloride. In a subsequent report (168), differential thermal analysis and thermogravimetric analysis showed that while the hydrochloride easily undergoes thermal degradation, the cyclamate anion confers a considerably greater thermal stability on the lincomycin moiety.

Mullins and Macek (169) showed that the physical and chemical stability of the calcium salt of novobiocin makes it the form of choice for the formulation of a liquid preparation of the antibiotic. The amorphous calcium novobiocin salt proved to be tasteless, yet fully biologically active and perfectly stable in aqueous suspension. Neither the sodium salt nor the free acid is suitable; the sodium salt cannot be formulated in a liquid due to its chemical instability, while the crystalline free acid is not absorbed from the GI tract. Amorphous novobiocin is absorbed but is metastable in solution and slowly converts to the unabsorbed crystalline form.

Other reports of alterations in stability characteristics due to salt formation are listed in Table VI.

Miscellaneous Properties—The salt form has been reported to influence other physicochemical properties of a drug substance. Studies illustrating the effect of the salt-forming radical on surface tension, deaggregation behavior, and ion-pair extraction have appeared.

The influence of the anion on the absorption processes of two charged species, dextromethorphan and tetracycline, was studied in the rat stomach (186, 187). A linear relationship existed between the rate of absorption from buffer solutions of the anions under investigation and their surface tensions. Thus, the absorption process was related to the surface activity of the various salts and not to their lipid solubilities. This change of surface activity with the buffer (or salt) species is similar to the results reported in a study of the surface activity of various phenothiazine salts (188).

The antibacterial chlorhexidine possesses surface activity. A study of the colloidal properties of some chlorhexidine salts showed that the counterion can affect the critical micelle concentration of a surface-active agent, and this effect was usually associated with a change in micellar size (189).

The deaggregation behavior of a relatively insoluble acid and its sodium salt was studied, and deaggregation was postulated to be a possible rate-limiting step in the absorption of a drug from a dosage form (190). While no direct comparisons of the two forms were made, inspection of the data shows that the deaggregation rate of the salt

Table VI—Additional References on Salt Form and Stability


Topic	Reference
Stability of chlorhexidine solutions	170
Stability of chlorhexidine when autoclaved	171
Anhydrotetracycline and 4-epianhydrotetracycline in marketed tetracycline and aged tetracycline products	172
Solid-state stability of some crystalline vitamin A compounds	173
Physicochemical studies on the stability of penicillin salts	174
Light sensitivity of tetracyclines	175
Hygroscopic properties, thermostability, and solubility of oleandomycin salts	176
Stability of orotic acid and its amine salts in aqueous solution	177
Some factors influencing the stability of tablets (aspirin)	178
Stability of aqueous solutions of sodium aminosalicylate	179
Hygroscopic properties of various preparations of erythromycin	180
Physicochemical studies on the decomposition of aminosalicylic acid and its salts	181
Stabilities of aqueous solutions of 2-diethylaminoethyl-3-methyl-2-phenylvalerate hydrochloride and its methobromide	182
Investigation of some properties of penicillin G salts	183
Stability of ferrous iron tablets on storage	184
Stability of aspirin aluminum compounded with antacids	185

was considerably more rapid than that of the free acid in equivalent dosage forms. Therefore, if absorption is dependent on the dissolution rate, which in turn is dependent on the deaggregation rate, the salt should produce the highest and earliest blood levels. On the other hand, it is possible that hygroscopic (and deliquescent) salts can absorb atmospheric moisture, cause a sticky surface, and inhibit deaggregation.

Higuchi and coworkers presented an extensive study on the physicochemical basis of the ion-pair extraction of pharmaceutical amines. Distribution ratios of dextromethorphan (191) and chlorpheniramine (192) between an organic layer and water were highly dependent on the concentration and nature of the anion present. Less hydrophilic anions yielded more readily extractable ion-pairs. A study of the thermodynamic properties, enthalpy, free energy, and entropy, involved in the extraction equilibria of dextromethorphan ion-pairs indicated that the entropy change associated with transfer of the different anions between phases is the main controlling factor in the extraction process (193).

BIOAVAILABILITY

Most drugs prescribed in the United States are administered in solid and polyphasic dosage forms. Consequently, dissolution of the drug must precede the absorption process. The simplest model that adequately describes this process is shown in Scheme II.



Since the dissolution rate is generally slow for drugs with poor solubility, Step 1 is frequently rate limiting in the overall absorption process. As a result, the onset, intensity, duration of pharmacological activity, and, hence, bioavailability are affected by changes in dissolution rate. As discussed previously, administering a salt of the parent drug often proves to be an effective means of altering dissolution rate and absorption.

Table VII—Additional References on Bioavailability and Formulation Effects

Topic	Reference
Effects of various substances on the absorption of tetracycline in rats	197
Effects of dosage form upon the GI absorption rate of salicylates	136
Determination of <i>in vivo</i> and <i>in vitro</i> release of theophylline aminoisobutanol in a prolonged-action system	198
Ion-exchange resin salts for oral therapy: carbinoxamine	199
Latentiation of dihydrostreptomycin by pamoate formation	10
Solid-state ophthalmic dosage systems in effecting prolonged release of pilocarpine in the cul-de-sac	17
Absorption of erythromycin: various pharmaceutical forms	200
Comparative study of the absorption of drugs from old and new rectal preparations	201

Formulation Effects—Choice of the salt form of a drug may have a pronounced effect on the formulation of the parent compound. For example, Fenton and Warren (194) found there was no release of medicament from proflavine cream BPC, a water-in-oil emulsion containing 0.1% proflavine as the hemisulfate salt. They also investigated the release of various salts of proflavine with aliphatic carboxylic acids from water-in-oil cream emulsions. Salts formed with the water-soluble, oil-insoluble "lower" acids, such as formic and acetic acids, showed very poor release from a water-in-oil cream. The "higher" acid salts (e.g., *n*-valeric, caproic, cyclohexanecarboxylic, and caprylic) all showed increased diffusion from similar emulsions since these salts are soluble in both water and oil. Their release was even greater from oil-in-water emulsions, however, in agreement with their preferential oil solubility. The *n*-valerate salt provided the most effective water-in-oil cream. The primary factor responsible for diffusion of proflavine from a water-in-oil cream is the low hydrophilic-lipophilic balance conveyed to the salt by the acid. This finding illustrates the desirability of carefully selecting the salt anion of a cationic drug in lieu of the nature of the dosage form.

Studies of the effect of formulation on the bioavailability of warfarin sodium relative to warfarin yielded interesting results (107, 195). Absorption of warfarin upon administration of the sodium salt as a lactose-base tablet was no better than that from a similar formulation of the free acid. In fact, absorption was further depressed when the salt was formulated with starch instead of lactose. Later results indicated that the *in vitro* water dissolution rate of a warfarin sodium tablet was 350 times that of a slowly dissolving warfarin tablet formulation, yet the latter exhibited rapid and complete absorption *in vivo*. The virtual insolubility of warfarin in acidic gastric fluids precluded its absorption from the stomach. However, the strongly acidic medium was necessary for tablet disintegration, which, in turn, was critical for absorption. Following initial exposure to 0.1 *N* HCl, *in vitro* dissolution of the warfarin tablet in pH 7.4 buffer was 14 times faster than that of the sodium salt, a result that explained the otherwise contradictory *in vivo* blood level data. Therefore, absorption was ultimately dependent upon gastric emptying rate and gastric pH, as long as the formulation disintegrated properly in the stomach.

The rectal absorption of aspirin, aspirin aluminum, and

calcium carbaspirin from several suppository bases was studied in dogs (196). The absorption of aspirin aluminum from either cocoa butter or a polyethylene glycol base was poor. While the maximum salicylate levels produced by aspirin and calcium carbaspirin from the cocoa butter base occurred at a later time than from the other bases studied, minimal plasma levels were exhibited by a polysorbate 61 base formulation. The highest peak and largest area under the blood level curve were seen with calcium carbaspirin in a vegetable fatty acid glyceride base. The poor absorption of aspirin aluminum from suppositories was not unexpected since it is poorly soluble. Furthermore, as pointed out for aspirin aluminum tablets (105, 106), an insoluble aluminum compound may form on the surface of the dissolving drug, further impeding its dissolution rate and bioavailability.

Additional references on bioavailability and formulation effects are given in Table VII.

Absorption Alteration—Several years ago, clinicians claimed that certain salts of theophylline were therapeutically preferable to other salts or to the free acid (202–204). For example, Schluger *et al.* (204) found higher blood theophylline levels after administering uncoated tablets of theophylline ethylenediamine than were observed with enteric-coated tablets of choline theophyllinate. These results were at variance with the *in vivo* work of Gagliani *et al.* (202), who found that the oral ingestion of choline theophyllinate produced significantly higher blood levels than the ethylenediamine salt. This apparent discrepancy could be explained by the formulation effects of tablet coating, *etc.*, which was not discussed in the work of Gagliani *et al.* In another study, a slightly more rapid rise in blood concentration and a greater area under the curve were observed with theophylline isopropanolamine than with theophylline ethylenediamine (203). It was suggested that the difference was a result of the greater water solubility of the isopropanolamine salt.

The *in vitro* dissolution rates of the choline and isopropanolamine salts of theophylline have been observed to be three to five times greater than the ethylenediamine salt, depending on the dissolution medium (98). It has been suggested that these differences in dissolution rate are consistent with, and offer an explanation for, the clinical results.

In a comparative study of the absorption of ampicillin trihydrate and ampicillin potassium following oral administration (205), the potassium salt yielded 37% higher peak levels and a larger area under the curve. Only 36% of the administered ampicillin trihydrate was absorbed while 53% of the potassium salt was absorbed. Determining the percentage of each drug eliminated in the urine showed that 39% was eliminated following administration of the trihydrate and 52% from the potassium salt. The entire difference between the two drug forms was accounted for in the initial 4 hr postadministration.

Several studies compared blood levels obtained with erythromycin and its salts and esters. Erythromycin estolate produced blood levels that were severalfold higher than those obtained with erythromycin base or erythromycin stearate (206–208). These differences were found to persist in the fasting as well as nontasting subjects (207), indicating that food did not appreciably alter the absorption of erythromycin estolate when given under similar con-

multiple dosing (207). This finding is explained by the fact that this salt is acid stable and alkaline dissociable, permitting its passage through the acid of the stomach both in fasting and nonfasting subjects (209). Accordingly, the antibacterial activity remained essentially the same when this form of erythromycin was given, regardless of the state of fasting of the subject (209).

On first inspection, the higher serum levels attained with erythromycin estolate suggest that the salt form is more readily absorbed. Also critical to efficacy, however, is the volume of distribution of the drug, since extensive binding to plasma proteins can render a drug unavailable for activity at the biophase. Therefore, the significance of blood level data greatly depends on the measure of the free or unbound fraction of total antibiotics in the blood, which more directly indicates probable therapeutic benefit.

Wiegand and Chun (210) showed that, despite the higher blood levels attained with erythromycin estolate (after correction for half-life differences), the stearate salt produced seven times more free drug in serum than did the estolate salt. This finding explained the higher total tissue levels observed on administration of the stearate. They attributed the difference to a greater serum protein binding of the intact erythromycin estolate, proving that its higher serum levels did not necessarily reflect more efficient absorption.

Marked differences have been observed following oral administration of various salts of penicillin. Penicillin G potassium has been compared with penicillin G benzathine (benzethacil) (211, 212), penicillin G hydrabamine (213), penicillin V (214), penicillin G procaine (212), and penicillin G ammonium (215). As anticipated, penicillin G potassium produced higher and earlier blood levels than penicillin G benzathine (211, 212). Furthermore, tablets of penicillin G potassium buffered with sodium citrate yielded higher peak levels than unbuffered penicillin G potassium. While the absorption of buffered tablets was apparently not significantly affected by food intake, the unbuffered tablets yielded lower average levels and irregular absorption under similar conditions.

When penicillin G potassium was compared with penicillin G hydrabamine (213), a less soluble salt, blood levels similar to those produced by penicillin G benzathine were observed. When equivalent doses were administered, the penicillemia that occurred with penicillin G hydrabamine was only one-third or one-fourth as great and was of shorter duration than that produced by penicillin G potassium.

Budolfson *et al.* (212) found that peak concentrations of penicillin G potassium were three to four times those obtained with penicillin G procaine and five to six times those of penicillin G benzathine, indicating a more rapid rate of absorption. The therapeutic action was related to the maximum concentration attained, but it also depended on the persistence of penicillemia, which was greater with penicillin G potassium than with the other two compounds. The authors suggested that the lower blood levels attained with the relatively insoluble penicillin G benzathine were caused by its destruction in the GI tract prior to absorption. This suggestion seems unlikely, however, since the drug should not degrade very rapidly as an undissolved suspension.

Because of its superior stability in gastric juice, penicillin

V produces higher blood penicillin levels than corresponding doses of penicillin G. As a result, extensive investigations have been conducted with various salts of penicillin V (99, 214-220). For instance, tablets, capsules, and oral suspensions of penicillin V acid produced significantly higher blood concentrations than comparable penicillin G preparations (214). In the same study, the average serum levels produced by the benzathine salt of penicillin V were significantly higher than comparable doses of penicillin G benzathine for the first 4 hr but lower thereafter, again illustrating the value of using an insoluble salt to prolong blood levels of an acid-unstable compound. In another study (215), penicillin V acid was shown to produce higher and more prolonged plasma concentrations than either penicillin G potassium or ammonium, whose properties were comparable.

Plasma levels were correlated with dissolution rates of various forms of penicillin V (99). As solid dosage forms, the readily soluble potassium and calcium salts produced earlier and higher blood levels in fasting subjects than either the free acid or its benzathine salt. On the other hand, when the potassium and benzathine salts were administered orally as solutions, absorption was the same, implying that the poor solubility of the benzathine salt was responsible for the inferior blood levels obtained from its solid dosage forms. Other studies found that, while the potassium salt is 40% better absorbed than the free acid in fasting subjects, both forms produce therapeutic levels when administered with food (218).

Experiments with fistulated dogs indicated that penicillin V is absorbed primarily from the stomach. Therefore, it is not surprising that the potassium salt should show higher blood levels on oral administration since it is the most soluble salt in gastric pH (216). In accordance with this observation, it was also reported that the benzathine salt exhibited higher serum levels in patients with gastric achlorhydria (pernicious anemia) than in patients with normal gastric function (219). Differences in gastric emptying time may also explain this result.

Several studies compared the absorption of tetracycline and its salts (103, 221, 222). For example, serum concentrations in dogs and humans showed that a phosphate complex salt of tetracycline was absorbed more rapidly and gave higher blood levels during the first 6-8 hr than did tetracycline hydrochloride (221). The total amount of drug absorbed was about twice as great with the former compound.

Another study (222) suggested that tetracycline base produced higher blood levels than tetracycline hydrochloride. However, a subsequent investigation (223) showed that, in the absence of adjuvants or fillers, tetracycline hydrochloride and tetracycline base were absorbed equally well. Results obtained in this same study indicated that tetracycline hydrochloride encapsulated with citric acid produced higher serum concentrations than tetracycline hydrochloride mixed with hexametaphosphate or the phosphate complex salt of tetracycline.

In a study comparing urinary excretion rates and *in vitro* dissolution, the absorption of tetracycline and tetracycline phenolsulfonaphthaleinate was rate limited by their dissolution rates, whereas tetracycline hydrochloride absorption was rate limited by the absorption process itself (103).

Several lincomycin salts were studied for their comparative availability (224). In particular, the blood levels obtained with the relatively water-insoluble hexadecylsulfamate salt were compared to those of the hydrochloride following oral administration. Higher and extended whole blood and serum concentrations were obtained in mice, rats, and dogs with the hexadecylsulfamate. However, subcutaneously administered lincomycin did not produce significantly different fractions absorbed, regardless of which salt was administered. It is not known whether the greater area under the curve with oral administration of lincomycin hexadecylsulfamate is due to greater absorption from the GI tract, slower renal clearance, or greater enterohepatic circulations.

Salts of streptomycin, neomycin, viomycin, and streptothricin have been formed with: (a) polyacrylic acids, (b) sulfonic or phosphorylated polysaccharides, and (c) natural polycarboxyl acids from a series of polyuronic substances and polysaccharide derivatives containing carboxyl groups (18). The report indicated that these salts were absorbed from the injection locus primarily by the lymph system. Blood levels from the salts were generally lower but were maintained for a longer time than the equivalent amount of antibiotic alone, and higher concentrations of longer duration may actually be produced in the lymphatic drainage.

The influence of salt formation on the onset and duration of pharmacological activity also was illustrated with tolbutamide and several of its salts (101). Following oral administration, the sodium salt produced a rapid decrease in blood sugar level followed by a rapid recovery. By contrast, the free acid of tolbutamide caused a slow and prolonged drop in blood sugar level, a preferred effect since the chance of hypoglycemic shock would be lessened. This finding also illustrates the often overriding influence of the actual disease state on the choice of drug form.

Additional references on the implications of salt formation on absorption are listed in Table VIII.

Pharmacokinetics—Because of the various new properties that are usually imposed on a compound by salt formation, the pharmacokinetics of the drug necessarily change as a function of these properties.

For example, a pharmacokinetic evaluation comparing ampicillin sodium and potassium with ampicillin trihydrate was performed after oral administration to beagle dogs (243). The absorption rate constants of the sodium and potassium salts, which were similar, proved significantly greater than the rate constant of ampicillin trihydrate, resulting in earlier, higher peak concentrations with two to three times higher serum concentrations during the 1st hr. Yet, any differences between the fraction absorbed for the three products were not statistically significant. Apparently, although dissolution of the ampicillin trihydrate was the rate-limiting step in its absorption, the overall extent of bioavailability remained unaffected.

An interesting study of the biliary excretion of erythromycin base and erythromycin estolate was reported (244). The biliary excretion of erythromycin base was high, while that of erythromycin estolate was much lower; preferential secretion of erythromycin in the bile could partially account for the lower serum levels exhibited by the base. However, the proportion of the ingested dose secreted in the bile was small, and the total amounts in-

Table VIII—Additional References on Bioavailability and Absorption Alteration

Topic	Reference
Blood levels produced by three theophylline-containing elixirs	225
Naproxen oral absorption characteristics	226
Effect of food on absorption of a new form of erythromycin propionate	227
Effect of the anion on the absorption of tetracycline from the rat stomach	186
Blood levels following oral administration of different preparations of novobiocin	228
Absorption of inipronic acid and its sodium salt	229
Oral absorption of secobarbital (quinabarbitone) and its sodium salt	230
Absorption rate of barbiturates in humans	231
Morphine and atropine mucate	232
Excretion of buphenium salts in urine of human volunteers	233
Polymethylene bis(isothiuronium) salts: antituberculosis activity	234
Prolonged antitussive action of a resin-bound noscapine preparation	235
Pharmacology of sulfapyridine and sulfathiazole	236
Evaluation of plasma concentrations of propoxyphene utilizing a hybrid principal component analysis of variance technique: equimolar doses	237
Antrycide, a new trypanocidal drug	238
Pralidoxime methanesulfonate: plasma levels and pharmacokinetics after oral administration to humans	239
Intestinal absorption of pralidoxime and other aldioximes	240
Blood plasma levels and elimination of salts of pralidoxime (2-PAM) in humans after oral administration	241
Enhancement of GI absorption of a quaternary ammonium compound by trichloroacetate	242

involved were not sufficient to account entirely for the differences in serum concentrations attained. Undoubtedly, the protein binding studies of Wiegand and Chun (210) (discussed under *Absorption Alteration*) more satisfactorily explain the difference in serum concentrations.

Often, salt formation can be used to modify drug absorption and dose tolerance favorably. For example, aminosalicic acid exhibits a short half-life and, therefore, requires large and frequent doses which may cause gastric irritation. Consequently, different chemical forms such as salts have been prepared (119, 245–247) to reduce the incidence of gastric irritation, increase absorption, and prolong blood levels.

Aminosalicic acid is an interesting example in other ways; considerable confusion about this drug exists because many fail to recognize its nonlinear pharmacokinetics. Several definitive studies were reported regarding the absorption of the acid and its sodium, potassium, and calcium salts from solution, suspension, and tablet formulations (245, 246). Comparison of the relative bioavailabilities of aminosalicic acid suspended in water and its salts dissolved in water showed that, while differences in rate of absorption were found to exist, absorption of both the acid and its salts was essentially complete. Absorption of the free acid from tablets reached only 77% of the dose, whereas that of the tableted salts was rapid and complete.

Regardless of formulation, the area under the plasma concentration–time curve of unmetabolized drug from free acid administration was less than that for the salts. This result was attributed to concentration-dependent metabolism during absorption; when the rate of absorption is high, the metabolic processes become saturated and more unmetabolized drug remains in the blood; conversely,

Table IX—Additional References on Bioavailability and Pharmacokinetics

Topic	Reference
Pharmacodynamics of fosfomycin (phosphonomycin) after intravenous administration to humans	248
Pharmacodynamics of phosphonomycin after oral administration to humans	249
Comparative studies on distribution, excretion, and metabolism of ³ H-hydroxyzine and its ¹⁴ C-methiodide in rats	250
Pharmacokinetics of ampicillin trihydrate, ampicillin sodium, and dicloxacillin sodium following intramuscular injection	251
Physiological disposition of fenoprofen in humans: pharmacokinetic comparison of calcium and sodium salts administered orally	252

when the absorption rate is low, as for the free acid, a higher percentage of drug is metabolized.

Additional references regarding bioavailability and pharmacokinetics are presented in Table IX.

GENERAL PHARMACY

Pharmacological Effect—Chlorpromazine hydrochloride and quaternary chlorpromazine chloride were investigated with respect to their effects on the central nervous system (CNS) (253). The quaternized compound was less potent and more toxic in rodents than the parent tertiary compound.

Naloxone, an effective opiate antagonist, is generally used as the hydrochloride salt; however, the drug has a very short duration of action. The mucate salt was prepared to extend its duration of action, since mucic acid is only slightly soluble in water (254). In a test on the blocking of morphine activity in mice, however, the mucate salt did not differ in duration from the hydrochloride. These investigators assumed the same receptor site for naloxone as for morphine and, since Heron's (232) work suggested that the receptor had a greater affinity for morphine mucate than for the free base, it also should have a greater affinity for naloxone mucate. The results disproved this hypothesis. Furthermore, this theory implies that intact salt reaches the receptor, which is highly unlikely, regardless of whether the drug is administered as a solution or as a suspension.

A series of salts of 9-aminoacridine and its derivatives was prepared and screened for antifungal and antibacterial activity (255–257). By using salts of fatty acids, the antifungal action was found to parallel the length of the carbon chain of the anion, with maximal activity occurring with acridine caproate, undecylate, and undecylenate (where undecylenic acid also exhibits some intrinsic antifungal activity) (255). This result appears reasonable, because these salts would be more lipid soluble and could be expected to pass through the cell wall of the infecting organism more readily, probably as an ion-pair.

The efficacy of bases or salts as topical anesthetics for relieving cutaneous itch, burning, and pain in unbroken skin has also been examined (258). In these experiments, itching and pricking were induced by an alternating current of low amperage and voltage applied to the skin or by exposure of the skin to UV light. Interestingly, aqueous solutions of salts of the local anesthetics did not alleviate itching or burning in any of the subjects, although saturated solutions of their bases in a mixture of water, 40%

Table X—Additional References on General Pharmacy and Pharmacological Effect

Topic	Reference
Differential excretion of bromide and chloride ions and its role in bromide retention	259
Pharmacological study of calcium methionate	260
Synthesis and <i>in vitro</i> fungistatic evaluation of some <i>N</i> -substituted amides and amine salts of sorbic acid	261
Antiamoebic studies on clamoxyquin [5-chloro-7-[[[3-diethylaminopropyl]amino]methyl]-8-quinolinol] <i>in vitro</i> and in experimentally infected animals	262
Adjunctive value of oral prophylaxis with the oximes pralidoxime (2-PAM) lactate and pralidoxime methanesulfonate to therapeutic administration of atropine in dogs poisoned by inhaled sarin vapor	263
Pralidoxime (2-hydroxyiminomethyl- <i>N</i> -methylpyridinium) methanesulfonate and atropine in the treatment of severe organophosphate poisoning	264
Efficacy and limitations of oxime-atropine treatment of organophosphorus anticholinesterase poisoning	265
Antitussive activity of enoxolone (glycyrrhetic acid) and its derivatives	266
Pharmacological properties of glycyrrhetic acid hydrogen succinate (disodium salt)	267
Ganglionic blocking activity of diastereomeric dimethylaminobornyl acetates and their methiodides	268
A new potent nonnarcotic antitussive, 1-methyl-3-[bis(2-thienyl)methylene]piperidine: pharmacology and clinical efficacy	269

alcohol, and 10% glycerol were claimed to be effective. Such transport phenomena across the stratum corneum are often dependent on the polarity of the drug and vehicle and on the binding of the drug to keratin.

Additional references on pharmacological effects can be found in Table X.

Dialysis—Dialysis through a cellophane membrane of the hydrochloride or sodium salts has been studied with several drugs (270). In many cases, it appeared that the ionic form of the drug was bound to the membrane whereas the nonionized form was not. Ephedrine hydrochloride presented an interesting example, however, since it dialyzed considerably faster than its corresponding base. It was theorized that the chloride ion dialyzed rapidly, enhancing the rate of dialysis of the ephedrine ion. Accordingly, when chloride ion was present on both sides of the membrane, the observed rate of dialysis for the ephedrine ion was comparable to the ephedrine base.

The diffusion of sodium chloride through a lipoprotein interface was very slow, especially if calcium chloride was present on both sides of the interface (271). In the presence of low concentrations of choline chloride or carbamylcholine chloride, the diffusion of sodium chloride is more rapid. Apparently, choline salts are able to increase the permeability of the lipoprotein to salts, which may relate to the physiological action of choline salts.

Miscellaneous—Release rates were determined for aminophylline, ephedrine alkaloid, and ephedrine hydrochloride from theobroma oil suppositories containing nonionic surfactants (133). While surfactants with hydrophilic-lipophilic balance (HLB) values less than 11 only minimally affected release rate, rates increased with surfactants of HLB values greater than 11. Under optimal conditions, aminophylline was faster than ephedrine hydrochloride which, in turn, was superior to the ephedrine base.

Willis and Banker (272) reported on the formation of polymer-drug salts as an approach to the physicochemical design of dosage forms. Poly(methyl vinyl ether/maleic

anhydride) salts of methapyrilene were prepared and tested with the free base for *in vitro* dissolution and dialysis. Their dissolution and dialysis rates were not appreciably different from the free drug or its hydrochloride salt. Various poly(methyl vinyl ether/maleic anhydride) hemiester salts of methapyrilene exhibited substantially slower release than the polymer ether salts, hydrochloride salt, or free base forms. Polymer-drug salts thus appear to have promise.

A series of metallic salts of edetic (ethylenediamine-tetraacetic) acid were tested *in vitro* to determine their effect on blood coagulation (273). The results showed that only the dipotassium and disodium salts had any effect on coagulation. It was theorized that the lack of anticoagulant activity resulted from an almost complete suppression of ionization of the heavy metal salts.

Interesting research regarding the angina-preventive effect of some chromone-2-carboxylate salts showed a direct correlation between biological activity and pKa of the salt-forming amines (274).

Lin *et al.* (112) investigated the relationship between salt form and biological activity of a given antihypertensive. While the intrinsic dissolution rates of the dihydrochloride and disulfate salts were many fold greater than the monohydrochloride, the hypotensive potencies of the salts did not differ significantly from one another in an anesthetized dog study. Yet, when administered to renal hypertensive dogs, the dihydrochloride and disulfate salts produced greater hypotensive effects than did the monohydrochloride.

TOXICOLOGICAL CONSIDERATIONS

Toxicity of Salt Ion—Any discussion regarding the toxicity of salts of a drug must consider the pharmacological properties of the cation or anion used to form the salt as well as those of the free drug, since any of these may produce toxic effects. The toxicology of several ions that are commonly used to form salts and that are relevant to this review were discussed in depth (275).

Toxicity from ingestion of calcium salts of drugs is rare. If hypercalcemia occurs, however, calcium deposits in the kidney can bring on a reduction of renal function. The principal toxic effects of lithium also involve the kidneys. When small amounts of lithium are taken, no apparent damage occurs; yet large amounts of the metal can lead to irreversible damage. An apparent correlation was observed between lithium dosage and sodium intake (276). When lithium dosage was low or sodium intake was high, rats were able to excrete all lithium given and sustained a reversible polyuria. Conversely, if large amounts of lithium were administered to the rats or if their sodium intake was lowered, they incurred irreversible kidney damage. Ammonium ion, although it serves a major role in maintenance of the acid-base balance of the body, can be toxic in high concentrations and initiate CNS derangements.

Sulfate ions given orally tend to be minimally absorbed and may act as a laxative. The nitrate ion is irritating to the GI tract, causing nausea and gastric distress. Also, intestinal bacteria may convert the nitrate ion to nitrite which oxidizes hemoglobin to methemoglobin. The citrate ion, an intermediary in carbohydrate metabolism, can form a soluble complex with calcium which is poorly dissociable

and rarely causes any toxic reactions. While tartrate ions are usually absorbed minimally from the GI tract, high concentrations reaching the circulation can cause renal damage.

Acetate and lactate ions are normal metabolites and appear to be well tolerated in relatively large amounts. Iodide and bromide ions can produce conditions known as iodism and bromidism, respectively. Bromide intoxication occurs quite frequently, since bromides are used as ingredients in some nonprescription preparations (277-280). Bromide is slowly excreted by the kidney (its half-life is 12 days) and tends to accumulate when taken for prolonged periods or when used by patients with decreased renal function (277).

Toxicity of Salt Form—Provided the salt-forming agents are nontoxic, the relative toxicities of a series of salts of a compound are often observed to reflect directly their absorption rates. For example, the toxicities of dibromide, dichloride, diiodide, and dimethylsulfate salts of quina-pyramine³, a trypanocidal drug, were determined (238). The sparingly soluble halogen salts were much less toxic subcutaneously or intramuscularly than the freely soluble dimethylsulfate, yet all salts showed about equal toxicity upon intravenous administration. The difference in toxicities obviously resulted from rapid absorption of the methylsulfate compared to the slowly absorbed, poorly soluble halogen salts. Similar reasoning has been used to explain the acute oral toxicity of propoxyphene hydrochloride in rodents, which is twice that of equimolar doses of the napsylate salt (281).

Several salts of benzphetamine and etryptamine were prepared as potential sustained-release formulations (114). The water solubility, *in vitro* dissolution rates at pH 1.0 and 7.2, and the median lethal times (LT₅₀) were determined for each salt. Both the LT₅₀ and LD₅₀ (determined on only a few salts) increased as the *in vitro* dissolution rate at pH 7.2 decreased. While dissolution at pH 1.0 did not correlate well with toxicity, the LT₅₀'s were inversely related to the square root of the dissolution rates at pH 7.2.

Toxicity studies comparing iopanoic acid, a cholecystographic contrast medium, with its sodium salt (115) showed that the salt form has 10-fold greater toxicity. The LD₅₀'s of the free acid and the salt were 22 and 2.32 g/kg, respectively. It was postulated that the free acid precipitated from the sodium salt upon its reaction with gastric hydrochloric acid. The fine, amorphous particles of precipitated acid had a greatly increased surface area and, therefore, dissolved more rapidly than even fine crystals of the free acid. The faster and more complete drug absorption then resulted in increased toxicity.

Salts exhibiting greater water solubility than their parent compounds or less soluble salts are not always more toxic. For example, various inorganic and organic ions were used to prepare salts of methyl pyridinium-2-aldoxime that would have greater water solubility and would eliminate undesirable side effects due to the iodide ion (95). Even though the aqueous solubility of the majority of these salts was many times greater than the iodide, their toxicity on a molar basis was not significantly different, with the exception of the dihydrogen phosphate salt which was 15%

Table XI—Additional References on Toxicological Considerations

Topic	Reference
Toxicity and absorption of 2-sulfanilimidopyridine and its soluble sodium salt	285
Sorbic acid as a fungistatic agent for foods: harmlessness of sorbic acid as a dietary component	286
Toxicity and distribution of erythromycin	287
Further toxicological studies with erythromycin	288
Pharmacology and toxicology of erythromycin estolate	289
Erythromycin propionate (propionylethromycin): a review of 20,525 case reports for side-effect data	290
New class of antibiotic salts of reduced toxicity	22
GI intolerance to oral iron preparations	291
Comparative toxicology of iron compounds	292
Influence of the dissolution rate of lithium tablets on side effect	123
Toxicity and tissue distribution studies on the hydrochloride, bismuth iodide complex, and a resinate of emetine	293
Bacitracin zinc in pharmaceutical preparations	145
New approach to quaternary ammonium compounds	151
Pharmacology of choline theophyllinate	294

more toxic. Further research with oximes revealed that other salts are also toxic (282).

GI bleeding is a common toxic effect of aspirin for a large percentage of the population. Consequently, a search was initiated for an aspirin derivative that would not induce GI blood loss (283). All compounds prepared, however, including the sodium and calcium salts, caused GI hemorrhage with a severity similar to aspirin.

Polyene antibiotics are potent antifungal agents but bear considerable toxicity. Even though the methyl ester hydrochlorides of these compounds are more soluble, they retain almost all of their antifungal activity and, more significantly, show a uniform decrease in toxicity compared to their parent compounds (284).

Additional references on toxicological considerations of salt formation are given in Table XI.

CONCLUSIONS

Salt formation is a means of altering the physical, chemical, and biological characteristics of a drug without modifying its chemical structure. Clearly, the salt form can have a dramatic influence on the overall properties of the parent compound. At present, selecting a salt form that exhibits the desired combination of properties is a difficult semiempirical choice. Pharmaceutical scientists now recognize these facts and are beginning to study the effects of different salt forms on the physicochemical properties, bioavailability, and toxicity of drug substances.

Although now only a few generalizations are available to predict the effect of particular salt forms on the characteristics of a drug, perhaps in time it will be possible to evolve increasingly more powerful generalizations regarding the effect of a salt on the properties of its parent compound. In addition, we predict that polymer-drug salts will have a revolutionary effect on future trends in drug therapy, particularly in the areas of reducing drug toxicity and in controlling the release profile of novel drug delivery systems.

REFERENCES

- (1) D. Warkling and J. Appino, *Drug Cosmet. Ind.*, 112 (3), 39 (1973).
- (2) N. J. Harper, *J. Med. Pharm. Chem.*, 1, 467 (1959).
- (3) N. J. Harper, *Progr. Drug Res.*, 4, 221 (1962).
- (4) K. Munzel, *ibid.*, 10, 255 (1966).
- (5) V. J. Stella, *Aust. J. Pharm. Sci.*, NS2 (2), 57 (1973).
- (6) A. A. Sinkula and S. H. Yalkowsky, *J. Pharm. Sci.*, 64, 181 (1975).
- (7) "Martindale The Extra Pharmacopoeia," 26th ed., Pharmaceutical Press, London, England, 1973.
- (8) L. C. Miller and W. H. Heller, in "1974-75 Drugs of Choice," W. C. Modell, Ed., Mosby, St. Louis, Mo., p. 26.
- (9) E. Saias, A. Jondet, and J. Phillippe, *Ann. Pharm. Fr.*, 27, 557 (1969); through *Chem. Abstr.*, 72, 125018e (1970).
- (10) H. C. Caldwell, A. B. Rednick, G. C. Scott, G. J. Yakatan, and D. Ziv, *J. Pharm. Sci.*, 59, 1689 (1970).
- (11) G. R. Coatney, P. G. Contacos, and J. S. Lunn, *Am. J. Trop. Med. Hyg.*, 13, 383 (1964).
- (12) P. E. Thompson, B. J. Olaszewski, E. F. Elsager, and D. F. Worth, *ibid.*, 12, 481 (1963).
- (13) W. C. Miller, Jr., D. B. Marcotte, and L. McCurdy, *Curr. Ther. Res., Clin. Exp.*, 15, 700 (1973).
- (14) H. L. Goldberg and L. Nathan, *Psychosomatics*, 13, 131 (1972).
- (15) E. F. Elsager, *Ann. Rep. Med. Chem.*, 1965, 137.
- (16) H. A. M. El Shibini, M. Abdel Nasser, and M. M. Motawi, *Pharmazie*, 26, 630 (1971).
- (17) S. P. Loucas and H. M. Haddad, *J. Pharm. Sci.*, 61, 985 (1972).
- (18) P. Málek, J. Kolc, M. Herold, and J. Hoffman, in "Antibiotics Annual, 1957-1958," Medical Encyclopedia, New York, N.Y., 1958, p. 546.
- (19) B. F. Duesel, H. Berman, and R. J. Schacter, *J. Am. Pharm. Assoc., Sci. Ed.*, 43, 619 (1954).
- (20) B. F. Duesel and T. I. Fand, *Int. Rec. Med. Gen. Pract. Clin.*, 167, 245 (1954).
- (21) R. H. Broh-Kahn, *ibid.*, 173, 217 (1960).
- (22) F. A. Alves, M. F. C. A. N. Graca, and H. L. Baptista, *Nature*, 181, 182 (1958).
- (23) H. Keller, W. Krüpe, H. Sous, and H. Mückter, *Arzneim.-Forsch.*, 5, 170 (1955).
- (24) *Ibid.*, 6, 61 (1956).
- (25) H. Keller, W. Krüpe, H. Sous, and H. Mückter, in "Antibiotics Annual, 1955-1956," Medical Encyclopedia, New York, N.Y., 1956, p. 35.
- (26) A. C. Osterberg, J. J. Oleson, N. N. Yuda, C. E. Rauh, H. G. Parr, and L. W. Will, in "Antibiotics Annual, 1956-1957," Medical Encyclopedia, New York, N.Y., 1957, p. 564.
- (27) R. Ducrot, O. Leau, and C. Cosser, *Antibiot. Chemother.*, 6, 404 (1956).
- (28) R. S. Brigham and J. K. Nielsen, *ibid.*, 8, 122 (1958).
- (29) M. Khristov, *Khim.-Farmatsert. Zh.*, 11, 19 (1972).
- (30) A. Lasslo, C. Pfeiffer, and P. D. Waller, *J. Am. Pharm. Assoc., Sci. Ed.*, 48, 345 (1959).
- (31) J. A. Campbell and J. G. Slater, *J. Pharm. Sci.*, 51, 931 (1962).
- (32) J. A. Campbell, *ibid.*, 51, 270 (1962).
- (33) G. A. Neville and J. C. Ethier, *ibid.*, 60, 497 (1971).
- (34) T. Sciortino, *Boll. Chim. Farm.*, 105, 223 (1966); through *Chem. Abstr.*, 65, 622h (1966).
- (35) *Ibid.*, 104, 292 (1965); through *Chem. Abstr.*, 63, 6783g (1965).
- (36) W. P. Boger, S. C. Strickland, and J. M. Gylfe, *Antibiot. Med. Clin. Ther.*, 1, 372 (1955).
- (37) C. L. Fox, Jr., South African pat. 68 03, 461 (Oct. 31, 1968); through *Chem. Abstr.*, 71, 33401a (1969).
- (38) J. W. Cusic, U.S. pat. 2,499,058 (Feb. 28, 1950); through *Chem. Abstr.*, 44, 4926g (1950).
- (39) J. W. Cusic, U.S. pats. 2,534,235-2,534,247 (Dec. 19, 1950); through *Chem. Abstr.*, 46, 527b-i (1952).
- (40) J. W. Cusic, British pat. 677,798 (Aug. 20, 1952); through *Chem. Abstr.*, 48, 4010a (1954).
- (41) G. D. Searle Co., British pats. 683,645 (Dec. 3, 1952) and 683,236 (Nov. 26, 1952); through *Chem. Abstr.*, 48, 2769b (1954).
- (42) J. W. Cusic, *Science*, 109, 574 (1949).
- (43) M. L. Robinette and F. W. Bope, *J. Am. Pharm. Assoc., Sci. Ed.*, 44, 32 (1955).
- (44) D. J. Lamb and F. W. Bope, *ibid.*, 45, 178 (1956).
- (45) W. Bickers and M. Woods, *Tex. Rep. Biol. Med.*, 9, 106 (1951).

- (46) W. Bickers and M. Woods, *N. Engl. J. Med.*, 245 453 (1951).
- (47) J. M. Holbert, I. W. Grote, and H. Smith, *J. Am. Pharm. Assoc., Sci. Ed.*, 44, 355 (1955).
- (48) W. Morozowich and F. W. Bope, *ibid.*, 47, 173 (1958).
- (49) A. Halpern, N. Shaftel, and G. Schwartz, *Antibiot. Chemother.*, 9, 97 (1959).
- (50) A. Halpern, N. Shaftel, and A. J. Monte Bovi, *Am. J. Pharm.*, 130, 190 (1958).
- (51) P. A. Fernander, German Offen. 2,259,151 (June 7, 1973); through *Chem. Abstr.*, 79, 53102x (1973).
- (52) A. Reiner, German Offen. 2,330,380 (Jan. 31, 1974); through *Chem. Abstr.*, 80, 100206b (1974).
- (53) J. R. Blanco, F. J. U. Fernandez, and L. S. Vinals, German Offen. 2,144,679 (Dec. 21, 1972); through *Chem. Abstr.*, 78, 71781b (1973).
- (54) VEB Berlin-Chemie, German Offen. 2,316,721 (Dec. 20, 1973).
- (55) M. T. Davies, J. Forrest, F. Hartley, and V. Petrow, *J. Pharm. Pharmacol.*, 6, 707 (1954).
- (56) Laboratorios Hoshon S. A., French Demande 2,138,498 (Feb. 9, 1973); through *Chem. Abstr.*, 79, 83485s (1973).
- (57) B. J. Magerlein, *J. Pharm. Sci.*, 54, 1065 (1965).
- (58) E. H. Massey, German Offen. 2,138,049 (Feb. 3, 1972); through *Chem. Abstr.*, 76, 117507f (1972).
- (59) R. Tizier, German Offen. 1,936,723 (May 14, 1970); through *Chem. Abstr.*, 73, 28895b (1970).
- (60) P. Wirth, German Offen. 2,117,902 (Nov. 4, 1971); through *Chem. Abstr.*, 76, 46462z (1972).
- (61) Takeda Chem. Ind. Ltd., German Offen. 2,332,878 (Jan. 17, 1974); through *Chem. Abstr.*, 80, 96362v (1974).
- (62) Takeda Chem. Ind. Ltd., German Offen. 2,332,840 (Jan. 17, 1974); through *Chem. Abstr.*, 80, 87531x (1974).
- (63) G. Fabrizio, U.S. pat. 3,764,595 (Oct. 9, 1973); through *Chem. Abstr.*, 80, 6945k (1974) or *Chem. Abstr.*, 73, 133984e (1970).
- (64) Koninklijke Nederlandsche Gist en Spiritusfabriek, French pat. 2,126,443 (Oct. 6, 1972).
- (65) R. Aries, French pat. 2,190,410 (Mar. 8, 1974).
- (66) Otsuka Pharmaceutical Co., Ltd., Japanese pat. 71 03,600 (Jan. 28, 1971); through *Chem. Abstr.*, 75, 40421t (1971).
- (67) V. C. Stephens, U.S. pat. 3,728,379 (Apr. 17, 1973).
- (68) Investigations Scientifiques Pharmaceutiques S. A., French Demande 2,097,064 (Apr. 7, 1972); through *Chem. Abstr.*, 77, 168654e (1972).
- (69) C. Jarowski, *Trans. N.Y. Acad. Sci., Ser. II*, 21, 290 (1959).
- (70) Andreu SA, West German pat. 2,237,267 (Feb. 1, 1973).
- (71) E. N. Lazareva, L. A. Kovaleva, V. K. Vasil'ev, and P. S. Braginskaya, *Antibiotiki (Moscow)*, 14, 813 (1969); through *Chem. Abstr.*, 71, 111183x (1969).
- (72) O. B. Ferno, T. O. E. Linderat, and B. Hansen, South African pat. 68 01,104 (July 12, 1968); through *Chem. Abstr.*, 70, 60832c (1969).
- (73) A. Allais and M. Paturet, French M. 5,309 (Sept. 25, 1967); through *Chem. Abstr.*, 71, 64078e (1969).
- (74) Cent. Ind. Pharmaceutique, French pat. 2,193,586 (Mar. 29, 1974).
- (75) G. Guadagnini and F. Fabi, German Offen. 2,040,143 (Feb. 25, 1971); through *Chem. Abstr.*, 74, 126005b (1971).
- (76) Ciba-Geigy A.G., Canadian pat. 916,713 (Dec. 12, 1972).
- (77) R. Ferrari, S. Magnaghi, and G. Ghielmetti, British pat. 1,205,441 (Sept. 16, 1970); through *Chem. Abstr.*, 73, 133979e (1970).
- (78) L. G. Goodwin, L. G. Jayewardene, and O. D. Standen, *Br. Med. J.*, 2, 1572 (1958).
- (79) A. Zaffaroni, U.S. pat. 3,708,492 (Jan. 2, 1973).
- (80) F. K. Hansel, *Ann. Allergy*, 1, 199 (1943).
- (81) Cent. Ind. Pharmaceutique, French pat. 2,193,587 (Mar. 29, 1974).
- (82) N. H. Creasey and A. L. Green, *J. Pharm. Pharmacol.*, 11, 485 (1959).
- (83) J. M. De Muylder, German Offen. 2,310,447 (Sept. 13, 1973); through *Chem. Abstr.*, 80, 6982v (1974).
- (84) V. C. Stephens, U.S. pat. 3,065,261 (1962).
- (85) Merck & Co., Inc., West German pat. 2,256,538 (May 24, 1973).
- (86) C. J. Cavallito and R. Jewell, *J. Am. Pharm. Assoc., Sci. Ed.*, 47, 165 (1958).
- (87) R. L. Kile, *Antibiot. Med. Clin. Ther.*, 5, 578 (1958).
- (88) Whitefin Holding S. A., Belgian pat. 793,548 (Apr. 16, 1973).
- (89) Officina Therapeutica Italiana SRL, French pat. 2,399,449 (Mar. 17, 1972).
- (90) J. Kloss, West German pat. 2,134,672 (Jan. 25, 1973); through *Chem. Abstr.*, 78, 97334h (1973).
- (91) T. J. Roseman and S. H. Yalkowsky, *J. Pharm. Sci.*, 62, 1680 (1973).
- (92) L. C. Miller and A. H. Holland, *Mod. Med.*, 28, 312 (1960).
- (93) J. G. Wagner, *J. Pharm. Sci.*, 50, 359 (1961).
- (94) T. H. Simons, abstracted from a paper presented at the APHA Academy of Pharmaceutical Sciences, Las Vegas meeting, Apr. 1967.
- (95) A. A. Kondritzer, R. I. Ellin, and L. J. Edberg, *J. Pharm. Sci.*, 50, 109 (1961).
- (96) H. M. Koehler and J. J. Hefferren, *ibid.*, 53, 1126 (1964).
- (97) W. Nernst and E. Brunner, *Z. Phys. Chem.*, 47, 52, 56 (1904).
- (98) E. Nelson, *J. Am. Pharm. Assoc., Sci. Ed.*, 46, 607 (1957).
- (99) H. Juncher and F. Raaschou, *Antibiot. Med. Clin. Ther.*, 4, 497 (1957).
- (100) E. Nelson, *J. Am. Pharm. Assoc., Sci. Ed.*, 47, 297 (1958).
- (101) E. Nelson, E. L. Knoechel, W. E. Hamlin, and J. G. Wagner, *J. Pharm. Sci.*, 51, 509 (1962).
- (102) J. G. Wagner, *ibid.*, 50, 375 (1961).
- (103) E. Nelson, *J. Am. Pharm. Assoc., Sci. Ed.*, 48, 96 (1959).
- (104) L. Benet, in "Drug Design," vol. 4, E. Ariens, Ed., Academic, New York, N.Y., 1973, p. 1.
- (105) G. Levy and B. A. Sahli, *J. Pharm. Sci.*, 51, 58 (1962).
- (106) G. Levy and J. A. Procknal, *ibid.*, 51, 294 (1962).
- (107) R. A. O'Reilly, E. Nelson, and G. Levy, *ibid.*, 55, 435 (1966).
- (108) W. I. Higuchi and W. E. Hamlin, *ibid.*, 52, 575 (1963).
- (109) W. I. Higuchi, N. A. Mir, A. P. Parker, and W. E. Hamlin, *ibid.*, 54, 8 (1965).
- (110) W. I. Higuchi, E. Nelson, and J. G. Wagner, *ibid.*, 53, 333 (1964).
- (111) S. Solvang and P. Finholt, *ibid.*, 59, 49 (1970).
- (112) S.-L. Lin, L. Lachman, C. J. Swartz, and C. F. Huebner, *ibid.*, 61, 1418 (1972).
- (113) S. Miyazaki, M. Nakano, and T. Arita, *Chem. Pharm. Bull.*, 23, 1197 (1975).
- (114) W. Morozowich, T. Chulski, W. E. Hamlin, P. M. Jones, J. I. Northam, A. Purmalis, and J. G. Wagner, *J. Pharm. Sci.*, 51, 993 (1962).
- (115) R. Peterhoff, *Acta Radiol.*, 46, 719 (1956).
- (116) G. Levy, *J. Mond. Pharm.*, 3, 237 (1967).
- (117) S. S. Davis, *Br. Med. J.*, 1, 102 (1972).
- (118) E. Nelson, *J. Am. Pharm. Assoc., Sci. Ed.*, 47, 300 (1958).
- (119) E. J. Middleton, H. S. Chang, and D. Cook, *Can. J. Pharm. Sci.*, 3, 97 (1968).
- (120) J. G. Wagner, *Drug Intell. Clin. Pharm.*, 4, 17 (1970).
- (121) *ibid.*, 4, 232 (1970).
- (122) T. Paal and P. Regos, *Gyogyszereszet*, 17, 59 (1973); through *Chem. Abstr.*, 78, 128377f (1973).
- (123) K. O. Borg, J. Jeppsson, and J. Sjögren, *Acta Pharm. Suec.*, 11, 133 (1974).
- (124) P. Finholt and S. Solvang, *J. Pharm. Sci.*, 57, 1322 (1968).
- (125) G. Levy, *ibid.*, 50, 388 (1961).
- (126) W. A. Cressman, C. A. Janicki, P. C. Johnson, J. T. Dolusio, and G. A. Braun, *ibid.*, 58, 1516 (1969).
- (127) L. W. Dittert, T. Higuchi, and D. R. Reese, *ibid.*, 53, 1325 (1964).
- (128) R. Anderson, *Aust. J. Pharm.*, 42, 919 (1961).
- (129) S. F. Kramer and G. L. Flynn, *J. Pharm. Sci.*, 61, 1896 (1972).
- (130) P. H. Jones, E. K. Rowley, A. L. Weiss, D. L. Bishop, and A. H. C. Chun, *ibid.*, 58, 337 (1969).
- (131) N. Senior, *J. Soc. Cosmet. Chem.*, 24, 259 (1973).
- (132) J. J. Sciarra, J. M. Patel, and A. L. Kapoor, *J. Pharm. Sci.*, 61, 219 (1972).
- (133) J. M. Plaxco, Jr., C. B. Free, Jr., and C. R. Rowland, *ibid.*, 56, 809 (1967).
- (134) J. Kucera and V. Vebler, *Cesk. Dermatol.*, 41, 229 (1966); through *Chem. Abstr.*, 65, 18431e (1966).
- (135) J. R. Leonards, *Clin. Pharmacol. Ther.*, 4, 476 (1963).
- (136) G. Levy, R. H. Gumtow, and J. M. Rutowski, *Can. Med. Assoc. J.*, 85, 414 (1961).
- (137) C. P. Schaffner and W. Mechliniski, *J. Antibiot. (Tokyo)*, 25, 259 (1972).
- (138) H. Nakatani, *Yakugaku Zasshi*, 83, 6 (1963); through *Chem. Abstr.*, 58, 11170e (1963).
- (139) H.-C. Wang and P.-Y. Wang, *Yao Hsueh Hsueh Pao*, 13, 63

- (1966); through *Chem. Abstr.*, 65, 5307b (1966).
- (140) H. Nakatani, *Yakugaku Zasshi*, 84, 1057 (1964).
- (141) P. J. Weiss, M. L. Andrew, and W. W. Wright, *Antibiot. Chemother.*, 7, 374 (1957).
- (142) P. J. Weiss and M. L. Andrew, *ibid.*, 9, 277 (1959).
- (143) J. Marsh and P. J. Weiss, *J. Assoc. Offic. Anal. Chem.*, 50, 457 (1967).
- (144) V. C. Stephens, J. W. Conine, and H. W. Murphy, *J. Am. Pharm. Assoc., Sci. Ed.*, 48, 620 (1959).
- (145) H. M. Gross, *Drug Cosmet. Ind.*, 75, 612 (1954).
- (146) H. M. Gross, W. A. Johnson, and G. J. Lafferty, *J. Am. Pharm. Assoc., Sci. Ed.*, 45, 447 (1956).
- (147) C. M. Gruber, Jr., V. C. Stephens, and P. M. Terrill, *Toxicol. Appl. Pharmacol.*, 19, 423 (1971).
- (148) N. Brudney, *Can. J. Pharm.*, 92, 245 (1959).
- (149) B. Spross, M. Ryde, and B. Nyström, *Acta Pharm. Suec.*, 2, 1 (1965).
- (150) S. BoRodkin and D. P. Sundberg, *J. Pharm. Sci.*, 60, 1523 (1971).
- (151) W. J. Shibe, Jr., and D. H. Hanson, *Soap Chem. Spec.*, 40, 83 (1964).
- (152) G. E. Schumacher and W. J. Crowell, *Am. J. Hosp. Pharm.*, 21, 226 (1964).
- (153) M. A. Schwartz and F. H. Buckwalter, *J. Pharm. Sci.*, 51, 1119 (1962).
- (154) R. Brunner, *Monatsh. Chem.*, 86, 767 (1955).
- (155) R. Brunner and H. Margreiter, *ibid.*, 86, 958 (1955).
- (156) J. V. Swintosky, E. Rosen, M. J. Robinson, R. E. Chamberlain, and J. R. Guarini, *J. Am. Pharm. Assoc., Sci. Ed.*, 45, 34 (1956).
- (157) W. Storbeck, German pat. 971,830 (Apr. 2, 1959); through *Chem. Abstr.*, 55, 4893d (1961).
- (158) F. H. Buckwalter, *J. Am. Pharm. Assoc., Pract. Ed.*, 15, 694 (1954).
- (159) W. A. Woodward, *Q. J. Pharm. Pharmacol.*, 20, 197 (1947).
- (160) C. A. Johnson, in "Advances in Pharmaceutical Sciences," vol. 2, H. S. Bean, A. H. Beckett, and J. E. Carless, Eds., Academic, New York, N.Y., 1967, p. 227.
- (161) A. Bojarski, D. Blitek, and B. Borkowski, *Diss. Pharm. Pharmacol.*, 19, 297 (1967); through *Chem. Abstr.*, 67, 102734t (1967).
- (162) A. Bojarski, D. Blitek, and B. Borkowski, *Diss. Pharm.*, 17, 345 (1965); through *Chem. Abstr.*, 64, 4874c (1966).
- (163) J. C. Bird and R. S. Shelton, *J. Am. Pharm. Assoc., Sci. Ed.*, 39, 500 (1950).
- (164) T. J. Macek, B. A. Feller, and E. J. Hanus, *ibid.*, 39, 365 (1950).
- (165) A. Taub, I. Katz, and M. Katz, *ibid.*, 38, 119 (1949).
- (166) R. Yamamoto, I. Takahashi, and M. Harada, *J. Pharm. Soc. Jpn.*, 76, 853 (1956).
- (167) R. Yamamoto, I. Takahashi, and K. Inazu, *ibid.*, 77, 82 (1957).
- (168) G. A. Nevill, J. C. Ethier, N. F. H. Bright, and R. H. Lake, *J. Assoc. Offic. Anal. Chem.*, 54, 1200 (1971).
- (169) J. D. Mullins and T. J. Macek, *J. Am. Pharm. Assoc., Sci. Ed.*, 49, 245 (1960).
- (170) R. R. Goodall, J. Goldman, and J. Woods, *Pharm. J.*, 200, 33 (1968).
- (171) J. Dolby, B. Gunnarsson, L. Kronberg, and H. Wikner, *Pharm. Acta Helv.*, 47, 615 (1972).
- (172) V. C. Walton, M. R. Howlett, and G. B. Selzer, *J. Pharm. Sci.*, 59, 1160 (1970).
- (173) J. K. Guillory and T. Higuchi, *ibid.*, 51, 100 (1962).
- (174) N. Narasimhachari and G. R. Rao, *Hind. Antibiot. Bull.*, 4, 163 (1962); through *Chem. Abstr.*, 57, 16758b (1962).
- (175) D. Kodrnja and K. Weber, *Sci. Pharm.*, 39, 34 (1971); through *Chem. Abstr.*, 75, 40339x (1971).
- (176) A. M. Nagle, E. I. Rodionovskaya, D. M. Trakhtenberg, and G. I. Kleiner, *Antibiotiki*, 12, 420 (1967); through *Chem. Abstr.*, 67, 76253p (1967).
- (177) H. Nakatani, *Yakuzaigaku*, 23, 75 (1963); through *Chem. Abstr.*, 59, 12596h (1963).
- (178) L. Kiss, B. Rozsonдай, and T. Scholz, *Gyogyszereszet*, 8, 341 (1964); through *Chem. Abstr.*, 62, 405d (1965).
- (179) D. Stefanescu, N. Tuchel, and V. Antonescu, *Farmacia (Bucharest)*, 12, 465 (1964); through *Chem. Abstr.*, 62, 1520b (1965).
- (180) M. G. Kostareva, *Antibiotiki (Moscow)*, 16, 312 (1972); through *Chem. Abstr.*, 75, 40334s (1971).
- (181) N. Tanaka and S. Takino, *Yakugaku Zasshi*, 82, 329 (1962).
- (182) H. Nogami, K. Kigasawa, N. Ikari, H. Ohtani, and M. Takayama, *ibid.*, 90, 967 (1970).
- (183) I. I. Inozemtseva, D. M. Trakhtenberg, and E. S. Zinatullina, *Antibiotiki*, 19, 448 (1974); through *Chem. Abstr.*, 81, 158634s (1974).
- (184) H. Jalil and A. W. H. Daoud, *J. Fac. Med., Baghdad*, 9, 175 (1967); through *Chem. Abstr.*, 69, 54272h (1968).
- (185) F. Kubo, K. Imaoka, and A. Kaneko, *Kyoritsu Yakka Daigaku Kenkyu Nempo*, 6/7, 5 (1961/2); through *Chem. Abstr.*, 60, 375d (1964).
- (186) G. Fiese and J. Perrin, *J. Pharm. Sci.*, 58, 599 (1969).
- (187) J. Perrin and J. Vallner, *J. Pharm. Pharmacol.*, 22, 758 (1970).
- (188) G. Zografi and I. Zarenda, *Biochem. Pharmacol.*, 15, 591 (1966).
- (189) D. D. Heard and R. W. Ashworth, *J. Pharm. Pharmacol.*, 20, 505 (1968).
- (190) A. J. Aguiar, J. E. Zelmer, and A. W. Kinkel, *J. Pharm. Sci.*, 56, 1243 (1967).
- (191) T. Higuchi, A. Michaelis, T. Tan, and A. Hurwitz, *Anal. Chem.*, 39, 979 (1967).
- (192) T. Higuchi and K. Kato, *J. Pharm. Sci.*, 55, 1080 (1966).
- (193) A. F. Michaelis and T. Higuchi, *ibid.*, 58, 201 (1969).
- (194) A. H. Fenton and M. Warren, *Pharm. J.*, 188, 5 (1962).
- (195) R. A. O'Reilly, P. M. Aggeler, and L. S. Leong, *Thromb. Diath. Haemorrhag.*, 11, 1 (1964).
- (196) W. Lowenthal, J. F. Borzelleca, and C. D. Corder, Jr., *J. Pharm. Sci.*, 59, 1353 (1970).
- (197) E. H. Dearborn, J. T. Litchfield, Jr., H. J. Eisner, J. J. Corbett, and C. W. Dunnett, *Antibiot. Med. Clin. Ther.*, 4, 627 (1957).
- (198) L. L. Kaplan, *J. Pharm. Sci.*, 54, 457 (1965).
- (199) D. A. Schlichting, *ibid.*, 51, 134 (1962).
- (200) L. E. Josselyn, C. Endicott, and J. C. Sylvester, in "Antibiotics Annual, 1954-1955," Medical Encyclopedia, New York, N.Y., 1955, pp. 279-282.
- (201) F. Neuwald and P. Ackad, *Am. J. Hosp. Pharm.*, 23, 347 (1966).
- (202) J. Gagliani, A. C. DeGraff, and H. S. Kupperman, *Int. Rec. Med. Gen. Pract. Clin.*, 167, 251 (1954).
- (203) A. E. Vivino, *J. Am. Pharm. Assoc., Sci. Ed.*, 43, 234 (1954).
- (204) J. Schluger, J. T. McGinn, and D. J. Hennessy, *Am. J. Med. Sci.*, 233, 296 (1957).
- (205) G. Hitzengerber and I. Jaschek, *Int. J. Clin. Pharmacol., Ther. Toxicol.*, 9, 114 (1974).
- (206) R. S. Griffith and H. R. Black, *Antibiot. Chemother.*, 12, 398 (1962).
- (207) R. S. Griffith and H. R. Black, *Am. J. Med. Sci.*, 247, 69 (1964).
- (208) S. M. Bell, *Med. J. Aust.*, 2, 1280 (1971).
- (209) R. S. Griffith, *Antibiot. Med. Clin. Ther.*, 7, 320 (1960).
- (210) R. G. Wiegand and A. H. C. Chun, *J. Pharm. Sci.*, 61, 425 (1972).
- (211) S. S. Wright, E. M. Purcell, E. H. Cass, and M. Finland, *J. Lab. Clin. Med.*, 42, 417 (1953).
- (212) S. E. Budolfson, S. E. J. Hansen, and E. Rud, *Acta Pharmacol. Toxicol.*, 11, 49 (1955).
- (213) S. C. Strickland, J. M. Gylfe, and W. P. Boger, *Antibiot. Med. Clin. Ther.*, 1, 388 (1955).
- (214) L. E. Putnam, W. W. Wright, A. DeNunzio, and H. Welch, in "Antibiotics Annual, 1955-1956," Medical Encyclopedia, New York, N.Y., 1956, p. 483.
- (215) W. P. Boger and S. C. Strickland, *Antibiot. Med. Clin. Ther.*, 4, 452 (1957).
- (216) C. C. Lee, R. O. Froman, R. C. Anderson, and K. K. Chen, *Antibiot. Chemother.*, 8, 354 (1958).
- (217) W. J. Kaipainen and P. Härkonen, *Scand. J. Clin. Lab. Invest.*, 8, 18 (1956).
- (218) F. B. Peck, Jr., and R. S. Griffith, in "Antibiotics Annual, 1957-1958," Medical Encyclopedia, New York, N.Y., 1958, pp. 1004-1011.
- (219) J. Colquhoun, E. C. Scorer, G. Sandler, and G. M. Wilson, *Br. Med. J.*, 1, 1451 (1957).
- (220) W. W. Wright and H. Welch, *Antibiot. Med. Clin. Ther.*, 5, 139 (1958).
- (221) M. A. Kaplan, H. L. Dickison, K. A. Hubel, and F. H. Buckwalter, *ibid.*, 4, 99 (1957).
- (222) H. Welch, W. W. Wright, and A. Kirshbaum, *ibid.*, 4, 293 (1957).

- (223) W. M. Sweeney, S. M. Hardy, A. C. Dornbush, and J. M. Ruegger, *ibid.*, 4, 642 (1957).
- (224) C. Lewis, K. F. Stern, and J. E. Grady, *Antimicrob. Ag. Chemother.*, 1964, 13.
- (225) J. T. McGinn, *Curr. Ther. Res. Clin. Exp.*, 7, 110 (1965).
- (226) R. A. Runkel, K. S. Kraft, G. Boost, H. Sevelius, E. Forchielli, R. Hill, R. Magoun, J. B. Szakacs, and E. Segre, *Chem. Pharm. Bull.*, 20, 1457 (1972).
- (227) H. A. Hirsch, C. V. Pryles, and M. Finland, *Am. J. Med. Sci.*, 239, 198 (1960).
- (228) S. Fürész, *Antibiot. Chemother.*, 8, 446 (1958).
- (229) K. H. Holmdahl and H. Lodin, *Acta Radiol.*, 51, 247 (1959).
- (230) K. W. Anderson, *Arch. Int. Pharmacodyn. Ther.*, 147, 171 (1964).
- (231) J. Sjögren, L. Sölvell, and I. Karlsson, *Acta Med. Scand.*, 178, 553 (1965).
- (232) J. S. Heron, *Can. Med. Assoc. J.*, 72, 302 (1955).
- (233) E. W. Rogers, *Br. Med. J.*, 2, 1576 (1958).
- (234) A. C. Glasser and R. M. Doughty, *J. Pharm. Sci.*, 54, 1055 (1965).
- (235) O. Wulff, *ibid.*, 54, 1058 (1965).
- (236) O. W. Barlow and D. R. Climenko, *J. Am. Med. Assoc.*, 116, 282 (1941).
- (237) B. E. Rodda, N. E. Scholz, C. M. Gruber, Jr., and R. L. Wolen, *Toxicol. Appl. Pharmacol.*, 19, 554 (1971).
- (238) F. H. S. Curd and D. G. Davey, *Br. J. Pharmacol.*, 5, 25 (1950).
- (239) F. R. Sidell, W. A. Groff, and A. Kaminskis, *J. Pharm. Sci.*, 61, 1136 (1972).
- (240) R. R. Levine and G. M. Steinberg, *Nature*, 209, 269 (1966).
- (241) A. A. Kondritzer, P. Zvirblis, A. Goodman, and S. H. Paplanus, *J. Pharm. Sci.*, 57, 1142 (1968).
- (242) G. M. Irwin, H. B. Kostenbauder, L. W. Dittert, R. Staples, A. Misher, and J. V. Swintosky, *ibid.*, 58, 313 (1969).
- (243) B. E. Cabana, L. E. Willhite, and M. E. Bierwagen, *Antimicrob. Ag. Chemother.*, 1969, 35.
- (244) J. B. Hammond and R. S. Griffith, *Clin. Pharmacol. Ther.*, 2, 308 (1961).
- (245) S. H. Wan, P. J. Pentikainen, and D. L. Azarnoff, *J. Pharm. Sci.*, 63, 708 (1974).
- (246) S. H. Wan, P. Pentikainen, and D. L. Azarnoff, *J. Pharmacokin. Biopharm.*, 2, 1 (1974).
- (247) R. V. Cohen, L. Molthan, and C. J. D. Zarafonitis, *Dis. Chest*, 30, 418 (1956).
- (248) E. L. Foltz and H. Wallick, *Antimicrob. Ag. Chemother.*, 1969, 316.
- (249) E. L. Foltz, H. Wallick, and C. Rosenblum, *ibid.*, 1969, 322.
- (250) S. F. Pong and C. L. Huang, *J. Pharm. Sci.*, 63, 1527 (1974).
- (251) J. T. Doluisio, J. C. LaPiana, and L. W. Dittert, *ibid.*, 60, 715 (1971).
- (252) A. Rubin, B. E. Rodda, P. Warrick, A. Ridolfo, and C. M. Gruber, *ibid.*, 60, 1797 (1971).
- (253) N. Watzman, A. A. Manian, H. Barry, III, and J. P. Buckley, *ibid.*, 57, 2089 (1968).
- (254) M. Jain, E. Bakutis, and J. C. Krantz, Jr., *Am. J. Pharm.*, 145, 174 (1973).
- (255) S. M. Viscia and D. C. Brodie, *J. Am. Pharm. Assoc., Sci. Ed.*, 43, 52 (1954).
- (256) G. R. Goetchius and C. A. Lawrence, *J. Lab. Clin. Med.*, 29, 134 (1944).
- (257) *ibid.*, 30, 145 (1945).
- (258) H. Dalili and J. Adriani, *Clin. Pharmacol. Ther.*, 12, 913 (1971).
- (259) O. Bodansky and W. Modell, *J. Pharmacol. Exp. Ther.*, 73, 51 (1941).
- (260) G. V. Rossi, T. S. Miya, and L. D. Edwards, *J. Am. Pharm. Assoc., Sci. Ed.*, 45, 47 (1956).
- (261) L. W. Morgan, D. H. Cronk, and R. P. Knott, *J. Pharm. Sci.*, 58, 942 (1969).
- (262) P. E. Thompson, A. Bayles, P. McClay, and J. E. Meisenhelder, *J. Parasitol.*, 51, 817 (1965).
- (263) J. W. Crook, A. I. Goodman, J. L. Colbourn, P. Zvirblis, F. W. Oberst, and J. H. Wills, *J. Pharmacol. Exp. Ther.*, 136, 397 (1962).
- (264) D. R. Davies, A. L. Green, and G. L. Willey, *Br. J. Pharmacol.*, 14, 5 (1959).
- (265) J. F. O'Leary, A. M. Kunkel, and A. H. Jones, *J. Pharmacol. Exp. Ther.*, 132, 50 (1961).
- (266) D. M. Anderson and W. G. Smith, *J. Pharm. Pharmacol.*, 13, 396 (1961).
- (267) R. S. H. Finney and A. L. Tárnoky, *ibid.*, 12, 49 (1960).
- (268) G. H. Copper, D. M. Green, R. L. Rickard, and P. B. Thompson, *ibid.*, 23, 662 (1971).
- (269) Y. Kasé, T. Yulzono, T. Yamasaki, T. Yamada, S. Io, M. Tamiya, and I. Kondo, *Chem. Pharm. Bull.*, 7, 372 (1959).
- (270) A. Agren, *Acta Pharm. Suec.*, 5, 37 (1968).
- (271) L. Saunders, *J. Pharm. Pharmacol.*, 15, 348 (1963).
- (272) C. R. Willis, Jr., and G. S. Banker, *J. Pharm. Sci.*, 57, 1598 (1968).
- (273) R. Brendel, V. Swayne, R. Preston, J. M. Beiler, and G. J. Martin, *J. Am. Pharm. Assoc., Sci. Ed.*, 42, 123 (1953).
- (274) J. Couquelet, P. Bastide, J. B. Le Polles, and A. Paturet, *C. R. Soc. Biol.*, 164, 329 (1970); through *Chem. Abstr.*, 74, 21748t (1971).
- (275) "The Pharmacological Basis of Therapeutics," 3rd ed., L. S. Goodman and A. Gilman, Eds., Macmillan, New York, N.Y., 1965, p. 741 and chaps. 37 and 38.
- (276) M. Schou, *Acta Pharmacol. Toxicol.*, 15, 70 (1958).
- (277) G. Torosian, K. F. Finger, and R. B. Stewart, *Am. J. Hosp. Pharm.*, 30, 716 (1973).
- (278) M. W. P. Carney, *Lancet*, 2, 523 (1971).
- (279) J. A. Ewing and W. J. Grant, *South. Med. J.*, 58, 148 (1965).
- (280) R. B. Stewart, *Am. J. Hosp. Pharm.*, 30, 85 (1973).
- (281) J. L. Emerson, W. R. Gibson, and R. C. Anderson, *Toxicol. Appl. Pharmacol.*, 19, 445 (1971).
- (282) R. I. Ellin and J. H. Wills, *J. Pharm. Sci.*, 53, 1143 (1964).
- (283) P. H. N. Wood, E. A. Harvey-Smith, and A. St. J. Dixon, *Br. Med. J.*, 1, 669 (1962).
- (284) D. P. Bonner, W. Mechlinski, and C. P. Schaffner, *J. Antibiot. (Tokyo)*, 25, 261 (1972).
- (285) E. K. Marshall, Jr., A. C. Bratton, and J. T. Litchfield, Jr., *Science*, 88, 597 (1938).
- (286) H. J. Deuel, Jr., R. Alfin-Slater, C. S. Weil, and H. F. Smyth, Jr., *Food Res.*, 19, 1 (1954).
- (287) R. C. Anderson, P. N. Harris, and K. K. Chen, *J. Am. Pharm. Assoc., Sci. Ed.*, 41, 555 (1952).
- (288) *ibid.*, 44, 199 (1955).
- (289) R. C. Anderson, C. C. Lee, H. M. Worth, and P. N. Harris, *ibid.*, 48, 623 (1959).
- (290) H. V. Kuder, *Clin. Pharmacol. Ther.*, 1, 604 (1960).
- (291) D. N. S. Kerr and S. Davidson, *Lancet*, 2, 489 (1958).
- (292) L. C. Weaver, R. W. Gardier, V. B. Robinson, and C. A. Bunde, *Am. J. Med. Sci.*, 241, 296 (1961).
- (293) K. J. Child, B. Davis, M. G. Dodds, and E. G. Tomich, *J. Pharm. Pharmacol.*, 16, 65 (1964).
- (294) R. J. Schachter, E. T. Kimura, G. M. Nowarra, and J. Mestern, *Int. Rec. Med. Gen. Pract. Clin.*, 167, 248 (1954).

ACKNOWLEDGMENTS AND ADDRESSES

Received from Central Research, Pfizer Inc., Groton, CT 06340.
The authors thank Ms. L. Van Campen for assistance with the manuscript.
* College of Pharmacy, University of Iowa, Iowa City, IA 52242.
† 1974 Pfizer summer student in physical pharmacy.
* To whom inquiries should be directed.

BEST AVAILABLE COPY

Copyright © 1979 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

Library of Congress Cataloging in Publication Data:

Connors, Kenneth Antonio, 1932-
Chemical stability of pharmaceuticals.

"A Wiley-Interscience publication."

Includes bibliographical references and index.

1. Drug stability. I. Amidon, Gordon L., joint author. II. Kennon, Lloyd, 1929- joint author.
- III. Title. [DNLM: 1. Drug stability—Handbooks. 2. Kinetics—Handbooks. QV38 C572c]

RS189.C628 615'.19 78-1759
ISBN 0-471-02653-0

Printed in the United States of America.

10 9 8 7 6 5 4 3

81/207

Hässle
Biblioteket

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.